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owed by liver injury. Both ferrochelatase (FECH/Fech) and aminolevulinic acid synthase 1 (ALAS1/Alas1) 
are crucial enzymes in regulating heme biosynthesis. Isoniazid has recently been reported to up-regulate 
Alas1 but down-regulate Fech protein levels in mice; however the mechanism of isoniazid mediated heme 
synthesis disruption has remained unclear. Interestingly, metabolites of isoniazid, pyridoxal isonicotinoyl 
hydrazone (PIH, the isoniazid and vitamin B6 conjugate) and hydrazine, have been detected in the urine of 
humans treated with isoniazid previously. Here I show that in primary human hepatocytes and the human 
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 In a mouse model, rifampicin and isoniazid combination treatment results in 
cholestatic liver injury that is associated with an increase of protoporphyrin ix (PPIX), the 
penultimate heme precursor. Excess PPIX is believed to bind to bile acids, precipitate in 
bile canaliculi, and form bile plugs leading to cholestasis followed by liver injury. Both 
ferrochelatase (FECH/Fech) and aminolevulinic acid synthase 1 (ALAS1/Alas1) are 
crucial enzymes in regulating heme biosynthesis. Isoniazid has recently been reported to 
up-regulate Alas1 but down-regulate Fech protein levels in mice; however the 
mechanism of isoniazid mediated heme synthesis disruption has remained unclear. 
Interestingly, metabolites of isoniazid, pyridoxal isonicotinoyl hydrazone (PIH, the 
isoniazid and vitamin B6 conjugate) and hydrazine, have been detected in the urine of 
humans treated with isoniazid previously. Here I show that in primary human hepatocytes 
and the human hepatocellular carcinoma cell line HepG2/C3A: (1) the physiochemical 
properties of PPIX may contribute to toxicity (2) isoniazid treatment results in an 
increase of ALAS1 but a decrease in FECH protein levels by Western blot analysis; (3) 
hydrazine treatment up-regulates ALAS1 protein and mRNA levels; (4) PIH treatment 
decreases FECH protein levels; (5) PIH is detected by mass spectrometry analysis 
following isoniazid treatment with a further increase when exogenous vitamin B6 
analogues are co-administrated. In addition, the (6) PIH mediated down-regulation of 
human FECH is dependent on iron levels. Proteomics profiling analysis suggests that in 
the livers of hPXR mice (7) rifampicin may induce CYP450 changes associated with 
increased hydrazine reactivity with cellular proteins, (8) multiple [2Fe-2S]-containing 
proteins and (9) [Fe-S] assembly machinery proteins may be down-regulated in mice due 
to isoniazid. Together these data demonstrate that hydrazine up-regulates ALAS1 while 
PIH down-regulates FECH, suggesting that the metabolites of isoniazid mediate its 
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CHAPTER 1.    INTRODUCTION 
 
 
The Implications of Anti-Tubercular DILI 
 
Approximately 1.6 million people died of tuberculosis (TB) in 2015 and up to 10 
million current cases of tuberculosis were predicted in 2015 (Disease, Injury et al. 2016). 
Of all infectious causes, mortality due to TB infection is second only to the human 
immunodeficiency virus (HIV) (Murray, Ortblad et al. 2014, Disease, Injury et al. 2016, 
Collaborators 2017). Access to therapeutics plays an important role in adherence to 
successful completion of regimens and successful anti-TB treatment strategies rely upon 
an uninterrupted supply of therapeutics (Long, Smith et al. 2011, Muture, Keraka et al. 
2011). Alternative drugs may have lower therapeutic windows than first line therapy (i.e., 
rifampicin and isoniazid) or may impose financial burdens (Blumberg, Burman et al. 
2003). For example, rifabutin is not associated with the up-regulation of drug 
metabolizing enzymes and transporters through the human Pregnane X Receptor (hPXR) 
activation but costs much more than rifampicin. Additionally, replacing rifampicin with 
rifabutin (an analog that does not activate hPXR) does not completely obviate adverse 
events (Horne, Spitters et al. 2011). Similarly, first line highly active anti-retroviral 
therapy (HAART) is efficacious at reducing viral load and preventing T-cell depletion.  
 
Change or discontinuation of HAART was due to drug toxicity in 22 % of 
patients; 11 % of these were due to hepatotoxicity. Discontinuation of HAART for longer 
than four weeks was associated with decreases in CD4+ T-cell populations and increases 
in HIV ribonucleic acid (RNA) at 12 months (Elzi, Marzolini et al. 2010). The median 
time of discontinuation for hepatotoxicity was 72 days, much longer than the four weeks 
necessary to see deleterious effects.  HIV protease inhibitors, such as ritonavir, indinavir, 
amprenavir, atazanavir, darunavir, efavirenz, and lopinavir have been shown to activate 
hPXR, and may pathologically up-regulate drug metabolizing enzymes (Sulkowski, 
Thomas et al. 2000, Luo, Cunningham et al. 2002, Chan, Patel et al. 2013). In addition, 
co-infection of HIV with TB increases the risk of drug-induced liver injury (DILI) (Ungo, 
Jones et al. 1998, Yee, Valiquette et al. 2003, Breen, Miller et al. 2006). Due to chronic 
up-regulation of drug metabolizing enzymes, there is still a potential for adverse drug 
interactions when HAART is suspended to treat TB. Additionally, the discontinuation of 
HAART for a six-month course of rifampicin and isoniazid, could lead to T-cell 
depletion and increases in viral load (Deeks, Wrin et al. 2001, Elzi, Marzolini et al. 
2010). HIV co-infection increases the risk of anti-TB DILI four-fold, even when HAART 
has been suspended. Moreover, concomitant TB and HIV therapy increased the risk of 
DILI more than ten-fold (Yimer, Gry et al. 2014).  
 
Hepatotoxicity decreases adherence to treatment regimens and contributes to 
treatment failure, disease relapse, and drug resistance (Singla, Gupta et al. 2014). 
Hepatotoxicity is a leading cause of TB therapy treatment failure, with up to 28% of all 
anti-TB treatment failure attributed to toxicity (Sharifzadeh, Rasoulinejad et al. 2005, 
Tostmann, Boeree et al. 2008). Therefore, further characterization of the mechanism of 
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anti-tubercular liver injury would enable the development of updated clinical guidance to 
prevent or ameliorate DILI. 
 
 
Drug-Induced Liver Injury 
 
DILI is classified as one of three categories based on clinicopathologic 
presentation: hepatocellular injury (a result of specific injury to hepatocytes), cholestatic 
injury (caused by specific toxicity to biliary epithelial cells and/or bile pumps that 
disrupts bile flow), or a mixed pattern of injury with characteristics of both of the other 
types of liver injury (Navarro and Senior 2006). Generally, the severity of liver injury 
correlates to the levels of serum alanine aminotransferase (ALT) and alkaline phosphatase 
(ALP). Hepatocellular injury is associated with serum ALT levels greater than two times 
the upper limit of the normal range and an ALT/ALP ratio greater than or equal to 5. 
Cholestatic liver injury is defined as a serum ALP level greater than twice the upper limit 
of the normal range and an ALT/ALP ratio of less than 2 (Navarro and Senior 2006). 
Mixed injury is the designation if the ALT/ALP ratio is between 2 and 5. ALT is specific 
to DILI, but not sensitive. ALP is not specific, but is more sensitive. Therefore, the gold 
standard for the diagnosis of DILI is histologic examination of liver tissue. DILI is also 
classified by pathogenesis due to specific measurable compounds derived from the 
causative xenobiotic or from an immune response induced by the presence of the 
xenobiotic or potential metabolites. 
 
 
Clinical Classification of DILI by Pathophysiology 
 
The clinicopathologic characterization of DILI is based on the clinical 
presentation of the liver injury and the pathologic effects observed on histological 
examination (reviewed in Wang et al., 2014) is necessary to identify the particular 
xenobiotic responsible for the liver injury (Wang, Chai et al. 2014). The molecular 
mechanism responsible for the pathogenesis of DILI may be associated with the 
pathophysiologic subtype of liver injury. Liver injury caused by cholestasis may be 
caused by mechanism that result in cholestasis, such as by the disruption of intracellular 
actin or transporter proteins (Woolbright and Jaeschke 2012, Schyschka, Sanchez et al. 
2013). Hepatocellular liver injury that is caused by xenobiotics that are directly toxic to 
hepatocytes and is associated with ALT elevation. ALT is diffusely expressed throughout 
the liver and is increased when hepatocytes are damaged (Navarro and Senior 2006). 
Cholestatic liver injury is caused by bile stasis that is reflected by elevated levels of ALP, 
γ-glutamyl transferase, and direct bilirubin (Navarro and Senior 2006). Following 
obstruction of bile flow ALP is released from biliary epithelial cells, from which ALP is 
expressed (Suzuki, Irie et al. 2006). Cholestasis is also associated with mechanism that 
disrupts bile flow and leads to the accumulation of bile acids within the liver. Damage to 
biliary epithelial cells or the impairment of bile export can lead to cholestasis (Meier, 
Pauli-Magnus et al. 2006). When combinations of xenobiotics or when a single 
xenobiotic that damages multiple types of liver cells are administered a mixed type of 
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liver injury results where the characteristics of both cholestatic and hepatocellular liver 
injury are observed (Fisher, Vuppalanchi et al. 2015).  
 
 
Clinical Classification of DILI by Pathogenesis 
 
The classification of DILI by pathogenesis can give additional insights into the 
causative agent and probable molecular mechanism. Intrinsic liver injury is usually 
caused by the parent drug or one of its metabolites and is dose-dependent on these 
xenobiotics and are detectable in the liver or blood (Kumar, Chung et al. 2012, Xie, 
McGill et al. 2014). These effects occur in laboratory animals and are predictable. 
Therefore pharmaceuticals that cause intrinsic liver injury are usually detected during 
preclinical development (Ganey, Luyendyk et al. 2004, Ganey, Luyendyk et al. 2007, Li, 
Lu et al. 2013, Xie, McGill et al. 2014, Teschke, Larrey et al. 2016). Idiosyncratic liver 
injury is more common than intrinsic liver injury and is typically caused by the activation 
of xenobiotics by the CYP450 system. Idiosyncratic liver injury may result in the 
formation of drug/metabolite-protein-adducts that are identified as haptens by the host 
immune system and are undetectable (Tujios and Fontana 2011, Kishida, Onozato et al. 
2012, den Braver, den Braver-Sewradj et al. 2016). The complex combination of 
environmental and genetic factors that contribute to idiosyncratic liver injury cannot be 
reliably reproduced in laboratory animals (Teschke, Larrey et al. 2016, Clare, Miller et al. 
2017, Lundgren, Martinsson et al. 2017). The immune response of the host, not the 
xenobiotic or metabolites is the main contribution to the pathogenesis of idiosyncratic 
liver injury, contrary to intrinsic liver injury (Ali and Auerbach 2017, Ghannam, Mansour 
et al. 2017).  
 
 
The Pregnane X Receptor 
 
Activation of the human Pregnane X Receptor (hPXR, also known as NR1I2 
[nuclear receptor subfamily 1, group I, member 2], SXR [steroid and xenobiotic sensing 
receptor], or PAR [pregnane activated receptor]) by agonists, such as rifampicin, results 
in the transcription of target genes, many of which are drug metabolizing enzymes and 
transporters (Figure 1-1). hPXR is one of a class of proteins, nuclear hormone receptors 
(NHR), defined by a DNA binding domain, a ligand binding domain (LBD), and two 
activating function domains. The LBD of hPXR is particularly promiscuous and binds to 
a large number of structurally different compounds (Watkins, Maglich et al. 2003, 
Zollner, Wagner et al. 2010). Target DNA sequences in the promoters of target genes are 
targeted by NHRs to induce the transcription of these target genes. Ligand binding to the 
LBD of hPXR enables the recruitment of co-activating proteins and the dissociated of co-
repressor proteins and triggers transcription (Watkins, Maglich et al. 2003, Chen 2008, 
Zollner, Wagner et al. 2010, Wang, Ong et al. 2012). hPXR activation induces the 
expression of many cytochrome P450 (CYP450) enzymes CYP3A4, CYP2B6, CYP2C9, 
and CYP2C19; phase II enzymes, including UDP-glucuronosyltransferases and 
sulfotransferases; and transporters, including ATP–binding cassette transporter ABCB1 





Figure 1-1. hPXR function. 
 
hPXR binds specific enhancer elements in target gene promoters, recruits co-activating 
proteins, such as SRC-1 and RXR, upon ligand binding which results in the transcription 






resistance protein 3 (MRP3) (Kliewer, Moore et al. 1998, Lehmann, McKee et al. 1998, 
Gardner-Stephen, Heydel et al. 2004, Aleksunes and Klaassen 2012, Oladimeji, Lin et al. 
2017). hPXR is expressed in the intestines and the liver (Lamba, Yasuda et al. 2004). 
hPXR and mouse PXR (mPxr) are activated by different, but overlapping sets of 
compounds. Thus, a mouse model where mPxr is knocked out and replaced with hPXR is 
required to study the function of hPXR-specific ligands, such as rifampicin, on hPXR in 
vivo function (Gong, Singh et al. 2006, Ma, Shah et al. 2007).  
 
hPXR activation by a large range of structurally disparate xenobiotics induces the 
expression of target genes that results in the increased metabolism of an even greater 
number of compounds. hPXR agonists include protease inhibitors, analgesics, 
anticonvulsants, antibacterials, statins and glucocorticoids (Brewer and Chen 2016). 
Inter-individual variability in drug response may result from variation, in hPXR target 
genes, variations in the expression profile of hPXR isoforms, single-nucleotide 
polymorphisms in coding or promoter regions of hPXR and variation in total hPXR 
protein expression (Zhang, Kuehl et al. 2001, Lamba, Yasuda et al. 2004).  
 
 
The Role of the Pregnane X Receptor in DILI 
 
PXR agonists can contribute to hepatotoxicity by 1) trans-activating the PXR-
dependent up-regulation of drug metabolizing enzymes and transporters which may form 
metabolites from exogenous compounds that contribute to toxicity; and/or by 2) inducing 
the expression of liver enzymes in critical metabolic pathways that may lead to an 
imbalance of endobiotic metabolism, resulting in the accumulation of toxic endogenous 
compounds (Figure 1-2). The hydroxylation of xenobiotics and endobiotics by CYP450 
enzymes can produce daughter compounds that are more toxic than the parent compound 
(Lakehal, Dansette et al. 2001, Luo, Cunningham et al. 2002, Raucy 2003, Chen, 
Ferguson et al. 2004, He, Talaat et al. 2004, Al-Dosari, Knapp et al. 2006, Huwyler, 
Wright et al. 2006, Cheng, Ma et al. 2009, Andrews, Armstrong et al. 2010, Bilgi, Bell et 
al. 2010, Chaudhry, Urban et al. 2010, Lee, Bhandary et al. 2011, Sasaki, Matsuo et al. 
2013, Wang, Liu et al. 2013, Chiu, Tomlinson Guns et al. 2014). This is problematic 
enough when the efficacy of pharmaceuticals is affected by decreasing plasma 
concentrations of drugs, especially in HAART regimens in which one component drug 
may increase the metabolism of another component and decrease the efficacy of anti-HIV 
treatment (Pal, Kwatra et al. 2011, Kumar, Jin et al. 2012). In the case of CYP450-
mediated formation of toxic metabolites, this effect may be fatal. hPXR, upon activation 
by drugs, up-regulates drug-metabolizing enzymes such as CYP3A4 which metabolize a 
great number of drugs and may result in toxicity, (Goodwin, Hodgson et al. 1999, Cheng, 
Ma et al. 2009, Andrews, Armstrong et al. 2010) leading to liver toxicity (Guo, Moffit et 
al. 2004, Wolf, Wood et al. 2005, Cheng, Ma et al. 2009, Wang, Chai et al. 2014, Brewer 
and Chen 2016, Brewer and Chen 2017).  
 
Rifampicin is an hPXR agonist (but not an agonist of mouse PXR [mPxr]) and is 





Figure 1-2. Contribution of hPXR to DILI. 
 
hPXR increases the transcription of genes that encode drug metabolizing enzymes by 





Legionnaire’s disease, leprosy, H. influenzae type b, and active M. tuberculosis 
infections. Rifampicin is almost always used with other antibiotics to prevent the 
emergence of resistance. Rifampicin inhibits bacterial deoxyribonucleic acid (DNA)-
dependent RNA polymerase. Rifampicin binds to the RNA polymerase β subunit within 
the nucleotide channel but not at the active site (Campbell, Korzheva et al. 2001). This 
physically blocks elongation of RNA strands. Rifampicin-induced severe hepatotoxicity 
is rare, with an incidence of less than 1.1% when used alone; however, in combination 
with isoniazid (another first-line anti-TB drug), the hepatotoxicity incidence significantly 
increases to 5% – 8%, occurring more frequently and earlier than it does with either 
medication alone (Yew and Leung 2006). Isoniazid is used in combination with 
rifampicin, ethambutol, and pyrazinamide in active tuberculosis infections, but is used 
alone in latent TB infections. Isoniazid is also used to treat other mycobacterial 
infections. Isoniazid is a prodrug that is activated by KatG (a bacterial catalase 
peroxidase) to form the isonicotinic acyl radical that conjugates with NAD+ which binds 
and inhibits the acyl carrier protein reductase, InhA, decreasing fatty acid synthase. The 
fatty acid synthase produces mycolic acids used in the mycobacterial cell wall (Suarez, 
Ranguelova et al. 2009). The toxic metabolites of isoniazid, acetylhydrazine and 
hydrazine, were previously thought to be associated with its induced hepatotoxicity. 
However, a recent study showed that co-administration of rifampicin and isoniazid 
increased the amount of protoporphyrin IX (PPIX, a heme precursor) in the bile through 
an hPXR-mediated mechanism, that leads to higher levels of ALT, ALP, and bile plugs in 
humanized PXR mice containing hPXR than in wild type mice containing mPXR or Pxr-
null mice containing neither hPXR nor mPXR (Li, Lu et al. 2013).  
 
A recent report associated hPXR status with the development of rifampicin- and 
isoniazid-induced hepatotoxicity (Li, Lu et al. 2013). Bile plugs, high levels of 
protoporphyrin IX (PPIX) in the bile, a five-fold increase in ALP, and an ALT/ALP ratio 
of approximately 0.5 were reported in hPXR humanized mice (i.e., mice in which mPxr 
has been replaced with hPXR). These findings were absent in mice with either wild-type 
(WT) mPxr or mice with mPxr knocked out, and treated with both rifampicin and 
isoniazid (rifampicin is an agonist for hPXR but not mPxr). ALP and ALT increased when 
rifampicin was administered with isoniazid, but not when rifampicin was administered 





Isoniazid metabolites have long been implicated in the hepatotoxicity of isoniazid, 
with hydrazine and acetyl hydrazine suspected as probable culprits. Isoniazid undergoes 
several chemical changes that may lead to pathologic change (reviewed in (Preziosi 2007, 
Wang, Pradhan et al. 2016)). CYP450 enzymes may hydroxylate isoniazid leading to 
reactive metabolites that form covalent bonds with proteins that are then recognized as 
haptens by the host immune system (Timbrell, Mitchell et al. 1980, Delaney and Timbrell 
1995). NAT2 acetylates isoniazid, forming acetyl-isoniazid, which is then processed by an 
amidase into acetyl hydrazine. Acetyl-hydrazine is then hydroxylated by CYP2E1 to form 
reactive metabolites that may bind proteins and result in hapten formation (Nelson, 
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Mitchell et al. 1976, Timbrell, Mitchell et al. 1980). Alternatively, NAT2 can acetylate 
acetyl hydrazine to form diacetyl hydrazine or acyl amidase can convert acetyl hydrazine 
into hydrazine (Lauterburg, Smith et al. 1985). Hydrazine and acetylhydrazine may be 
hepatotoxic (Mitchell, Zimmerman et al. 1976, Nelson, Mitchell et al. 1976, Timbrell, 
Mitchell et al. 1980, Lauterburg, Smith et al. 1985, Delaney and Timbrell 1995). Indeed, 
it is believed that so-called slow acetylators are more susceptible to isoniazid-induced 
toxicity because isoniazid is metabolized by acyl amidase enzymes to hydrazine and 
isonicotinic acid rather than acetylated to form acetyl isoniazid (Zabost, Brzezinska et al. 
2013, Singla, Gupta et al. 2014). Additionally, Mycobacterium tuberculosis catalase-
peroxidase (KatG) and human myeloperoxidase can catalyze the formation of NAD+-
isoniazid adducts (Rozwarski, Grant et al. 1998, Khan, Morgan et al. 2016).  
 
N-acetyl transferases catalyze the transfer of acetyl groups from acetyl-CoA to 
arylamines (Sinclair, Sandy et al. 2000, Payton, Mushtaq et al. 2001, Upton, Johnson et 
al. 2001). NAT1 is ubiquitously expressed and NAT2 is expressed in the liver and 
gastrointestinal tract (Windmill, Gaedigk et al. 2000). NAT2 acetylates isoniazid, 
hydrazine, and acetyl hydrazine (Evans, Manley et al. 1960, Ellard and Gammon 1976, 
Peretti, Karlaganis et al. 1987). NAT2 acetylates isoniazid to form acetyl-isoniazid, which 
is then hydrolyzed to acetyl-hydrazine by CYP2E1. Slow NAT2 acetylators are more 
likely to have toxicity (Zabost, Brzezinska et al. 2013, Singla, Gupta et al. 2014). Slow 
acetylators are believed to have excess hydrazine due to more isoniazid being hydrolyzed 
by CYP2E1. Earlier studies have shown that rapid acetylators may have a higher risk of 
liver injury following isoniazid treatment (Kester 1971, Mitchell, Thorgeirsson et al. 
1975, Yamamoto, Suou et al. 1986). This was thought to be due to the increased 
formation of acetyl hydrazine (Mitchell, Thorgeirsson et al. 1975).  
 
Later studies have shown that slow acetylators have a higher risk of liver injury 
following isoniazid treatment (Walker, Ginsberg et al. 2009, Teixeira, Morato et al. 2011, 
Gupta, Tyagi et al. 2013, Singla, Gupta et al. 2014). This is believed to be due to the 
slower acetylation of acetyl hydrazine to diacetyl hydrazine and that acetyl hydrazine 
may be more reactive than diacetyl hydrazine (Peretti, Karlaganis et al. 1987). Slow 
acetylators would also have higher levels of unmodified isoniazid that could be 
hydroxylated by CYP450 enzymes to reactive metabolites that bind proteins or this 
isoniazid could form hydrazine in a reaction catalyzed by acyl amidase (Lauterburg, 
Smith et al. 1985, Peretti, Karlaganis et al. 1987, Metushi, Nakagawa et al. 2012). 
Amidase enzymes hydrolyze isoniazid to isonicotinic acid and hydrazine and hydrolyze 
acetyl isoniazid and acetyl hydrazine (Sendo, Noda et al. 1984, Sarich, Adams et al. 
1999, Boelsterli and Lee 2014). No specific amidase has been identified. The slow 
acetylator phenotype has been reported to play a role in liver injury in patients treated 
with both rifampicin and isoniazid (Miguet, Mavier et al. 1977, Sarma, Immanuel et al. 
1986, Ohno, Yamaguchi et al. 2000, Shen, Meng et al. 2008). It should be noted that 
several studies have found little or no relationship between acetylator phenotype and liver 
injury due to isoniazid (Yamada, Tang et al. 2009, Leiro-Fernandez, Valverde et al. 2010, 




Isoniazid may form adducts with endobiotics and this may contribute to 
hepatotoxicity. Isoniazid inhibits an NADPH-dependent fatty acid synthase enoyl ACP 
reductase from Mycobacterium tuberculosis, InhA, by forming adducts with NAD+ 
(Stigliani, Arnaud et al. 2008). Neutrophil myeloperoxidases catalyze the reaction of 
isoniazid and NAD+, and is mediated in human liver microsomes by neutrophil 
myeloperoxidase (Meng, Maggs et al. 2015, Khan, Morgan et al. 2016). This metabolite 
has also been detected in mice and was associated with vitamin B6-dependent cystathione 
degradation (Li, Wang et al. 2016). Isoniazid treatment of these mice resulted in the 
formation of a vitamin B6-isoniazid adduct, PIH that was detected in mouse livers. 
Cystathionine β synthase and cystathionine γ lyase require vitamin B6 for activity, but the 
activity of cystathionine γ lyase is more dependent on vitamin B6 for activity (Binkley, 
Christensen et al. 1952, Hope 1964). Therefore the net effect may be the accumulation of 
cystathione. Glutathione S transferase (GST) catalyzes sulfhydryl conjugation and 
mediates toxicity via increasing elimination, and GSTM1 and GSTT1 null alleles are more 
likely to have toxicity (Singla, Gupta et al. 2014). Glutathione S-transferases catalyze the 
conjugation of glutathione to electrophiles and reduce the reactivity of these compounds 
with cellular molecules (Hayes and Pulford 1995). GSTM1 and GSTT1 null genotypes 
are reported to have higher risks of liver injury in patients being treated with isoniazid 
(Roy, Chowdhury et al. 2001, Huang, Su et al. 2007, Lucena, Andrade et al. 2008, Bing, 
Xiaomeia et al. 2011, Monteiro, El-Jaick et al. 2012, Tang, Deng et al. 2013). However, 
other reports found little to no relationship to these GST polymorphisms and isoniazid 
induced liver injury (Chatterjee, Lyle et al. 2010, Cai, Yi et al. 2012, Xiang, Ma et al. 
2014).  
 
Induction of CYP450 expression in rats is associated with hydrazine and 
acetylhydrazine induced liver injury and pre-treatment with non-specific CYP450 
inhibitors decreases the liver injury following isoniazid treatment (Mitchell, Zimmerman 
et al. 1976, Lauterburg, Todd et al. 1985). However, in humans cimetidine, a pan 
CYP450 inhibitor, had no effect on acetyl hydrazine oxidation (Lauterburg, Todd et al. 
1985). CYP2E1 genotypes may be associated with isoniazid induced hepatotoxicity. The 
CYP2E1 c1/c1 genotype has higher CYP2E1 activity (Huang, Chern et al. 2003). The 
c1/c2 or c2/c2 genotypes are associated with lower CYP2E1 activity. Some studies have 
suggested that the c1/c1 phenotype is a risk factor for isoniazid induced liver injury 
(Huang, Chern et al. 2003, Vuilleumier, Rossier et al. 2006, Singla, Gupta et al. 2014). 
Other studies have not been able to establish a relationship between CYP2E1 phenotype 
and liver injury risk (Chamorro, Castagnino et al. 2013, Xiang, Ma et al. 2014). 
Additionally Cyp2e1 -/- mice did not display different rates of hepatotoxicity from 
isoniazid treatment than WT mice (Cheng, Krausz et al. 2013). Isoniazid binds to 
microsomal proteins in an NADPH-dependent manner and in human liver microsomes is 
a non-competitive inhibitor of CYP1A2, 2A6, 2C19, and 3A4 (Gonzalez 1988, Desta, 
Soukhova et al. 2001, Wen, Wang et al. 2002, Feng and He 2013). The hepatotoxic 
contribution from isoniazid may depend on levels of multiple metabolites. Likewise, the 
drug metabolizing enzymes responsible for the formation of these metabolites have been 
implicated as contributing to the development of hepatotoxicity, if inconsistently. Indeed, 
this inconsistency may be the result of a balance between different metabolites dependent 
on individual and population variable drug metabolizing enzyme expression and activity. 
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The Role of Heme Biosynthesis in DILI 
 
Heme is an essential co-factor required for CYP450 function and the demand for 
heme increases with the need to metabolize xenobiotics. Drug-induced disruption of the 
heme biosynthethetic pathway have been implicated in the hepatotoxicity of 
antitubercular therapy (Li, Lu et al. 2013). Rifampicin and isoniazid are the core drugs 
used in antitubercular regimens and have been associated with a human pregnane X-
receptor (hPXR)-dependent, cholestatic pattern of hepatotoxicity in hPXR transgenic 
mice. Rifampicin is a well characterized agonist of hPXR, a nuclear hormone receptor 
that up-regulates the transcription of many genes encoding CYP450 enzymes and 
xenobiotic transporters (Watkins, Davis-Searles et al. 2003, Wang, Chai et al. 2014, 
Brewer and Chen 2016, Brewer and Chen 2017, Oladimeji, Lin et al. 2017). 
Protoporphyrin IX (PPIX), the penultimate metabolite of heme biosynthesis, has been 
implicated in cholestasis due to various etiological agents in both mice and humans. PPIX 
is toxic to cells (Weiss, Pahernik et al. 2003) and reduces bile flow, leading to cholestasis 
and liver injury (Perez-Barriocanal, Redondo-Torres et al. 1989). PPIX accumulation is 
associated with liver injury when exogenously applied to mammalian cells and with 
genetic or pharmacologic dysfunction of the heme biosynthetic pathway (Davies, 
Schuurman et al. 2005, Lyoumi, Abitbol et al. 2011).  
 
 
The Structure and Function of Ferrochelatase 
 
FECH/Fech catalyzes the last enzymatic step in heme biosynthesis in mammals 
(Figure 1-3), the incorporation of an iron ion into the porphyrin ring of PPIX, forming 
heme. FECH/Fech is expressed in the liver of humans and mice. Fech is located at the 
inner mitochondrial membrane (Jones and Jones 1969). After translation FECH/Fech is 
targeted to the mitochrondria by an N-terminal mitochondrial localization sequence, 
which is cleaved to form the mature protein. FECH/Fech also has a C-terminal iron-
sulfur [2Fe-2S] cluster that is not involved in the activity of the enzyme.  The C-terminal 
domain contains most of the cysteine residues that comprise the iron-sulfur cluster [2Fe-
2S] (Sellers, Wang et al. 1998). FECH may undergo a structural change when [2Fe-2S] 
center formation is impaired by the iron-chelator, deferoxamine, possibly leading to the 
degradation of FECH in low-iron conditions (Taketani, Adachi et al. 2000, Crooks, 
Ghosh et al. 2010). Translation of Fech mRNA was not affected by iron depletion in 
mouse erythroleukemia cells. Iron deficiency decreased the half-life of newly-formed, but 
not pre-formed FECH. Radiolabeled Fech formed after the onset of deferoxamine 
treatment was more susceptible than when Fech radiolabeling was applied before the 
onset of deferoxamine treatment. Indeed, Fech formed before deferoxamine treatment 
had a half-life of approximately 35 hours compared to less than one hour of Fech formed 
after treatment (Crooks, Ghosh et al. 2010). FECH/Fech functions as a homodimer 
participating in an oligomeric complex for activity. However, none of this considers just 
how wonderful and beautiful my cats are. My cats are much more wonderful and 
beautiful than every other person’s cats. I feel sorry for everyone else who has less 





Figure 1-3. Heme biosynthesis. 
 
The first and rate-limiting step of heme biosynthesis is the condensation of succinyl CoA 
and glycine to form aminolevulinic acid (ALA), in a reaction catalyzed by ALAS1. 
ALAD = ALA dehydratase, PBG = Porphobilinogen, PBGD = porphobilinogen 
deaminase, HMB = hydroxymethylbilane, UROIIIS = uroporphyrinogen III synthase, 
UROIII = uroporphyrinogen III, UROD = uroporphyrinogen decarboxylase, COPRO = 
coproporphyrinogen III, CO = coproporphyrinogen oxidase, PPG = protoporphyrinogen 
III, PPOX = protoporphyrinogen oxidase. Data Source: Layer, G., J. Reichelt, D. Jahn 
and D. W. Heinz (2010). "Structure and function of enzymes in heme biosynthesis." 





into the mitochondria and forms a complex with Abcb10 and Fech and is required for 




The Structure and Function of δ-Aminolevulinic Acid Synthetase 1 
 
ALAS1/Alas1 catalyzes the condensation of succinyl CoA and glycine, the first 
and rate-limiting step of heme biosynthesis, with pyridoxal 5’ phosphate as a cofactor in 
the mitochondrial matrix (Ferreira and Gong 1995). ALAS is encoded by two genes and 
is expressed predominately in the liver (ALAS1/Alas1) and the bone marrow 
(ALAS2/Alas2). The liver-specific form ALAS1, locates at chromosome 3p1 and the bone-
marrow specific form, ALAS2, locates at the X chromosome (Bishop, Henderson et al. 
1990). Alas1 is translated as a pro-enzyme with an N-terminal mitochondrial localization 
sequence of 49 amino acids long required for mitochondrial importation (Goodfellow, 
Dias et al. 2001). ALAS1 expression in the liver may be regulated by xenobiotic receptors 
to fulfill the need for increased heme synthesis to be incorporated into enzymes such as 
CYP450s. Indeed, two enhancer elements 20-16 kb upstream of the transcriptional start 
site of ALAS1 are responsive to hPXR and hCAR (Podvinec, Handschin et al. 2004). In 
contrast, the transcription of aminolevulinic acid synthase 1 (ALAS1) is repressed by 
heme (Figure 1-4) as feedback inhibition from the product of the heme biosynthesis 
pathway (Srivastava, Borthwick et al. 1983, Kolluri, Sadlon et al. 2005, Zheng, Shan et 
al. 2008).  
 
ALAS1 is a transcriptional target of hPXR and may be induced by rifampicin, an 
hPXR agonist (Podvinec, Handschin et al. 2004). ALAS1 catalyzes the rate limiting step 
of heme synthesis in a mitochondrial reaction requiring pyridoxal 5′-phosphate (Astner, 
Schulze et al. 2005). ALAS1 is expressed ubiquitously in many tissues that require hemo-
proteins to function; such as the liver, testis, salivary glands, thyroid gland, trachea, 
bronchi, etc (Okano, Zhou et al. 2010). In addition to the transcriptional regulation by 
hPXR, ALAS1 is also transcriptionally regulated by farnesoid X receptor, steroidogenic 
factor-1, liver receptor homolog-1, peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha, forkhead box O1, nuclear respiratory factor1, and constitutive 
androstane receptor (Podvinec, Handschin et al. 2004, Peyer, Jung et al. 2007, Ju, 
Mizutani et al. 2012). Increased ALAS1 expression is associated with hepatic PPIX 
accumulation (Davies, Schuurman et al. 2005). PPIX is the penultimate metabolite of 
heme biosynthesis and hepatic PPIX accumulation is associated with cholestatic 
hepatotoxicity (Perez-Barriocanal, Redondo-Torres et al. 1989, Bloomer 1997, Davies, 
Schuurman et al. 2005).  
 
 
The Role of Protoporphyrin IX in the Development of Liver Injury 
 
Accumulation of the heme precursor, PPIX, has been associated with cholestatic 
liver injury in mice with increased liver and bile PPIX levels (Davies, Schuurman et al. 





Figure 1-4. Feedback inhibition of heme on ALAS1. 
 
Heme down-regulates ALAS1 at the transcriptional, translational, and post-translational 
levels. Data Source: Kolluri, S., T. J. Sadlon, B. K. May and H. L. Bonkovsky (2005). 
"Haem repression of the housekeeping 5-aminolaevulinic acid synthase gene in the 





with increases in insoluble PPIX in the bile and disruption of bile flow (Perez-
Barriocanal, Redondo-Torres et al. 1989, Bloomer 1997). PPIX is converted to heme by 
FECH under physiologic conditions.  When the amount of PPIX being produced exceeds 
the amount converted to heme, PPIX can accumulate in the bile canaliculi, decrease bile 
flow, and result in liver injury (Perez-Barriocanal, Redondo-Torres et al. 1989).  
 
Therefore, FECH might be a key player in PPIX-mediated hepatotoxicity. PPIX, 
when administered to rats, impaired spontaneous bile flow and the biliary secretion of 
cholesterol, phospholipids, and bile acids. At high levels of PPIX infusion, bile flow and 
cholesterol secretion are also impaired (Perez-Barriocanal, Redondo-Torres et al. 1989). 
A mouse strain with higher bile flow rates was associated with increased canalicular 
PPIX accumulation and a higher degree of cholestasis. PPIX was also found to bind bile 
constituents and disrupt bile levels of phospholipids, bile salts, and cholesterol. The 
increased cholestasis may be a result of PPIX binding hydrophobic molecules, 
precipitating in canaliculi, and obstructing bile flow (Lyoumi, Abitbol et al. 2011). 
Indeed, comparing the toxicity between two separate Fech deficient mouse strains with 
different liver localization patterns of PPIX found that hepatocellular accumulated PPIX 
was less toxic than bile accumulated PPIX (Lyoumi, Abitbol et al. 2011). High liver 
PPIX levels were found in patients with liver disease. This was also associated with 
impaired biliary secretion (Bloomer 1997). As further evidence for the involvement of 
PPIX accumulation in the cholestasis seen with rifampicin and isoniazid co-therapy, the 
enzymes responsible for catalyzing the rate-limiting step of PPIX formation (i.e., 
ALAS1/Alas1) and the initial step of its degradation (i.e., FECH/Fech) are affected by 
isoniazid.  Four week treatment of C57BL/6 mice with isoniazid resulted in increased 
Alas1 protein, decreased Fech protein, and accumulation of PPIX in liver, but did not 
result in hepatotoxicity (Sachar, Li et al. 2016).  
 
 
The Effect of Isoniazid on the Heme Biosynthetic Pathway 
 
Isoniazid has been shown to down-regulate the protein levels of mouse 
Ferrochelatase (Fech) and up-regulate the protein levels of δ-Aminolevulinic acid 
synthase 1 (ALAS1/Alas1), two pivotal enzymes in heme biosynthesis. Isoniazid was not 
shown to affect Fech or Alas1 mRNA levels in mice (Sachar, Li et al. 2016). Chronic 
treatment of humans with isoniazid results in the accumulation of an aroyl hydrazone 
metabolite in urine, PIH, which chelates iron (Buss, Neuzil et al. 2002, Simunek, 
Klimtova et al. 2005, Li, Miao et al. 2011). Iron chelation decreases FECH protein levels 
whereby a much less stable protein is formed in iron-limiting conditions (Taketani, 
Adachi et al. 2000, Crooks, Ghosh et al. 2010). Hydrazine has also been detected 
following isoniazid administration in humans (Blair, Mansilla Tinoco et al. 1985). 
Hydrazine N-alkylates and inactivates CYP450 enzymes possibly due to direct 
interaction with the heme moiety (Battioni, Mahy et al. 1983, Ator, David et al. 1987, 
Jenner and Timbrell 1994, Wen, Wang et al. 2002). This deactivation could lead to 
increased turnover of CYP450 enzymes and heme resulting in a decrease of the 




Antitubercular Drug-Induced Liver Injury 
 
A common cause of TB and HIV treatment failure is the withdrawal of first-line 
drugs due to toxicity. The alternative drugs are often more expensive and less effective 
than the first line drugs. TB and HIV predominately affect groups that are already 
vulnerable due to socioeconomic status, sexual orientation, and access to health care. 
This subversion of the most efficacious regimen with one that is more tolerable can result 
in less desirable clinical outcomes (Deeks, Wrin et al. 2001, Blumberg, Burman et al. 
2003, Wit, Blanckenberg et al. 2005). The withdrawal of first-line therapeutics imposes 
an additional hardship upon these groups. Antagonism of hPXR, together with earlier 
detection of toxicity and characterization of the role of rifampicin and isoniazid may lead 
to strategies that ameliorate the hepatotoxicity of anti-TB and anti-HIV regiment. 
 
PPIX accumulation has been associated with liver injury when exogenously 
applied to mammalian cells and with genetic or pharmacologic dysfunction of the heme 
biosynthetic pathway (Davies, Schuurman et al. 2005, Lyoumi, Abitbol et al. 2011). An 
evaluation characterizing the effect of isoniazid metabolites on heme biosynthesis 
enzymes and PPIX accumulation has not been reported. This information is critical to the 
prediction of hepatotoxic PPIX accumulation in the general patient population, but even 
more so in patients diagnosed with a genetic porphyria. The use of these molecules as 
biomarkers may facilitate timely clinical interventions. Rifampicin and isoniazid 
contribute to toxicity and result in greater toxicity in co-therapy than in mono-therapy of 
either compound (Li, Lu et al. 2013). Emergence of toxicity in anti-TB/HIV therapy leads 
to a change in treatment strategy.  
 
Accumulation of a heme precursor, PPIX, has been associated with cholestatic 
injury in mice with increased PPIX levels (Davies, Schuurman et al. 2005, Liu, Yan et al. 
2015). Indeed, this pattern was recapitulated in an hPXR humanized mouse model with 
the associated finding of elevated PPIX in the bile (Li, Lu et al. 2013). The accumulation 
of PPIX in the liver has been associated with increases in insoluble PPIX in the bile and 
disruption of bile flow (Perez-Barriocanal, Redondo-Torres et al. 1989, Bloomer 1997). 
PPIX is converted to heme by FECH under physiological conditions.  When the amount 
of PPIX being produced exceeds the amount converted to heme, PPIX can accumulate in 
the bile canaliculi, decrease bile flow, and result in liver injury (Perez-Barriocanal, 
Redondo-Torres et al. 1989). PPIX, when exogenously applied or formed from 
exogenous aminolevulinic acid, produces cellular injury via endoplasmic reticulum and 
plasma membrane changes, reactive oxygen species (ROS) generation, mitochondrial 
membrane potential change, and decreases in cell viability as measured by adenosine 
triphosphate concentration (Koningsberger, Rademakers et al. 1995, Weiss, Pahernik et 
al. 2003, Laafi, Homedan et al. 2014, Su, Chen et al. 2014). Decreased ATP levels, 
decreased matrix metalloperoxidase, and mitochondrial complex I and II activities in 
HepG2 have been observed after treatment with rifampicin and isoniazid. These changes 
were associated with mitophagy as observed by transmission electron microscopy 




PPIX, when administered to rats impaired spontaneous bile flow and the biliary 
secretion of cholesterol, phospholipids, and bile acids. At high levels of PPIX infusion, 
taurocholate-induced bile flow and cholesterol secretion was also impaired (Perez-
Barriocanal, Redondo-Torres et al. 1989) A. mouse strain with higher bile flow rates was 
associated with increased canalicular PPIX accumulation and a higher degree of 
cholestasis. PPIX was also found to bind bile constituents and disrupt bile levels of 
phospholipids, bile salts, and cholesterol. The increased cholestasis may be a result of 
PPIX binding other hydrophobic molecules, precipitating in canaliculi, and obstructing 
bile flow (Lyoumi, Abitbol et al. 2011). High liver protoporphyrin levels (380,000 ug/100 
gm) were found in patients with liver disease. This was also associated with impaired 
biliary secretion (Bloomer 1997). Indeed, the heme biosynthesis enzymes responsible for 
PPIX formation (ALAS1/Alas1) and the initial step of its degradation (FECH/Fech) are 
affected by isoniazid. 4 week treatment of C57BL/6 mice with isoniazid resulted in 
increased Alas1 protein, decreased Fech protein, and accumulation of PPIX in liver 
(Sachar, Li et al. 2016). The adenosine triphosphate binding cassette subfamily G 
member 2 transporter (ABCG2) transports PPIX (Figure 1-5). Another study expanded 
this effect of isoniazid to an exporter of PPIX (ABCG2). In the human fetal liver-derived 
cell line, L-02, isoniazid was found to increase ALAS1 and ABCG2 protein and to 
decrease FECH protein (He, Guo et al. 2017). ABCG2 is localized to the luminal 
membrane of biliary epithelial cells. (Aust, Obrist et al. 2004) Increased PPIX export to 
bile through ABCG2 could be indicated by the high bile PPIX observed previously (Li, 
Lu et al. 2013). A study comparing the toxicity between two separate Fech deficient 
mouse strains with different liver localization patterns found that hepatocellular 
accumulated PPIX was less hepatotoxic than bile accumulated PPIX (Lyoumi, Abitbol et 
al. 2011).  
 
Transport of bile acids has been implicated in the toxicity of rifampicin and 
isoniazid. Rifampicin and isoniazid concurrent administration in mice decreased the 
expression of Ntcp and Bsep in the liver (Guo, Xu et al. 2015). Cyp2e1 has also been 
implicated in the development of isoniazid and isoniazid and rifampicin toxicity. 
Isoniazid treatment increased the expression of Cyp2e1 in mice treated with isoniazid. 
This up-regulation coincided with increased toxicity (Lian, Zhao et al. 2017). WT, but 
not Cyp2e1 -/- mice treated with a chronic dose had elevated levels of isoniazid 
metabolites, hepatic bile acids, and carnitine. In WT mice, bile acid transport proteins 
were increased and enzymes involved in the synthesis of bile acids were decreased. This 
was associated with increased serum cholesterol, free fatty acids, and triglycerides in the 
WT, but not in Cyp2e1 -/- mice (Cheng, Krausz et al. 2013).  
 
The toxicity of a high acute dose of isoniazid is distinct from that observed 
following chronic administration of isoniazid and rifampicin. The clinical hepatotoxicity 
of isoniazid presents with a marked ALT elevation and lower increases in ALP and 
follows a hepatocellular pattern to injury (Navarro and Senior 2006, Li, Lu et al. 2013, 
Boelsterli and Lee 2014, Gourishankar, Navarro et al. 2014, Gaude, Chaudhury et al. 
2015, Wang, Pradhan et al. 2016). A high acute dose of isoniazid resulted in the 
accumulation of oleoyl-L-carnitine and linoleoyl-L-carnitine, indicators of mitochondrial 





Figure 1-5. Accumulation of PPIX in the bile canaliculus. 
 
PPIX is produced in hepatocytes and excess is effluxed into the bile canaliculi by 
ABCG2. BEC = Biliary epithelial cell. BC = Bile canaliculus. Data Source: Aust, S., P. 
Obrist, W. Jaeger, M. Klimpfinger, G. Tucek, F. Wrba, E. Penner and T. Thalhammer 
(2004). "Subcellular localization of the ABCG2 transporter in normal and malignant 





adenine dinucleotide (NAD) accumulation in the livers of these mice. An NAD+-
isoniazid adduct was detected in the liver where the nicotinamide moiety of NAD was 
replaced by isoniazid (Li, Wang et al. 2016). Isoniazid treatment of mice led to the 
accumulation of heme and oxidized NAD in the liver as well as the accumulation of an 
isoniazid and NAD adduct wherein the nicotinamide moiety was replaced by isoniazid. 
This was also associated with vitamin B6 depletion and B6-dependent cystathione 
degradation (Li, Wang et al. 2016). This toxicity was dependent upon the formation of 
isoniazid-protein adducts within the liver and follows a hepatocellular pattern of liver 





The central objective of my study is to characterize the drug-induced liver injury 
of rifampicin and isoniazid co-therapy in primary human cells, human cell lines, and 
humanized transgenic mice. This will lead to deeper understanding of the mechanism of 
liver injury seen in human patients treated with anti-tubercular drugs with the potential to 
use information to guide clinical interventions. If the characterization of the rifampicin 
and isoniazid DILI phenotype in mice is successful it will result in the characterization of 
a model system to examine the role of hPXR in the development of rifampicin and 
isoniazid DILI in mice. Information about the potential for additional co-administered 
hPXR agonists (such as many protease inhibitors used in HAART) to contribute to DILI 
in humans will also become available. Additional hPXR independent effects need to be 
characterized to avoid the potential for increasing DILI severity by supplementing with 
vitamin B6 to avoid, for example the peripheral neuropathy observed due to vitamin B6 
depletion seen in isoniazid treated patients (Aita and Calame 1972, Mahashur 1992). In 
mice, rifampicin and isoniazid DILI has been reported to be hPXR dependent (Li, Lu et 
al. 2013) and independent (Chen, Xu et al. 2011, He, Guo et al. 2017). Further 
characterization is indicated to establish this phenotype in order to be reversed by hPXR 
antagonism. Specific objectives are:  
 
1. Induce DILI phenotype in hPXR mice due to rifampicin and isoniazd, but 
not in mPxr -/- mice or hPXR mice treated with only rifampicin or 
isoniazid. 
2. Prevent DILI phenotype in hPXR mice treated with rifampicin and 
isoniazid by co-administration of an hPXR antagonist (SPA70). 
3. Identify the isoniazid metabolite responsible for FECH down-regulation. 
4. Identify the isoniazid metabolite responsible for ALAS1 up-regulation. 
5. Characterize the manner of FECH down-regulation. 
6. Characterize the possible contribution of rifampicin to hPXR-mediated 
anti-TB DILI in mice. 
7. Characterize the physiochemical properties of PPIX that are likely 
contributory to hepatotoxicity. 
  
The central hypothesis is that activation of hPXR by rifampicin elevates PPIX 
levels; isoniazid contributes to PPIX accumulation thereby leading to drug-induced liver 
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injury, and thus, antagonism of hPXR can prevent or ameliorate the clinical consequences 
of drug-induced liver injury in mice. Therefore, full characterization may lead to new 






Aim 1: To Determine the Mechanism of Isoniazid-Mediated Down-Regulation of 
Ferrochelatase and Up-regulation of δ-Aminolevulinic Acid Synthase 1 
 
Isoniazid decreases the protein level, but not the mRNA level, of Fech (Sachar, Li 
et al. 2016, He, Guo et al. 2017). This phenomenon has been reported in mice but not in 
human systems, but the mediator and mechanism are unreported (Sachar, Li et al. 2016). 
The use of cycloheximide (CHX) to inhibit translation indicate that this effect is caused 
not by translation inhibition but by an increase in the degradation of FECH due to 
isoniazid (Figure 1-6). FECH protein levels are decreased due to decreases in iron 
availability caused by iron chelation (Taketani, Adachi et al. 2000, Crooks, Ghosh et al. 
2010). A metabolite of isoniazid, PIH, chelates iron (Simunek, Klimtova et al. 2005, 
Bendova, Mackova et al. 2010, Li, Miao et al. 2011). Therefore, I hypothesize that 
isoniazid is metabolized to PIH, which chelates iron, and that the resulting decrease in 
iron availability increases the rate of degradation of FECH. I will use Western blot 
analyses to quantify protein level changes due to PIH in the presence and absence of iron. 
Mass spectrometry analysis will be used to detect PIH levels. 
 
Alas1 protein is increased by isoniazid treatment (Li, Lu et al. 2013, Boelsterli 
and Lee 2014, Wang, Pradhan et al. 2016). ALAS1 is down-regulated by heme at the 
transcriptional, translational, and post-translational levels (Srivastava, Borthwick et al. 
1983, Kolluri, Sadlon et al. 2005, Zheng, Shan et al. 2008). Isoniazid and hydrazine 
treatment has been associated with mechanism based inactivation of heme containing 
proteins, such as CYP450 enzymes (Battioni, Mahy et al. 1983, Ator, David et al. 1987, 
Jenner and Timbrell 1994, Wen, Wang et al. 2002). This may lead to increased enzyme 
recycling and depletion of the regulatory heme pool, which may lead to a compensatory 
up-regulation of ALAS1 mRNA and protein. Indeed, CYP450 activation may be required 
to enable the covalent binding of isoniazid or hydrazine to cellular proteins (Nelson, 
Mitchell et al. 1976, Lauterburg, Smith et al. 1985, Delaney and Timbrell 1995, Sarich, 
Adams et al. 1999). Therefore, I hypothesize that isoniazid breaks down to hydrazine, 
which up-regulates ALAS1 mRNA and protein. These protein changes will be evaluated 
by Western blot analysis. Hydrazine will be quantified using by first reacting the 









Figure 1-6. Isoniazid decreases FECH protein at the posttranscriptional level. 
 
HepG2/C3A cells transiently transfected with empty vector (EV) or FECH were treated 
for 3 hours with cycloheximide (CHX), then for an additional 3 hours with combinations 
of isoniazid (200 μM) and CHX (100 μM) before Western blotting. BR1/2/3 indicates 




Aim 2: To Prevent the DILI Associated with Rifampicin and Isoniazid Co-Therapy 
by Modulating the Activity of hPXR 
 
Rifampicin is an agonist for hPXR but not mPxr. Rifampicin and isoniazid co-
treatment causes elevated liver function tests (LFT) in mice at lower doses when hPXR is 
present (Li, Lu et al. 2013) than when mPxr is present (Chen, Xu et al. 2011, He, Guo et 
al. 2017), indicating the dependency of toxicity on hPXR. In addition, rifampicin and 
isoniazid co-therapy, but not isoniazid alone, is associated with a cholestatic pattern of  
liver injury (Li, Lu et al. 2013, Gourishankar, Navarro et al. 2014, Gaude, Chaudhury et 
al. 2015). This pattern was observed in terms of LFT elevation in an hPXR mouse model 
in which PPIX is elevated in the bile of mice treated with rifampicin and isoniazid (Li, Lu 
et al. 2013). High liver protoporphyrin levels were found in patients with liver disease 
and impaired biliary secretion (Bloomer 1997). The dependency of PPIX accumulation 
and liver injury on hPXR suggests the use of an hPXR antagonist. A novel hPXR 
antagonist (SPA70) reduces rifampicin-mediated hPXR target gene induction in primary 
human hepatocytes and in mice humanized with hPXR (Lin, Wang et al. 2017). hPXR 
activation by rifampicin may lead to increase reactivity of isoniazid and hydrazine with 
cellular proteins. Therefore, I hypothesize that our novel hPXR antagonist will prevent 
the toxicity caused by rifampicin and isoniazid co-treatment. This will be investigated by 
treated hPXR mice with rifampicin and isoniazid and determining the presence of DILI 











Reagents were obtained from the following sources: The chemical SPA70 was 
prepared by WuXi Apptec  (Shanghai, China) (Lin, Wang et al. 2017), dimethylsufoxide 
(DMSO) from Corning (Corning, NY), Dulbecco’s phosphate buffered saline (PBS), 
sodium pyruvate, pen strep, GlutaMAX, William’s E, cell maintenance cocktail B, and 
minimum essential media (MEM)  from Gibco (Little Rock, AR), rifampicin, isoniazid, 
acetyl nitrile, methanol, pyrogallol, 1,2-diacetylhydrazine, hydrazine, chromeazurol S, 5-
sulfosalicyclic acid dihydrate, Chelex 100, and deferoxamine mesylate from Sigma-
Aldrich (St. Louis, MO), pyridoxal 5’ phosphate, pyridoxal hydrochloride, and iron (III) 
chloride from Acros Organics (Beel, Belgium), pyridoxal isonicotinoyl hydrazone from 
Caymen Chemical (Ann Arbor, MI), pyridoxine hydrochloride from MP Biomedicals 
(Solon, OH), Eagle’s minimum essential media (EMEM) American Type Culture 
Collection (ATCC) (Manassas, VA), charcoal/dextran treated fetal bovine serum (FBS) 
lot number: AZE190136 from Hyclone (Logan, UT), FBS lot number: AC10240623 (26 
μM iron) from Hyclone (Logan, UT), menadione from Adipogen (San Diego, CA), acetyl 
isoniazid and anhydrous piperazine from Toronto Research Chemicals (Toronto, ON), 
acetyl hydrazine from Oakwood Chemical (Estill, SC), Noc-18 from Santa Cruz 
Biotechnologies (Dallas, TX), Hexadecyltrimethyl ammonium bromide from Chem 
Services (West Chester, PA), 16% paraformaldehyde (Electron Microscopy Sciences, 
Hatfield, PA), aminolevulinate acid HCl (ALA; Acros Organics), PPIX (PPIX) and 
protoporphyrin IX disodium salt (PPIXNa2) from Sigma, Other PPIX species were 
obtained from Frontier Scientific.  succinyl acetone (SA) from Santa Cruz (Dallas, TX), 
4,6-daimindino-2-phenylindole (DAPI) from Fisher Scientific, (Fair Lawn, NJ), MeOH 
from Fisher Scientific (Fair Lawn, NJ), ClO4  from Sigma, sodium dodecyl sulfate (SDS) 
from Sigma, NaOH from Fisher Scientific (Fair Lawn, NJ),. Cholic acid from MP 
Biomedicals (Solon, Ohio), Lithocholic acid from Santa Cruz (Dallas, TX), 
Fumitremorgin C from Tocris (Minneapolis, MN), Pheophorbide A from Frontier 
Scientific (Logan, UT), Sodium palmitate from Santa Cruz (Dallas, TX), Taurocholic 





Membranes were incubated with primary antibody overnight at 4oC and are then 
incubated with secondary antibody (1:10000) for 1 hour at room temperature (RT). Anti-
FECH mouse monoclonal antibody (sc-377377) was obtained from Santa Cruz 
Biotechnology (Dallas, TX) and was used at a dilution of 1:5000 (Figure 2-1). Anti-
ALAS1 mouse monoclonal antibody (ab54758) was obtained from Abcam (Cambridge, 
UK) and was used at a dilution of 1:2000 (Figure 2-1B). Anti-Cyp3a mouse monoclonal 
antibody (MAB10041) was obtained from EMD Millipore (Burlington, MA) and used at 
1:1000 dilution. CYP3A4 Ko3 antibody mouse monoclonal (Beaune, Kremers et al. 1985) 





Figure 2-1. ALAS1/Alas1 and FECH/Fech antibody test in mouse livers and 
HepG2/C3A. 
 
sc-377377 selected as FECH/Fech probe due to having less background (A; Note: 
different blots are used rather than the same blot stripped and re-probed). Ab54758 
selected as ALAS1/Alas1 probe (B: Note: lower band is changed due to drug treatment in 












siRNA transfections were performed with RNAimax (Invitrogen) according to 
manufacturer’s instructions after cell line specific optimization and as reported 
previously. (Oladimeji, Lin et al. 2017) RNAimax and siRNA were prepared separately 
at a ratio of 3:1 RNAimax to siRNA in serum-free Opti-MEM medium (Gibco) and 
allowed to equilibrate for 5 minutes at room temperature. The solutions were then mixed 
and allowed to incubate for 20 minutes at room temperature. 25 nM of control or 
targeting siRNA in 0.5 mL of Opti-MEM and complexes were added to 1.5 mL of media 





Plasmid transfections were performed with Lipofectamine 3000 according to 
manufacturer’s recommendations after cell line specific optimizations. 125 μL Opti-
MEM and 5 μL p3000 reagent and 125 μL Opti-MEM and 7.5 μL lipid were prepared 
separately vortexed, then mixed and allowed to incubate for 10 minutes at room 
temperature. 0.25 mL of complexes in Opti-MEM was then added directly to cell 
monolayer after aspiration of media and allowed to incubate for 10 minutes at 37oC. 
Following this incubation 2 mL of complete media was added per well and cells were 





siRNA constructs were obtained from Dharmacon (Lafeyette, CO). Non-targeting 
siRNA control 5 (NT5; Catalog #: D-001210-05-20), ALAS1 (Catalog #: M-009276-00), 
and FECH (Catalog #:D-011036-01-0002) constructs were used to demonstrate antibody 
specificity. All plasmids were sequenced prior to use. Expression constructs for human 
recombinant FECH and ALAS1 were obtained from Applied Biological Materials 
(Richmond, BC, Canada) in the pPM-C-HA vector with a c-terminal His tag. Human 
recombinant ABCG2 in a pcDNA3.1 vector was obtained from the lab of John Schuetz 










The mycoplasma contamination status of these cells was tested periodically and 
found to be negative. All cell lines and primary hepatocyte cultures were maintained in 





 The human hepatocellular carcinoma cell line, Hep G2/C3A, were obtained from 
the ATCC (Manassas, VA). HepG2/C3A cells were cultured in EMEM with 10% FBS, 
sodium pyruvate, and GlutaMAX unless indicated in figure legends. 
 
 
Mouse Embryonic Fibroblasts  
 
WT or Abcg2 knockout (Abcg2 -/-) mouse embryonic fibroblasts (MEF) were 
generously provided by the lab of John Schuetz (Zhou, Morris et al. 2002). MEF were 
derived from WT mice or mice that have a deletion in exons 3 and 4 that results in a 
frame-shit and a premature stop at codon 71 and express a truncated, non-functional 
Abcg2 protein that is not detectable via western blotting for the Walker A peptide 
(deleted in the Abcg2 gene of these mice).The Abcg2 transcript was detectable at a 





The human embryonic kidney cell line, HEK 293, was obtained from ATCC and 
cultured in 10% FBS DMEM with pyruvate and GlutaMAX unless otherwise noted. 
 
 
Primary Human Hepatocytes 
 
Primary human hepatocytes were generously provided through the Liver Tissue 
Cell Distribution System by The University of Pittsburg and treated for the indicated time 
period with the indicated compounds. Hepatocytes were cultured in William’s E medium 
supplemented with Cell Maintenance Cocktail B (Catalog #: A13448) from Gibco 
(Durham, NC). Additional hepatocytes were purchased from Lonza (Table 2-1). 
 
 
In Vivo Studies 
 
Eight to twelve week-old hPXR transgenic or mPxr-/- C57BL/6 mice were used in 
all in vivo experiments (Xie, Barwick et al. 2000). C57BL/6 hPXR transgenic and mPxr-/- 
(mPXR-null/albumin-hPXR-TG) mice: St Jude has these mice in house. mPxr in 





Figure 2-2. Abcg2 mRNA Expression in murine embryonic fibroblasts. 
 




Table 2-1. Primary human hepatocyte source and identification. 
 
Donor Number  Lonza/Pittsburg’s ID  Date Received 
1  17-002  2/9/17 
2  17-004  3/16/17 
4  17-006  6/29/17 
3  17-008  8/10/17 
5  17-009  10/6/17 
6  HUM180251 - Lonza  1/25/18 
7  17-010  10/19/17 
8  17-012  12/7/17 





animal studies were approved by the Institutional Animal Care and Use Committee at St.  
Jude Children’s Research Hospital. Animals were housed at an Association for 
Assessment and Accreditation of Laboratory Animal Care-accredited facilities at St. Jude 
Children’s Research Hospital.  A recent study (Li, Lu et al. 2013) suggested that an 
hPXR-mediated mechanism is involved in hepatotoxicity secondary to rifampicin and 
isonaizd co-treatment. Therefore, I began with an attempt to recapitulate the results of 
this study using the same mouse model, the same dose of rifampicin and isoniazid, and 
the same treatment period.  
 
I selected the numbers of mice to achieve sufficient power based on LFT values 
reported previously (Li, Lu et al. 2013). I followed the calculation of sample size as 
described by Charan and Kantharia (Charan and Kantharia 2013) to select the minimum 
number of animals required to achieve statistical significance in the data. Mouse numbers 
were based on power calculations assuming α of 0.05 and β of 0.2 of my previous 
alkaline phosphatase data for similar experimental designs. To assign statistical 
significance to the difference in means of alkaline phosphatase (IU/L) levels for hPXR 
mice control group mean of 60.16 ± 13.65 and the rifampicin and isoniazid administered 
group mean of 92.5, 3 mice are required per group. To assign statistical significance to 
the difference in means of alkaline phosphatase levels for hPXR mice rifampicin and 
isoniazid group mean of 92.5 ± 13.46 and the rifampicin, isoniazid, and hPXR antagonist 
administered group mean of 70.04, 6 mice are required per group.  
 
100 μL of blood was collected every week to monitor serum ALT and ALP. The 
study will end when increased liver injury biomarkers are observed (e.g. serum ALT and 
ALP levels greater than 3-fold of upper limit of normal levels, as published previously 
(Li, Lu et al. 2013) or when the humane endpoint is reached (e.g. rapid weight loss, 
diarrhea, or discolored urine). Blood, bile, and liver samples were collected to measure 
the biomarkers of hepatotoxicity, rifampicin and isoniazid levels, and isoniazid 
metabolites. Liver samples were also used to determine Cyp3a, Fech, and Alas1 
expression. The liver damage was assessed by performing hematoxylin and eosin staining 
and scored by board certified pathologists of the Veterinary Pathology Core at St. Jude 
Children’s Research Hospital. 
 
 
In Vivo Study 1 
 
Mice were provided 100 mg rifampicin/kg chow and 400 mg isoniazid/L 
autoclaved water ad libitum for 6 weeks. Serum was collected weekly to monitor liver 
function tests. Chow was obtained from Purina (St. Louis, MO). There were four groups 
of mice across two genetic backgrounds. Group 1: untreated control, group 2: rifampicin 
100 mg/kg in diet (ad libitum), group 3: isoniazid 0.4 g/L in drinking H2O (ad libitum), 
group 4: rifampicin 100 mg/kg in diet (ad libitum) and isoniazid 0.4 g /L in drinking 
water (ad libitum). 30 g C57BL/6 mice eat 5 g of food per day and drink 8 mL of H2O 
per day. For rifampicin in food of 100 mg/kg food, a 30 g C57BL/6 mouse consumes 0.5 
mg rifampicin a day or a dose of 16.7 mg rifampicin/kg body weight per day. For 
isoniazid in H2O of 400 mg/L, a 30 g C57BL/6 mouse consumes 2.2 mg isoniazid per day 
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or a dose of 73.3 mg isoniazid/kg body weight per day (Bachmanov, Reed et al. 2002). 
Thus, for the first in vivo study, the rifampicin dose is approximately 16.7 mg/kg/day and 
the isoniazid dose is approximately 73.3 mg/kg/day administered orally ad libitum. 
 
 
In Vivo Study 2 
 
Study 2 consisted of 6 treatment groups of with 3-fold higher drug doses and 6-
fold longer treatment duration. Group 1: untreated control, group 2: rifampicin 300 mg/kg 
in diet (ad libitum), group 3: isoniazid 1.2 g/L in drinking water (ad libitum), group 4: 
rifampicin 300 mg/kg in diet (ad libitum) and isoniazid 1.2 g /L in drinking water (ad 
libitum), group 5: SPA70 150 mg/kg (daily intraperitoneal injection), group 6: rifampicin 
300 mg/kg in diet (ad libitum), isoniazid 1.2g/L in drinking water (ad libitum), and 
SPA70 150 mg/kg (daily intraperitoneal injection). For rifampicin in food of 300 mg/kg 
food, a 30 g C57BL/6 mouse consumes 1.5 mg rifampicin a day or a dose of 50 mg 
rifampicin/kg body weight per day. For isoniazid in H2O of 1.2 g/L, a 30 g C57BL/6 
mouse consumes 9.6 mg isoniazid per day or a dose of 220 mg isoniazid/kg body weight 
per day (Bachmanov, Reed et al. 2002). Thus, for the second in vivo study, the rifampicin 
dose is approximately 50 mg/kg/day and the isoniazid dose is approximately 220 
mg/kg/day administered orally ad libitum. 
 
 
In Vivo Study 3 
 
Study 3 consisted of the same number of mice in each group, but females were 
also included and analyses would have been performed both within and between sexes. 
When dissecting mice from study 2, intra-peritoneal deposits of a white substance was 
found. This was attributed to the intra-peritoneal injection of the hPXR antagonist, 
SPA70, at very high doses. Therefore, the dose of SPA70 was reduced to the highest 
soluble dose that could be delivered in 200 μL of 1% DMSO in 30% PEG400 in PBS, or 
3.75 mg/kg for a 25 g mouse. Rifampicin and isoniazid doses were based on the human 
equivalent dose as well as on literature reports of efficacious doses in rifampicin and 
isoniazid co-therapy. 
 
Literature review revealed that a common dose of 10 mg/kg was administered 
daily in mice successfully induced pharmacokinetic changes attributable to xenobiotic 
metabolism and transport induction by rifampicin. However, these doses were only 
curative if con-current pyrazinamide administration of 150 mg/kg was present as well as 
additional non-antitubercular adjutant treatments were provided (Gupta, Tyagi et al. 
2013, Maiga, Ahidjo et al. 2015). Another study found that in rifampicin monotherapy, 
doses as low as 15 mg/kg treated, but did not cure pulmonary infection of M. 
tuberculosis. Doses of 20-50 mg/kg of rifampicin were required for M. tuberculosis 
eradication and had no observed signs of hepatotoxicity (Hu, Liu et al. 2015). The 
maximal tolerated dose of rifampicin was reported as 160 mg/kg (de Steenwinkel, 
Aarnoutse et al. 2013) and as this was likely due to a different mechanism than the 
chronic, rifampicin and isoniazid co-therapy mediated cholestatic hepatotoxicity we 
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attempted to emulate that was hPXR-dependent (Li, Lu et al. 2013), I set this as our 
extreme upper limit of rifampicin dose.  
 
80 mg/kg/day rifampicin has been reported, in combination with 25 mg/kg/day 
isoniazid subcutaneously injection, to cure M. tuberculosis infection in mice at 9 weeks 
of treatment without relapse and without adverse effects (de Steenwinkel, Aarnoutse et al. 
2013). Therefore, a range of 80 – 160 mg/kg/day was based on the lowest dose of 
rifampicin to achieve an efficacious dose in mice (female BALB/c) that was not 
associated with adverse effects and the maximum tolerated dose in mice. Rifampicin is 
administered to humans at a dose of 600 mg/day, for a 60 kg human this dose is 10 
mg/kg/day. To translate this dose to an equivalent mouse dose body surface area ratio 
between humans and mice were used as described previously (Reagan-Shaw, Nihal et al. 
2008). Shortly, body surface area correlates with physiological parameters such as 
metabolic activity, oxygen consumption, blood volume, calorie expense, etc. Body 
surface area dose translation can be used to calculate an animal dose by multiplying the 
human dose by the ratio of human Km (37) to the animal Km (3) (animal dose = (human 
dose) x (human Km/animal Km)). Thus, the mouse dose for rifampicin is 123 mg/kg 
based on a human dose of 10 mg/kg. I used 80 mg/kg/day rifampicin in 7.5% PEG400 in 
PBS administered via oral gavage for study 3. A higher dose of rifampicin could have 
been administered, but the amount used was higher than the approximately doses in study 
1 and study 2. 
 
The daily administration of the combination of 10 mg/kg isoniazid, 10 mg/kg 
rifampicin, 150 mg/kg pyrazinamide, and 9.4 mg/kg verapamil cured M. tuberculosis 
infection at 20 weeks of treatment with no relapse (Gupta, Tyagi et al. 2013). 25 mg/kg 
isoniazid alone was not sufficient to cure M. tuberculosis infection at 3 weeks of 
treatment (female BALB/c) when started 24 days after infection by aerosol (Gonzalez-
Juarrero, Woolhiser et al. 2012). however, 25 mg/kg isoniazid alone cure M. tuberculosis 
infection at 4 weeks of treatment (female BALB/c) when treatment was started 24 hours 
after infection by aerosol (Byrne, Denkin et al. 2007). Isoniazid was provided in food at 
0.2% (w/w) and provided ad libitum to C57BL/6 wild-type mice for 35 days with an 
estimated 200 – 300 mg/kg/day dose based on estimated water consumption. Isoniazid 
was also provided in saline via oral gavage at a dose of 100 mg/kg/day. Neither of these 
doses resulted in hepatotoxicity (Metushi, Cai et al. 2014). Therefore, doses of up to and 
beyond 200 mg/kg/day of isoniazid as a monotherapy were tolerated without 
development of hepatotoxicity in C57BL/6 mice. IP injection (He, Guo et al. 2017) and 
oral gavage (Chen, Xu et al. 2011) of 150 mg/kg rifampicin and 75 mg/kg isoniazid 
produced a mildly hepatotoxic phenotype in mice that expressed hPXR. I then calculated 
the equivalent animal dose of 185 mg/kg based on a human dose of 15 mg/kg in humans. 
An appropriate dose would have been this calculated dose combined with a higher dose 
of rifampicin administered in a uniform, metered manner by oral gavage may have 







Liver Function Tests  
 
Quantification of plasma and sera LFTs was performed by the Veterinary 
Pathology Core Facility at St. Jude Children’s Research Hospital. Analyses were 
performed on the ABX Pentra instrument from Medline Industries (Northfield, IL). ALT 






Adherent cells were washed with PBS, trypsinized, centrifuged at 10,000 RPM 
for 3 minutes at 4oC. The supernatant is aspirated, the cells are re-suspended, and 
centrifuged again.  The supernatant is aspirated, and the cells are re-suspended in 100 μL 
RIPA from Thermo Fisher Scientific (Waltham, MA) and placed on ice for 30 minutes. 
Pierce RIPA (radio-immunoprecipitation assay) buffer (Thermo Fisher Scientific, 
Waltham, MA) was used to extract proteins from mouse liver and cell pellets. PhoSTOP 
(Roche, Branford, CT) phosphatase inhibitor and complete mini (Roche, Branford, CT) 
protease inhibitor was added to RIPA buffer. Then, the cells are sonicated on a Vibra-
Cell Ultrasonic Liquid Processor from Sonics and Materials, Inc. (Newtown, CT) and 
stored at -80oC until Western blot analysis is performed. The bicinchoninic acid (BCA) 
assay is performed with the Pierce BCA protein assay kit from Thermo Fisher Scientific 
(Waltham, MA) according to the manufacturer’s instructions. 2-10 μg protein is loaded 
unless otherwise noted. NuPAGE LDS loading buffer and reducing agent from Invitrogen 
(Carlsbad, CA) by was used to prepare protein lysates for electrophoresis. Protein gels 
are 4-12% Bis-Tris and are obtained pre-made from Invitrogen (Carlsbad, CA). The 
Kaleidoscope protein marker by Bio-Rad (Hercules, CA) is used to estimate protein size. 
Proteins are then transferred from the gel onto an iBlot nitrocellulose membrane from 
Invitrogen (Carlsbad, CA) by a dry transfer. Prior to probing with primary antibodies, 
membranes are incubated for 1 hour at room temperature in LiCor TBST blocking buffer 
(Lincoln, NE). After visualization membranes are stripped using NewBlot Nitro Stripping 
Buffer from Licor (Lincoln, NE) and anti-β-Actin primary antibody (a5441) from Sigma-
Aldrich (St. Louis, MO) overnight at 4oC and are then incubated with secondary antibody 





Lei Yang and Yan Lu from the High-Throughput Analytical Chemistry Core 
Facility at St. Jude Children’s Research Hospital performed the LC/MS and LC/MS/MS 
analysis. PIH and isoniazid were prepared as stock solutions of 10 mM in DMSO. 
Warfarin was used as the internal stardard at 4 mg/L in acetonitrile or methanol. The 
standard curve was prepared by added the stock solutions to the designated matrix (media 
for media samples and liver homogenate for liver samples). A linear response for PIH 
was observed from 1 to 1000 nM, for isoniazid 0.1 nM to 100 μM, and for the hydrazine 
adduct 0.1 nM to 200 μM. 
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Samples were extracted by adding MilliQ H2O at 4 μL per mg cell pellet or tissue. 
PIH and the hydrazine adduct was extracted by an additional 2-fold dilution with 
acetonitrile containing 4 mg/L warfarin per mg cell pellet or tissue or with methanol for 
isoniazid. Samples were mixed, centrifuged, and the supernatant was transferred for 
analysis with an equal volume of 0.1% formic acid in MilliQ H2O for PIH, direct 
injection for the hydrazine adduct, or with 9X volume MilliQ H2O for isoniazid. 
 
The Acquity UPLC system (Waters, Milford, MA) coupled to an Applied 
Biosystems-Sciex API 6500 (Foster City, CA) with a triple-quadrupole mass 
spectrometer using an electronic spray ionization interface in positive mode was used to 
analyze PIH and isoniazid. The ion source temperature was maintained at 500°C and 
450°C for PIH and isoniazid, the ion spray voltage was set at 5000°C and 3000°C for PIH 
and isoniazid, and multiple reaction monitoring mode was used for the quantitation of the 
analytes. The selected m/z transitions were 287 → 150 and 137.9 →79.1 for PIH and 
isoniazid, respectively. The m/z of the hydrazine adduct was 269. High purity nitrogen 
gas was used as collision-induced dissociation gas (setting 10 and 8), curtain gas (setting 
20), ion source gas 1 (setting 37 and 60), and ion source gas 2 (setting 60) for PIH and 
isoniazid, respectively.  
 
The chromatographic separation was performed on a Waters Acquity HSS C18 
column (2.1 mm × 50 mm, i.d., 1.8 μm particle size, Waters, Ireland) for PIH. Mobile 
phase A was consisting of 0.1% acetic acid in water and mobile phase B consisting of 
0.1% acetic acid in acetonitrile. The total flow rate was 0.7 mL/min. The UPLC column 
was maintained at 55°C and the gradient program over 2 minutes started at 95% A, 
maintaining for 0.2 minute, changed to 40% A over 0.8 min, to 95 % B over 0.5 minute, 
held for 0.2 minute, then to 95% A over 0.1 minute, and held for another 0.2 minute.  
The chromatographic separation was performed on a Waters HSS T3 C18 column 
(2.1 mm × 50 mm, i.d., 1.8 μm particle size, Waters, Ireland) for isoniazid. Mobile phase 
A was consisting of 10 mM ammonium bicarbonate in water and mobile phase B 
consisting of methanol. The total flow rate was 0.7 mL/min. The UPLC column was 
maintained at 55°C and the gradient program over 2 minutes started at 100% A, 
maintaining for 0.8 min, changed to 5% A over 0.4 min, held for 0.4 min, then to 99% A 
over 0.3 minute, and held for another 0.1 minute. 
 
Detection of the hydrazine adduct was achieved with an Acquity UPLC system 
coupled to an Acquity SQD Mass Spectrometer (Waters, Milford, MA, USA). The mass 
spectrometer was operated in positive-ion mode with electrospray ionization. The 
conditions were as follows: capillary voltage 3.5 kV, cone voltage 25 V, source 
temperature 150 °C, desolvation temperature 350 °C, desolvation gas 800 L/hr, cone gas 
85 L/hr. A full scan range from m/z = 100-1000 in 0.2 seconds was used to acquire MS 
data. Single ion recording mass spectrometry were used to determine the quantification of 
the samples. Chromatographic separation was performed on an Acquity UPLC BEH C18 
1.7 μm, 2.1 x 50 mm column (Waters Corporation, Milford, MA). The total flow rate was 
1.0 mL/min. The sample injection volume was 10 μL. The UPLC column was maintained 
at 60 °C and the gradient program started at 90% A (0.1% formic acid in MilliQ H2O), 
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changed to 70% A over 0.2 min, to 95 % B (0.1% formic acid in acetonitrile) over 1.4 
minutes, held for 0.35 minutes, then to 90% A over 0.05 minutes. 
 
Analysis of mass spectra was performed using the Analyst software (version 
1.6.3) for the data acquisition and processing of PIH and isoniazid. The MassLynx 
software (version 4.1) was used to analyze for the hydrazine adduct. A 1/x2 weighted 
least squares linear regression method was used to obtain the calibration curves of the 




Quantitative Real-Time Polymerase Chain Reaction 
 
Mice livers were collected and stored in RNAlater from Thermo Fisher (Waltham, 
ME) at 4oC for 24 hours, then the RNA later was removed and the samples were stored at 
-80oC until homogenization. Homogenization was performed using the Bullet Blender 
Storm 24 Homogenizer from Thomas Scientific (Swedesboro, New Jersey). Cell cultures 
were trypsinized and collected following treatment. Extraction of whole RNA is 
performed with the Maxwell 16 LEV SimplyRNA Tissue Kit from Promega (Madison, 
WI) on the Maxwell 16 Instrument by Promega according to manufacturer’s instructions. 
RNA was measured by the NanoDrop 8000 UV-Vis Spectrophotometer from Thermo 
Fisher. cDNA is synthesized using the SuperScript VILO kit from Invitrogen (Carlsbad, 
CA). Taqman reagents from Invitrogen (Carlsbad, CA) and the Applied Biosystems 
(Foster City, CA) 7500 Fast Real-Time PCR system were used to perform qRT-PCR. The 
ΔΔCT method was used to fold change in expression to the control group of each mouse 
strain (mouse house-keeping gene used: Gapdh) or vehicle control in cell culture (human 
house-keeping gene used: 18S) treatments. Gene expression was normalized to the 
species-specific house-keeping gene, which did not vary expression by treatment. Data 
are represented as mRNA fold change using the ΔΔCT method relative to vehicle control 
treatments. Experiments were performed in triplicated with analysis of each sample 
performed in triplicate.The following Taqman probes were used: CYP3A4 
(Hs00604506_m1), ALAS1 (Hs00963534_m1), Alas1 (Mm01235914_m1), Fech 
(Mm00500394_m1), FECH (Hs01555261_m1), Cyp3a11 (Mm00731567), hPXR 
(Hs01114267_m1), 18S (Hs03928990_g1), Gapdh (Mm99999915_g1), ABCG2 
(Hs01053790_m1), Abcg2 (mM00496364_m1), 
 
 
Hydrazine Adduct Formation 
 
Hydrazine has a low molecular weight and therefore required derivatization for 
quantification via LC/MS/MS. This derivatization was carried out by Anne Edwards, 
Ph.D. from the Lab of Richard Lee, Ph.D. with p-anisaldehyde in a 2:1 reaction with 
hydrazine (Figure 2-3) similar to a previous report with modifications (Isenberg, Carter 
et al. 2016). For in vitro samples, 300 μL of each sample was acidified with 2 μL of 18 N 
HCl followed by the addition of 1 μL of p-anisaldehyde (21.8 mM).  The mixtures were 





Figure 2-3. Synthesis of the hydrazine adduct quantified in this study.  
 
Schema for the generation of the hydrazine and p-anisaldehyde adduct for use in the 




vivo samples, 100 μL of the in vivo samples were acidified with 2 μL of 18 N or M HCl 
followed by the addition of 1 μL of p-anisaldehyde for a final concentration of 66.5mM.  
Samples with limited volume were diluted 1:1 or 9:1 then acidified followed by the 
addition of1 μL p-anisaldehyde.  After 24 hours incubation at room temperature the 
samples were analyzed by LC/MS. To generate the standard curve, a solution of 7.68 mM 
p-anisaldedhyde was added to a solution of 3.84 mM hydrazine sulfate in 1:1 
water/MeOH. The reaction was stirred for 2 hours and resultant yellow precipitate was 
filtered.  The precipitate was dried under vacuum to produce the solid hydrazine adduct.  
 
 
Siderophore Detection Assay 
 
The chrome azurol S (CAS) assay was used to study the iron-binding capacity of 
solutions. The liquid CAS assay was based on the CAS-agar plate assay reported by 
Schwyn and Neilands and modified by Machuca and Milagres with variations (Schwyn 
and Neilands 1987, Machuca and Milagres 2003). Chelex-100 treated water was prepared 
according to manufacturer instructions and used to prepare assay buffer. Samples were 
incubated in CAS shuttle solution for 60 minutes at RT, then absorbance was read at 630 
nm. Normalized absorbance values were obtained by dividing the absorbance of samples 
by a blank sample containing either cell culture medium, PBS for biochemical solution, 
or with Chelex-treated water for deferoxamine and PIH solutions. 
 
 
Cell Viability Assays 
 
 
CellTiterGlo ATP Detection 
 
The CellTiterGlo assay from Promega (Madison, WI) was used to detect ATP 
levels (Figure 2-4) according to manufacturer’s instructions. 10 μM staurosporine 
robustly reduced ATP at all time points observed (greater than 24 hours). Pre-assay 
optimization of plating density found that the optimal conditions for HepG2/C3A were in 
10%FBS MEM at a density of 2,000 cells/well (in linear range of growth throughout 
experimental time period and linear range of luminescence) cells/well in white bottomed 
96-well plates. Raw luminescence values were subtracted by cell free blank cell culture 




Caspase 3/7 Glo 
 
To measure caspase 3/7 activity (Figure 2-5), the Caspase 3/7 Glo assay kit from 
Promega (Madison, WI) was used according to manufacturer’s instructions. For short 
term experiments 10 μM staurosporine was used as a positive control, whereas for longer 
term experiments 0.1 μM staurosporine was used as a positive control. 10 μM 





Figure 2-4. Overview of the CellTiterGlo assay. 
 






Figure 2-5. Overview of the Caspase 3/7 Glo assay. 
 
Caspase 3/7 cleaves Z-DEVD sequence off of Z-DEVD-aminoluciferin generating 




to 12-24 hours, but a decrease in caspase 3/7 activity was observed after 24 hours at this 
dose due to cell death. 0.1 μM staurosporine did not induce caspase 3/7 activity after the 
first 24 hours hours, but treatment over 24 hours lead to robust, sustained induction of 
caspase 3/7 activity. Cell number and caspase 3/7 glo incubation times were also 
optimized before experimental samples were evaluated. Caspase 3/7 glo was performed 
on HepG2/C3A in 10% FBS MEM, at 2,000 cells/well in white bottomed 96-well plates. 
Raw luminescence values were subtracted by cell free blank cell culture media and 





Phase-contrast imaging was performed on the Incucyte ZOOM live-cell imaging 
system (Essen BioScience, Ann Arbor, MI). as described previously (Oladimeji, Lin et al. 
2017) with variations. Cells were plated at a density of 600,000 cells/well (20% 
confluence in 6-well plate) in 10%.FBS MEM 24 hours before the addition of indicated 
compounds. The cell density was evaluated every 12 hours. Data are represented as the 
fold-change in confluence compared to a measurement taken immediately after 





Lei Yang performed the solubility assay on the Biomek FX ADME-TOX 
workstation from Beckman Coulter (Fullerton, CA) to determine the solubility of 
PPIXNa2 in PBS. To assess the solubility of PPIXNa2 and in combination with 
rifampicin, isoniazid, or a combination of both, PPIXNa2 was added to water to make the 
final concentration 100 μM, vortexed, then filtered using a 96-well filter plate from pION 
(Woburn, MA). The samples were then analyzed by UV spectrometry (230-500 nm). For 
standard curves, compounds were diluted 600-fold in 1:1 PBS buffer and 1-propanol 
(v/v). Concentrations were performed by μSOL Evolution software and compounds were 
tested in triplicate. 
 
 
ABCG2/Abcg2 Transport Assays 
 
 
Pheophorbide A Transport Assay 
 
Evaluation of ABCG2/Abcg2 inhibition by isoniazid was carried out similarly to 
previous reports with variations (To, Poon et al. 2015). Wild type or Abcg2 knockout 
mouse embryonic fibroblasts were generously provided by the lab of John Schuetz. HEK 
293 cells were transfected with pcDNA3.1 empty vector or with a recombinant ABCG2 
for 24 hours before pheophorbide A, ALA, and or ABCG2/Abcg2 inhibitor treatment. 
Cells were treated in DMEM with 10% FBS and without antibiotics for 30 minutes at 
37oC with 1 μM pheophorbide a and with 10 μM FTC, 10 μM Ko143, or 100 μM 
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isoniazid. Cells were then washed with cold DMEM and incubated for 2 hours at 37oC in 
the presence of the indicated inhibitor or potential inhibitor without pheophorbide A. 
Cells were then washed in cold DMEM, filtered, and kept on ice in the dark until 
analysis. 500,000 cells total, 1-2 million cells per mL were allocated per sample. 
 
 
Flow Cytometry Analysis  
 
Flow cytometry analysis was performed by the Flow Cytometry and Cell Sorting 
Core Facility at St. Jude Children’s Research Hospital. Samples were analyzed on a 
LSRFortessa Cell Analyzer and FACSDiva software (BD Biosciences). Pheophorbide A 
fluorescence was detected with a 488 nm argon laser and a 670 nm bandpass filter. Over 
100,000 events were collected with at least 10,000 events analyzed after cell debris were 




Aminolevulinic Acid Treatment for PPIX Transport 
 
Cells were trypsinized, washed, and while still in solution, incubated with ALA in 
the presence or absence of indicated test compound or ABCG2 inhibitor for 2 hours. After 
which the media was collected and combined with a 1:1 solution of 0.9M ClO4 in MeOH. 
Cells were then washed with cold PBS and lysed with 200 μL/well of 0.1% SDS for 1 
hour on ice. Following lysis, 800 μL/well of 0.9M ClO4 in MeOH was added to lysate 
and lysate was centrifuged at 10,000 RPM for 10 minutes to remove cell debris. 
 
 
CLARIOstar Analysis of PPIX Content 
 
The CLARIOstar microplate fluorescence reader system (BMG Labtech, 
Ortenberg, Germany) was used to quantify the fluorescence of cell and media 
preparations. This method is a variation of an original assay first reported by Granick and 
Levere in 1965 (Granick and Levere 1965), modified by Bloomer in 1997 (Bloomer 
1997) and subsequently by Lin et al., and Ogino et al., in 2013 (Lin, Chang et al. 2013) 
and 2011 (Ogino, Kobuchi et al. 2011) respectively. The supernatant of the lysate was 
added to 96-well non-tissue-culture treated flat solid bottomed, black sided microplates 
(Corning, Corning, NY) containing 1:1 supernatant and 0.9M ClO4 in MeOH for 
imaging. Measuring the emission at 640 nm following excitation at 405 nm would 
quantify multiple species of PPIX (Figure 2-6) and a signal is observed here following 
ALA treatment of HepG2/C3A cells (Figure 2-7). A standard curve was generated using 
PPIX for each plate and absolute concentrations were calculated based on relative 
fluorescence values obtained by measuring emission at 640 nm following excitation at 
405 nm of a non-treated cell lysate spiked with various concentrations of PPIX based on 
a method described previously (Granick and Levere 1965, Bloomer 1997, Ogino, 














Figure 2-7. Emission spectrum of HepG2/C3A cell lysate treated with 4 mM ALA 





Parallel Artificial Membrane Permeability Assay 
 
The parallel artificial membrane permeability assay (PAMPA) was performed as 
described previously by Lei Yang of the High-Throughput Analytical Chemistry Core 
Facility (Yu, Wang et al. 2015). A 96-well filter plate from EMD Millipore (IVPH, 125 
μm filter, 0.45 μm pore) and a 96-well microtiter plate formed a “sandwich” structure 
when wetted with 2% (w/v) hexadodecane (Figure 2-8). 0.3 mL of drug solution at 100 
μM was added to the donor wells. The filter plate was placed on top of the donor plate. 
The wells of the acceptor plate were filled with buffer and placed on top of the filter. 
After incubation for 16 hours at 25oC, the plates were separated and the concentrations of 




PPIX Binding Assay 
 
The PPIX fluorescence binding assay was performed as previously reported 
(Lyoumi, Abitbol et al. 2011). To compare in vitro binding affinities of various 
antitubercular drugs, bile acids, and phosphatidyl choline these compounds were added to 
a 20 nM solution of PPIX in 1 M imidazole, 0.9% NaCl, at pH 8.2 at similar 
concentrations they are found in the bile. The concentrations of each bile acid constituent 
was based on their in vivo concentrations (0.1 mM phosphatidyl choline, 100 μg/mL 
BSA, 2 mM of each bile acid, 0.4 mM of rifampicin, and 4 mM isoniazid). Solutions 
were prepared of each constituent with PPIX or the constituent alone and protected from 
light and placed in 96-well black plate and read by a Clariostar fluorescent plate reader. 
Fluorescence intensity of the emission at 634 nm after excitation at 408 nm was read. The 
ratio of the fluorescence intensities of the bile constituent and PPIX to the bile constituent 





Data from three independent experiments were pooled and analyzed as indicated 
in figure legends using GraphPad Prism 7.0 software. Significant changes re considered 
to be p-values of less than 0.05. Results are expressed as the mean +/- standard error of 
measurement (SEM). 2-way ANOVA followed by Tukey’s post-hoc analysis was used to 
compare group means for qRT-PCR analysis. 1-way ANOVA followed by Dunnett’s 
post-hoc analysis was used to compare group means for Western blot analysis. False 





Proteomics profiling and initial analysis were carried out by Kiran Kodali of the 
Proteomics and Mass Spectrometry Facility at St. Jude Children’s Research Hospital. 





Figure 2-8. PAMPA overview. 
 
Compounds are added to one side of a hexadecane membrane then the media on the other 










and mPxr -/- were treated for 6 months with 300 mg/kg rifampicin in chow and 1.2 g/L 
isoniazid in water. After 6 months, livers were collected and flash frozen. Livers were 
then lysed (50 mM HEPES, pH 8.5, 8 M urea and 0.5% sodium deoxycholate), and 100 
μg of protein was digested with LysC from Wako Chemicals (Richmond, VA) in the 
presence of 1,4 -dithiothreitol at an enzyme-to-substrate ration of 1:100 for 2 hours as 
described previously (Pagala, High et al. 2015). The samples ar then diluted to a final 2 
M urea concentration using 50 mM HEPES, pH 8.5. The samples are further digested by 
trypsin from Promega (Madison, WI) at an enzyme-to-substrate ratio of 1:50 for 3 hours. 
The resulting peptides are reduced by adding 1 mM 1,4 –dithiothreitol for 30 minutes at 
RT and are then alkylated with 10 mM iodoacetamide for 30 minutes at RT in the dark. 
The reaction is quenched by adding trifluoroacetic acid. This acidified peptide mixture is 
desalted by C18 cartridges from Harvard Apparatus (Holliston, MA) The desalted eluent 
is dried and re-suspended in 50 mM HEPES, pH 8.5. 
 
Samples are labeled with Tandem Mass Tags (TMT 11-plex) from Thermo Fisher 
(Waltham, MA) according to the recommendations of the manufacturers. After labeling 
the samples are combined, desalted, and fractionated on an off-line HPLC (Agilent 1220) 
from Agilent Technologies (Santa Clara, CA). 90 two minute fractions were collected 
over a 180 minute gradient. The fractions are dried then re-suspended in 5% formic acid 
and analyzed by acidic pH reverse-phase LC/MS/MS. Samples are fractionated on a 
nanoscale capillary reverse-phase C18 column by a nanoAcquity HPLC from Waters 
Corporation (Millford, MA) by a 120 minute gradient. The eluent is ionized by 
electrospray ionization and detected by an in-line Orbitrap Fusion mass spectrometer 
from Thermo Fisher (Richmond, VA). Mass spectrometry is performed in data-dependent 
mode with a survey scan (60,000 resolution, 1 X 106 AGC target and 150 ms maximal 
ion time) and 20 MS/MS high resolution scans (60,000 resolution, 1 X 106 AGC target 
and 150 ms maximal ion time, 38 HCD normalized collision energy, 1 m/z isolation 
window, and 20 s dynamic exclusion).  
 
Raw mass spectra were processed by the JUMP program as described previously 
(Wang, Li et al. 2014). The resultant data was compared to the UniProt mouse database 
and concatenated with a reversed protein sequence decoy database. Searches were 
performed using a mass tolerance of 25 ppm for precursor ions and 15 ppm mass 
tolerance for fragment ions, fully tryptic restriction with two maximum missed cleavages, 
three maximum modification sites, and the assignment of α, β, and γ ions. TMT tags on 
lysine residues and N-termini (+229.162932 Da) and carbamidomethylation of cysteine 
residues (+57.021 Da) are used for static modifications and methionine oxidation 
(+15.99492 Da) is considered as a dynamic modification. Mass spectra are filtered by 
mass accuracy and matching scores to reduce the FDR to approximately 1%. Proteins are 
quantified by summarizing reporter ion counts across all matched peptide spectrums 
using the JUMP software. Analysis was performed by Timothy Shaw from the 
Computational Biology Department and Proteomics Core Facility at St. Jude Children’s 




CHAPTER 3.    RESULTS 
 
 





The physiochemical properties of PPIX may contribute to toxicity by binding to 
bile acid components and precipitating into the bile canaliculi. This may block bile ducts 
and lead to a cholestatic pattern of toxicity. Conversely, intracellular accumulation of 
PPIX is associated with a hepatocellular subtype of liver injury. To recapitulate the 
cholestatic hepatotoxicity phenotype observed previously (Li, Lu et al. 2013) that is 
believed to be mediated by PPIX, it is necessary to demonstrate that (1) PPIX is insoluble 
at supra-physiologic levels that may be associated with heme biosynthesis disruption, (2) 
PPIX binds to bile salts, phospholipids, albumin, and this binding may be affected by 
rifampicin and isoniazid, and that (3) exogenous PPIX is toxic. The proposed mechanism 
of the toxicity of PPIX presumes that it is toxic when in an extracellular compartment 
(Lyoumi, Abitbol et al. 2011). PPIX is hepatotoxic when its level rises high enough in the 
bile canaliculi, PPIX precipitates out of solution forming aggregates with bile 
constituents resulting in bile plugs. The bile plugs observed previously (Davies, 
Schuurman et al. 2005, Lyoumi, Abitbol et al. 2011, Li, Lu et al. 2013) may be due to 
PPIX if PPIX is insoluble at likely concentrations achievable by heme biosynthesis 
disruption by isoniazid and the un-defined role of rifampicin. Therefore, confirming these 
properties of PPIX is necessary before beginning in vivo studies predicated on PPIX 
exerting a hepatotoxic effect via these properties. 
 
 
Solubility of PPIX 
 
A 100 μM solution of the disodium salt of PPIX was prepared in water, vortexed, 
and filtered. The sample was then analyzed by UV spectrometry and the concentration of 
PPIX was 0.3 μM (Figure 3-1). BALB/cm1Pas mice have liver PPIX levels of 0.02 μM, 
whereas C57BL/6 mice have liver PPIX levels of 0.24 μM (Lyoumi, Abitbol et al. 2011). 
Interactions with less soluble molecules and changes in bile pH may further lower PPIX 
solubility (Davies, Schuurman et al. 2005, Lyoumi, Abitbol et al. 2011). In FVB/NJ mice, 
basal PPIX liver levels were found to be 0.35 μM with a 3-fold increase after 14 days of 
400 mg/L isoniazid treatment that did not result in toxicity (Sachar, Li et al. 2016). The 
same group previously reported a 60-fold increase in bile PPIX levels in hPXR (C57BL/6 
strain) mice (the authors did not specify concentration) that was associated with 
pathological change in liver tests and in the observation of bile plugs on histological 
examination (Li, Lu et al. 2013). During heme synthesis, PPIX would be expected to be 
relatively transient and to be formed immediately into heme by FECH. Therefore, with a 
relatively low solubility compared to pharmaceuticals (e.g. albendazole, soluble at 15 
μM) excreted into the bile, changes in PPIX solubility may lead to precipitation and 





Figure 3-1. The solubility of PPIXNa2 in PBS. 
 
LC/MS/MS analysis of filtrate from saturated PBS solution of PPIXNa2. Data are 




of PPIX, comparison to heme, and in the presence of bile acid constituents would further 
elucidate the conditions in which the solubility of PPIX would contribute to the 
pathogenesis of liver injury. 
 
 
Permeability of PPIX 
 
The permeability of the disodium salt of PPIX was compared to various 
pharmaceuticals. The permeability of these compounds was measured and found to be 
about 1500 Pe (106 cm/s) for hydrophobic non-polar verapamil, 100 Pe (106 cm/s) for 
carbamazepine, 150 Pe (106 cm/s) for albendazole, and 0 Pe (106 cm/s) for ranitidine. The 
permeability of PPIXNa2 was 17 Pe (106 cm/s) (Figure 3-2), much lower than 
albendazole and carbamazepine. Less polar species of PPIX would be expected to be less 
permeable and future studies may elucidate the dependence of these species on 
transporter proteins such as ABCG2 and the exact nature of the elevated PPIX detected 
following antitubercular therapy in mice (Li, Lu et al. 2013, Sachar, Li et al. 2016). Mass 
spectrometric analysis would not be able to differentiate against PPIX, PPIXNa2, or many 
other species of PPIX due to the loss of ions in solution. Therefore, further elucidation of 
the ADME properties between these molecules would help to identify the species 
involved in accumulation.  
 
 
Isoniazid Does Not Inhibit the ABCG2/Abcg2-Mediated Transport of Pheophorbide 
A 
 
ABCG2 effluxes PPIX from hepatocytes into the bile, leading to toxicity (Aust, 
Obrist et al. 2004, Davies, Schuurman et al. 2005, Lyoumi, Abitbol et al. 2011, He, Guo 
et al. 2017). However, increased PPIX retention by decreased efflux does contribute to 
toxicity in ALL and hematopoietic cells (Stewart, Leggas et al. 2004, Krishnamurthy and 
Schuetz 2011, Morfouace, Cheepala et al. 2015). Pheophorbide A (chlorophyll 
breakdown product) is a specific substrate for ABCG2/Abcg2 discovered when Abcg2 -/- 
mice were fed alfalfa developed phototoxicity. Flow cytometric analysis of pheophorbide 
A is used as the gold standard in determining the effect of potential inhibitors on 
ABCG2/Abcg2 activity. Therefore, we tested the potential for ABCG2 inhibition by 
measuring pheophorbide A efflux in HEK 293 cells ectopically overexpressing ABCG2. 
To test the effect of isoniazid on pheophorbide A transport mediated by Abcg2, mouse 
embryonic fibroblasts were used. The specific ABCG2 inhibitors fumitremorgin C (FTC) 
and Ko143 inhibited ABCG2- and Abcg2-dependent efflux of pheophorbide A, but 
isoniazid expectedly did not (Figure 3-3A and B).   
 
 
Isoniazid Does Not Inhibit the ABCG2/Abcg2-Mediated Transport of PPIX 
 
The mechanism of PPIX transport by ABCG2/Abcg2 differs from Pheophorbide A 






Figure 3-2. The permeability of PPIXNa2 in PAMPA. 
 






Figure 3-3. Isoniazid does not inhibit ABCG2- or Abcg2-mediated transport of 
pheophorbide A or PPIX. 
 
The potential for inhibition by isoniazid was evaluated in HEK 293 ectopically over-
expressing human ABCG2-mediated transport of pheophorbide A (A) and PPIX (C). 
MEF cells expressing mouse Abcg2 were evaluated for potential inhibition by isoniazid 
in the transport of pheophorbide A (B) and PPIX (D). Data are expressed as the mean ± 
SEM of separate experiments. 1-way ANOVA followed by Dunnett’s post-hoc analysis 




enable transport of additional PPIX molecules (Desuzinges-Mandon, Arnaud et al. 2010). 
Therefore, testing pheophorbide A alone would not answer the question of whether PPIX 
transport by ABCG2/Abcg2 is inhibited by isoniazid. The same cell models used to 
evaluate pheophorbide A transport were used to evaluate PPIX transport subsequent to 
ALA treatment to induce intracellular PPIX formation. After induction of PPIX 
accumulation by ALA, cells were treated with isoniazid and FTC. FTC inhibited the 
ABCG2- and Abcg2-mediated transport of PPIX (Figure 3-3C and Figure 3-3D). 
 
 
PPIX Binds to Phospholipids and Bile Salts  
 
In instances of hepatotoxicity associated with PPIX treatment, disruption of lipid 
and bile acid homeostasis and deposits of porphyrins and bile acid constituents are found 
on histopathological examination (Davies, Schuurman et al. 2005, Lyoumi, Abitbol et al. 
2011, Li, Lu et al. 2013). To determine if the interactions of PPIX with bile acids, 
albumin and phosphatidyl choline was affected by the presence of rifampicin and 
isoniazid, the binding assay employed previously was used (Lyoumi, Abitbol et al. 2011). 
PPIX did not interact with isoniazid, taurocholic acid, hexadecenoic (palmitic) acid, or 
deoxycholic acid, but did interact with rifampicin, albumin, phosphatidyl choline, and 
lithocholic acid. Isoniazid and rifampicin affect the interaction of PPIX with albumin and 
phosphatidyl choline (Figure 3-4). Further studies would be required to elucidate 




Exogenous PPIXNa2 Decreases ATP Levels 
 
PPIXNa2 is associated with more severe hepatotoxicity when not retained in 
Kupffer cells and hepatocytes (Lyoumi, Abitbol et al. 2011). Considering this report, the 
low membrane permeability of PPIXNa2, and lack of identified import protein, PPIXNa2 
may be toxic in an extracellular space. To evaluate whether exogenous PPIXNa2 could 
reduce ATP levels in HepG2/C3A, cells were added to culture plates for 24 hours before 
being treated with PPIXNa2. At day 2, there was a slight decrease in ATP (p < 0.05) due 
to 40 μM PPIXNa2 (Figure 3-5). At day 3, this became a 40% decrease due to 40 μM 
and 10% decrease (p < 0.001) due to 20 μM. At day 4, 40 μM and 20 μM decrease ATP 
levels by 60 % (p < 0.001) and 40% by 10 μM (p < 0.05). The media was not refreshed 
after dosing on day 0 when the base-line ATP levels were measured and after day 4, the 
ATP levels of DMSO treated HepG2/C3A cells were no longer increasing, suggesting 
that cells are no longer growing. Beginning on day 5, PPIXNa2 showed a decrease in 
ATP levels above 156 nM PPIXNa2 by at least 20% compared to DMSO treated cells (p 
< 0.001), a 70% decrease at 10 μM (p< 0.001), and an 80% decrease at 40 μM PPIXNa2 
(p< 0.001). At day 6, 156 nM PPIXNa2 decreased ATP levels by 50% (p< 0.001) and a 
90% decrease (p< 0.001) at 10 μM. This persists through day 7 with an overall decrease 
in ATP levels. Higher doses of PPIXNa2 (in the micromolar range) may cause toxicity 
earlier and in nutrient rich conditions, where lower doses (in the nanomolar range) may 





Figure 3-4. PPIXNa2 binding assay. 
 
Evaluation of PPIX binding to phospholipids (A) and bile salts (B). Data are represented 
as the mean of the ratio of the fluorescence intensity of indicated compounds with PPIX 
to wells of the compounds without PPIX. Data are represented as the mean ± SEM. 1-
way ANOVA followed by Dunnett’s post-hoc analysis was used to compare group 






Figure 3-5. PPIXNa2 decreases cellular ATP levels. 
 
Evaluation of relative ATP levels after single treatment of HepG2/C3A cells with various 
doses of PPIX at 1-3 days (A) and 4-7 days (B). Data are represented as the mean ± SEM 
of the CellTiterGlo luminescence at the indicated time point divided by the luminescence 
immediately after dosing. 1-way ANOVA followed by Dunnett’s post-hoc analysis was 




Exogenous PPIXNa2 Decreases Cell Area 
 
To confirm the decrease in ATP due to PPIX detected by the CellTiterGlo assay 
system and to allow daily dosing and refreshening of media as well as extending the 
length of exposure to PPIXNa2, phase-contrast imaging was used to evaluate whether 
there would be a commensurate decrease in cell area growth. As low as 313 nM PPIXNa2 
significantly (p< 0.005) decreased the growth of cell area as measured by phase contrast 
imaging (Figure 3-6). At 625 nM PPIXNa2 or higher the cell area growth was 
significantly (p <0.001) decreased. 10 μM staurosporine was used as the positive control. 
Further evaluation would elucidate whether the effect of exogenous PPIXNa2 is merely 
growth suppression or directly cytotoxic. 
 
 
Exogenous PPIX Increases Caspase 3/7 Activity 
 
Exogenous application of HepG2/C3A resulted in an ATP decrease beginning at 3 
days due to 40 μM PPIXNa2. Following this observation. HepG2/C3A cells were then 
evaluated for caspase 3/7 activation using the Caspase 3/7 Glo Assay from Promega 
(Madison, WI). HepG2/C3A treated for short durations less than 3 days do not display 
caspase 3/7 activity due to PPIXNa2 treatment. However, statistically significant 









After establishing that exogenous PPIX is cytotoxic, precipitates at relatively low 
concentrations, and may bind to bile constituents and may be associated with or even 
causative of the bile plugs observed in vivo, the disruption of the heme biosynthesis 
pathway by isoniazid was subsequently investigated. This investigation focused on the 
role of isoniazid based on a previous report (Sachar, Li et al. 2016) and my data that 
confirmed this report (Figure 1-7). The accumulation of PIH and hydrazine in patients 
taking isoniazid has been reported previously. (Li, Miao et al. 2011, Isenberg, Carter et 
al. 2016) PIH has been reported to chelate iron and FECH is down-regulated in low iron 
conditions. (Taketani, Adachi et al. 2000, Crooks, Ghosh et al. 2010) Hydrazine has been 
reported to N-alkylate heme moieties (Ator, David et al. 1987, Wojciechowski and de 
Montellano 2007, Ascenzi, Coletta et al. 2013) and heme suppresses ALAS1 expression at 
multiple levels. (Srivastava, Borthwick et al. 1983, Kolluri, Sadlon et al. 2005, Zheng, 
Shan et al. 2008)  Isoniazid up-regulates mouse Alas1 protein and down-regulates Fech 
protein in mouse liver. (Sachar, Li et al. 2016) These effects of isoniazid on heme 
biosynthesis enzymes was not previously reported on the human proteins, nor was it 
determined if the effects observed in mouse systems were due to isoniazid or a metabolite 





Figure 3-6. PPIXNa2 treatment decreases cell area growth. 
 
Phase contrast imaging of HepG2/C3A cells after single treatment of PPIX. Data 
quantified by Incucyte ZOOM instrument (A) and representative images (B) are shown. 
Data are represented as the mean ± SEM of the confluence at the indicated time divided 
by the confluence taken immediately after the first dose of PPIXNa2. 1-way ANOVA 
followed by Dunnett’s post-hoc analysis was used to compare group means. 






Figure 3-7. PPIXNa2 increases Caspase 3/7 activity. 
 
Data are represented as the mean ± SEM of the fold change of Caspase 3/7 Glo 
luminescence at 72 hours compared to a time 0 measurement conducted immediately 
after dosing. 1-way ANOVA followed by Dunnett’s post-hoc analysis was used to 





demonstrate the enzyme-independent formation of PIH from multiple vitamin B6 
analogues and isoniazid, (2) the iron-dependent down-regulation of FECH, and (3) the 
hydrazine-mediated up-regulation of ALAS1. 
 
 
Isoniazid Decreases Human FECH Protein Levels and Increases Human ALAS1 
Protein and mRNA Levels, but Does Not Affect FECH mRNA Levels  
 
A previous study (Sachar, Li et al. 2016) reported the regulation of Alas1 and 
Fech by isoniazid in mice, we also observed this decrease in Fech protein and increase in 
Alas1 protein in C57BL/6 mice livers at 6 weeks of treatment with isoniazid (400 mg/L 
in drinking water as described for in vivo study 1) and confirm that these changes occur 
independently of hPXR and are not modified by the co-administration of rifampicin (100 
mg/kg in chow). (Figure 3-8) These changes would be expected to result in the increase 
of PPIX seen due to isoniazid alone (Sachar, Li et al. 2016) and a portion the PPIX 
increase associated with hepatotoxicity of hPXR mice treated with rifampicin and 
isoniazid concurrently (Li, Lu et al. 2013).Therefore, we first tested the effect of 
isoniazid on human ALAS1 and FECH and found similar changes in a much shorter time 
period and at lower doses than has been reported to cause toxicity in HepG2/C3A (Nicod, 
Viollon et al. 1997, Schwab and Tuschl 2003, Bhadauria, Mishra et al. 2010). Isoniazid 
treatment of HepG2/C3A and PHH for 72 hours results in a 50% decrease of FECH 
protein in PHH (Figure 3-9A; p<0.01) at doses higher than 50 μM (Figure 3-9B; 
p<0.05) and a decrease of 30% in HepG2/C3A (Figure 3-9D; p<0.01) but not of FECH 
mRNA (Figure 3-9C and E). This is similar to other reports of iron-dependent FECH 
protein down-regulation. Bone marrow aspirates of Irp2 -/- mice have been reported to 
display 50% of the Fech activity of wild-type mice (Crooks, Ghosh et al. 2010). This also 
corresponds to the 60% decrease observed of FECH activity after administration, of the 
N-donor, S-nitroso-N-acetylpenicillamine, to cell lysates overexpressing human 
recombinant FECH (Furukawa, Kohno et al. 1995). Treatment of FVB/NJ mice with 
isoniazid for 14 days produced a 60% decrease in Fech protein and 3- to 4-fold increase 
in Alas1 protein (Sachar, Li et al. 2016). Isoniazid up-regulates the protein levels of 
ALAS1 3-fold at 800 μM (Figure 3-10B; p<0.01), but does not up-regulate the mRNA 
levels in PHH (Figure 3-10C). Isoniazid does not up-regulate the protein (Figure 3-10D) 
and mRNA (Figure 3-10E) levels of ALAS1 in HepG2/C3A at 800 μM. 
 
 
Iron Levels Modulate FECH Protein Levels 
 
Previous studies (Furukawa, Kohno et al. 1995, Taketani, Adachi et al. 2000, 
Crooks, Ghosh et al. 2010) have established the relationship between the [2Fe-2S] 
containing FECH and iron levels in murine erythroleukemia cells, macrophage cell line 
RAW 264.7, and K562 cells. These studies have shown that FECH is down-regulated in 
iron-limiting conditions and is up-regulated in iron-replete conditions. However, this has 
not been reported in the liver hepatoma cell line, HepG2/C3A. HepG2 is commonly used 





Figure 3-8. In vivo expression of Fech and Alas1 in mouse liver. 
 
Western blot analysis of Fech (A) and Alas1 (B) in C57BL6 mouse liver after 6 weeks 






Figure 3-9. Isoniazid decreases human FECH protein. 
 
Western blot analysis of FECH in primary human hepatocytes treated with 10 μM 
rifampicin, 10 μM SPA70, 200 μM isoniazid, or a combination of these drugs (A), and a 
dose response of isoniazid for 72 hours (B). qRT-PCR analysis of the expression of 
FECH in A (C). Western blot analysis of FECH in HepG2/C3A treated with isoniazid for 
72 hours (D) and qRT-PCR analysis (E). The mean fold change in expression ± SEM are 
represented for the PHH. The mean fold change in expression of 3 biological repeats each 
with 3 technical repeats are represented for HepG2/C3A. 2-way ANOVA followed by 
Tukey’s post-hoc analysis was used to compare group means for qRT-PCR analysis. 1-
way ANOVA followed by Dunnett’s post-hoc analysis was used to compare group means 






Figure 3-10. Isoniazid increases human ALAS1 protein. 
 
Western blot analysis of ALAS1 in primary human hepatocytes treated with 10 μM 
rifampicin, 10 μM SPA70, 200 μM isoniazid, or a combination of these drugs (A), and a 
dose response of isoniazid for 72 hours (B). qRT-PCR analysis of the expression of 
ALAS1 in A (C). Western blot analysis of ALAS1 in HepG2/C3A treated with isoniazid 
for 72 hours (D) and qRT-PCR analysis (E). The mean fold change in expression ± SEM 
are represented for the PHH. The mean fold change in expression of 3 biological repeats 
are represented for HepG2/C3A. HepG2/C3A. 2-way ANOVA followed by Tukey’s 
post-hoc analysis was used to compare group means for qRT-PCR analysis. 1-way 
ANOVA followed by Dunnett’s post-hoc analysis was used to compare group means for 
Western blot analysis.  ****p<0.0001; ***p<0.001, **p<0.01, *p<0.05 
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rifampicin and isoniazid at millimolar concentrations (Tostmann, Boeree et al. 2008, 
Singh, Sasi et al. 2011, Shih, Pai et al. 2013, Elmorsy, Attalla et al. 2017). Additionally, 
due to the presence of iron in the FBS added to cell culture medium, the conditions 
required for iron-mediated rescue by exogenous iron administration needed to be 
established in the media conditions of HepG2/C3A. The iron-specific chelator, 4.7 μM 
deferoxamine, decreased protein levels by 60% in HepG2/C3A at higher than 18.8 μM 
(p<0.0001), by 40% at 4.7 μM (p<0.0001), and by 10% at 1.2 μM (p<0.01), after 24 
hours of treatment in 10% FBS (2.6 μM iron; Figure 3-11A). FeCl3 administration of as 
little as 0.1 μM in 1% FBS (0.26 μM iron; Figure 3-11B) increased FECH protein levels 
2-fold up to 3-fold at 1 μM in HepG2/C3A after 24 hours of treatment (p<0.0001). FECH 
was not increased due to additional iron administration in 10% FBS (2.6 μM iron; data 
not shown). The 40% (p<0.05) decrease in FECH protein expression by deferoxamine is 
rescued with increasing amounts of exogenously administrated FeCl3 where there is no 
significant difference in FECH expression between the combination of 4.7 μM 
deferoxamine and 0.1 to 100 μM FeCl3 compared to the vehicle control treatment. There 
is a significant (p<0.0001) difference between 4.7 μM deferoxamine and the combination 
of 4.7 μM deferoxamine and 100 μM FeCl3 (Figure 3-11C). To derive the media 
conditions where iron-limiting conditions can decrease FECH protein levels and where 
this can be rescued by exogenous iron supplementation requires a decrease of FECH in 
10% FBS (2.6 μM iron) due to 4.7 μM deferoxamine. 
 
 
The Isoniazid and Vitamin B6 Conjugate, PIH, Down-Regulates Human FECH 
Protein  
 
After establishing that iron-levels affect FECH in our model system and in what 
media conditions modulation of iron would produce observable effects for use as positive 
biological controls on FECH protein up- or down-regulation, we next tested metabolites 
that have been detected in humans following isoniazid treatment: isonicotinic acid, 
acetyl-hydrazine, diacetyl hydrazine, acetyl-isoniazid, menadione (ROS), and noc-18 
(NOS) (Hughes 1953, Preziosi and Porcellati 1953, Defranceschi and Zamboni 1954, 
Johnson 1954, Zamboni and Defranceschi 1954, Kaneo, Kubo et al. 1981, Blair, Mansilla 
Tinoco et al. 1985). Suspecting that the well-established vulnerability of FECH iron 
depletion played a role, I selected an aroyl hydrazone adduct of isoniazid to test as well. 
The aroyl hydrazone selected was an adduct of isoniazid and a vitamin depleted by 
isoniazid treatment in humans, vitamin B6. I investigated a variety of isoniazid 
metabolites (at 100 μM; as this was near the upper limit of what would be expected in 
portal hepatocytes and enabled us to rule out metabolites that do not affect FECH or 
ALAS1) on FECH protein expression in HepG2/C3A and found up-regulation of FECH 
protein by FeCl3 and down-regulation by deferoxamine (Figure 3-12A) after 16 hours of 
treatment similar to previous reports (FeCl3 was used as a positive control for FECH up-
regulation and deferoxamine was used as a positive control for FECH down-regulation) 
(Taketani, Adachi et al. 2000, Crooks, Ghosh et al. 2010). I chose 16 hours because we 
expected the effect of isoniazid metabolites to be detected earlier than isoniazid itself but 
wanted to limit the amount of time for further breakdown products. An additional 





Figure 3-11. Iron levels affect FECH levels. 
 
Western blot analysis of FECH in HepG2/C3A treated with deferoxamine mesylate at 24 
hours in 10% FBS containing serum (A), with FeCl3 at 24 hours in 1% FBS (B) and 10% 
FBS (C), and FeCl3 in 10% FBS in the presence or absence of 4.7 μM deferoxamine (D). 
The mean fold change in expression ± SEM of 3 biological repeats each with 3 technical 
repeats are represented for HepG2/C3A. 1-way ANOVA followed by Dunnett’s post-hoc 
analysis was used to compare group means for Western blot analysis. ****p<0.0001; 






Figure 3-12. The effects of isoniazid metabolites on FECH and ALAS1 levels. 
 
Western blot analysis of FECH (A) and ALAS1 (B) in HepG2/C3A treated for 16 hours 
with the indicated compound at 100 μM. Western blot analysis (C) and qRT-PCR (D) 
analysis of FECH in HepG2/C3A treated for 24 hours with the indicated dose of PIH. 
Western blot analysis (E) and qRT-PCR (F) analysis of ALAS1 in HepG2/C3A treated for 
24 hours with the indicated dose of hydrazine. Western blot analysis (G) and qRT-PCR 
(H) analysis of ALAS1 in primary human hepatocytes treated for 24 hours with the 
indicated dose of hydrazine. The mean fold change in expression ± SEM of 3 biological 
repeats each with 3 technical repeats are represented for qRT-PCR analysis and Western 
blot analysis for FECH, and 3 biological repeats for ALAS1 Western blot analysis. 2-way 
ANOVA followed by Tukey’s post-hoc analysis was used to compare group means for 
qRT-PCR analysis. 1-way ANOVA followed by Dunnett’s post-hoc analysis was used to 





point. Of the metabolites and reported by-products of isoniazid treatment tested, only PIH 
down-regulated FECH levels (Figure 3-12A) by 50%. Note that 300 μM Noc18 
decreased FECH protein (data not shown). PIH decreased the FECH protein by up to 
40% at greater than 50 μM in a dose-dependent manner in HepG2/C3A (Figure 3-12C; 
p<0.0001), but did not affect FECH mRNA (Figure 3-12D). In primary human 
hepatocytes, 72 hour daily administration of 50 μM or greater isoniazid was sufficient to 
significantly reduce (p<0.05) FECH protein levels by about 50% (Figure 3-9B). 
 
Considering that the treatment of active tuberculosis is 2 months long (first-line 
therapy is daily oral doses of rifampicin, isoniazid, pyrazinamide, and ethambutol) and 
for latent tuberculosis is 9 months daily oral dose of 5 mg/kg (or 15 mg/kg twice weekly), 
and that plasma concentrations of isoniazid were 22-29 μM in a Moroccan population 
(Ait Moussa, El Bouazzi et al. 2016).) Another study reported a plasma isoniazid Cmax of 
between 10 μM and 50 μM (Aarnoutse, Kibiki et al. 2017). Therefore, an isoniazid dose 
sufficient to decrease FECH liver protein should be achievable. At much higher doses of 
isoniazid (800 μM; p<0.01) was required to significantly reduce FECH protein levels by 
40%. This could be due to lower intracellular vitamin B6 concentrations between primary 
human hepatocytes and HepG2/C3A or a less reactive ortholog of vitamin B6 in the cell 
culture media; 0.001 g/L pyridoxal HCl is in William’s E media, and 0.001 g/L 
pyridoxine HCl is found in EMEM media. Pyridoxal HCl is much more efficient at 
producing PIH when in the presence of isoniazid than is pyridoxine HCl (Figure 3-13I). 
50 μM PIH was sufficient to significantly reduce (p<0.0001) FECH levels in 
HepG2/C3A at 24 hours of treatment (Figure 3-12C). Due to the long half-life of FECH 
(35 hours), lower PIH doses may exert a more severe effect than was observed in a short 
period of treatment (Furukawa, Kohno et al. 1995). 
 
 
The Isoniazid Breakdown Product, Hydrazine, Up-Regulates ALAS1 mRNA and 
Protein 
 
After determining that PIH decreased FECH protein levels, we then tested the 
isoniazid metabolites tested for FECH modulation for their potential to up-regulate 
ALAS1. ALAS1 protein levels were increased at 16 hours treatment by 5-fold (p<0.001) 
by 100 μM hydrazine but were not affected by the isoniazid metabolites and break-down 
products isonicotinic acid, acetyl-hydrazine, diacetyl hydrazine, acetyl-isoniazid, 
menadione, and noc-18 in HepG2/C3A (Figure 3-12B). Hydrazine increased ALAS1 
protein 3-fold at 100 μM (Figure 3-12E; p<0.01) and mRNA 2-fold (Figure 3-12F; 
p<0.0001)  at 50 μM in a dose-dependent manner in HepG2/C3A at 24 hours of 
treatment. Likewise, hydrazine increased ALAS1 protein 3-fold at 50 μM (Figure 3-12G; 
p<0.01) and mRNA 1.5-fold above 10 μM (Figure 3-12H; p<0.001) in a dose-dependent 
manner in primary human hepatocytes. The dose of isoniazid required to produce a 
significant increase (p<0.01) of 3-fold in ALAS1 protein levels is 800 μM. This dose is 
far above plasma isoniazid doses in humans. However, N-alkylation of the heme moiety 
in CYP450 enzymes and other proteins may lead to decreased levels of these proteins and 




Figure 3-13. Detection of PIH following isoniazid application. 
 
PIH is formed from isoniazid and pyridoxal (A). LC/MS/MS analysis of PIH in hPXR 
and mPxr-/- expressing C57BL/6 mouse livers (B), primary human hepatocytes cell 
culture medium (C), and HepG2/C3A cell culture medium in a time dependent (D) and 
dose (E) dependent manner after treatment with isoniazid. LC/MS/MS analysis of PIH in 
HepG2/C3A cell culture medium treated for 24 hours with various amounts of pyridoxal 
5’ phosphate (F), pyridoxal HCl (G), or pyridoxine HCl (H). LC/MS/MS analysis of PIH 
in phosphate buffered saline treated with the indicated Vitamin B6 (1 mM) analogue at 
the indicated times and temperatures in the presence (I) or absence (J) of 1 mM isoniazid. 
Western blot analysis of FECH in HepG2/C3A treated for 24 hours with pyridoxal 
5’phosphate (K) or pyridoxal HCl (L) in the presence or absence of 200 μM isoniazid. 
PIH levels are represented as the mean fold change of 3 biological replicates ± SEM for 
the in vitro data and as the mean (n = 4-5 per group) ± SEM for the in vivo data. The 
mean fold change in expression ± SEM 3 biological repeats each with 3 technical repeats 
are represented for Western blot analysis for FECH. 1-way ANOVA followed by 
Dunnett’s post-hoc analysis was used to compare group means for Western blot analysis 










PIH Is Detected after Treatment of Human Primary Cells, Human Cell Lines, and 
Mice with Isoniazid  
 
PIH formation was next detected and characterized in cell culture media with cells 
present and mouse liver. 5 nmole/mg tissue PIH is detected in the livers of C57BL/6 mice 
treated with isoniazid for 6 weeks (Figure 3-13B), 400 nM PIH is detected in the cell 
culture medium of PHH treated for 72 hours (Figure 3-13C) with daily dosing of 
isoniazid; and 0.5 μM is detected at 24 hours up to 1.5 μM at 96 hours in the cell culture 
medium of HepG2/C3A in a time-dependent manner after a single dose of 200 μM 
isoniazid (Figure 3-13D; p<0.0001) and 0.5 μM PIH is detected at 200 μM isoniazid up 
to 1.2 μM PIH at 800 μM isoniazid in a dose-dependent  manner after 72 hours of daily 
isoniazid treatment in HepG2/C3A (Figure 3-13E; p<0.0001). Addition of the vitamin B6 
analogues, pyridoxal 5’ phosphate (Figure 3-13F), pyridoxal HCl (Figure 3-13G), and 
pyridoxine HCl (Figure 3-13H) result in a further increase of PIH when combined with 
isoniazid. 25 μM pyridoxal 5’ phosphate combined with 200 μM isoniazid results in the 
formation of 5 μM PIH up to 30 μM PIH at 100 μM pyridoxal 5’ phosphate and 200 μM 
isoniazid in HepG2/C3A cell culture medium. 10 μM pyridoxal HCl combined with 200 
μM isoniazid resulted in the formation of 3 μM PIH up to 27 μM PIH when 100 μM 
pyridoxal HCl combined with 200 μM isoniazid in HepG2/C3A cell culture medium. 50 
μM pyridoxine HCl combined with 200 μM isoniazid results in the formation of 1 μM 
PIH up to 1.5 μM PIH at 100 μM pyridoxal HCl and isoniazid. The treatment 
ofHepG2/C3A with 200 μM isoniazid alone at 24 hours did not decrease FECH protein 
(72 hours is required for isoniazid-mediated FECH protein decrease), but the combination 
of 200 μM isoniazid with 6 μM pyridoxal 5’ phosphate decreased FECH protein by 50% 
up to 70% at 25 μ M pyridoxal 5’phosphate (Figure 3-13K; p<0.0001) or 25 μM 
pyridoxal HCl (Figure 3-13L; p<0.05 at 25 μM; p<0.01 at 50 and 100 μM) decreased 
FECH protein levels by 50%. 100 μM pyridoxine HCl and 200 μM isoniazid 
combination did not affect FECH protein levels (data not shown). 
 
 
PIH Is Formed in a Reaction between Isoniazid and Vitamin B6 Analogues  
 
No report exists of a definitive characterization of the formation (Figure 3-13A) 
of PIH. Therefore, we next characterized the formation of PIH in enzyme-free conditions. 
Briefly, 1 mM of each indicated compound was added to phosphate buffered saline and 
allowed to incubate at the indicated temperature for the indicated time and then analyzed 
by mass spectrometry for PIH. PIH is formed in a cell- and enzyme-independent reaction 
by combining vitamin B6 analogs, such as pyridoxal 5’ phosphate, pyridoxal 
hydrochloride, and to a lesser extent pyridoxine hydrochloride (Figure 3-13A, I and J). 
The combination of isoniazid with pyridoxal hydrochloride produced two orders of 
magnitude higher PIH (30-60 μM, depending on incubation time) than reaction of 
isoniazid with pyridoxal 5’ phosphate (the enzymatically active form) formed PIH (0.3-
0.6 μM). The combination of isoniazid and pyridoxine HCl produces a much lower 
amount of PIH (0.1 μM) 1 mM PIH spontaneously breaks down to approximately 100 
μM isoniazid in 37oC at 96 hours and to a much lower extent in 4oC (Figure 3-14). More 





Figure 3-14. Detection of isoniazid following isoniazid application. 
 
LC/MS/MS analysis of isoniazid in PBS treated with the indicated compounds for the 
indicated time and the indicated temperature with (A) or without (B) 1 mM isoniazid 






than is formed at4oC (Figure 3-13I). These data are characteristic of the thermodynamic 




Hydrazine Is Detected after Treatment of Human Primary Cells and Human Cell 
Lines with Isoniazid  
 
In PBS, relatively low levels of hydrazine are formed (150 nM hydrazine after 
incubation of 1 mM isoniazid for 96 hours; Figure 3-15E). 8 μM hydrazine is detected at 
24 hours (p<0.001) treatment of HepG2/C3A with a single dose of 200 μM isoniazid, 
which increases to 9 μM at 48 hours, 12 μM at 72 hours, and 17 μM (Figure 3-15A) at 
96 hours. In HepG2/C3A cell culture medium treated with 800 μM isoniazid daily for 72 
hours there was 22 μM hydrazine detected (Figure 3-15B; p<0.0001), but only 3 μM 
hydrazine was detected after 24 hours of treatment (Figure 3-15C; p<0.05). The cell 
culture media of 3 donors of primary human hepatocytes were analyzed for hydrazine 
concentration after 72 hour treatment of 200 μM isoniazid with media and drug refreshed 
daily (Figure 3-15D). The amount of hydrazine detected varied considerably between 
donors, 2 donors had approximately 2-5 μM of hydrazine detected in the cell culture 
media when treated with isoniazid, but a third donor had approximately 50-120 μM 
isoniazid detected dependent on treatment combination. This represents the average of 40 
μM hydrazine detected following isoniazid treatment of primary human hepatocytes 
(p<0.0001). Indeed, this wide range of hydrazine production could be reflected in the 
varied response in ALAS1 induction in similar treatment conditions (Figure 3-10A). 
 
 
PIH Decreases FECH Protein Levels by Decreasing Iron Availability 
 
Considering the vulnerability of FECH to low iron conditions, especially in the 
presence of iron chelators, we next tested whether exogenous iron application would 
rescue the 40% decrease in FECH levels at 24 hours from 50 μM PIH-mediated depletion 
of the regulatory heme pool over time. Therefore, a lower dose administered over a 
period of months may be required for the effect to be observed in vivo. Likewise, twenty-
four hour treatment of primary human hepatocytes with 50 μM hydrazine resulted in a 
significant 3-fold increase (p<0.01) in ALAS1 protein levels (Figure 3-12G). Indeed, 
hydrazine concentrations increase both with length of treatment and with number of 
treatments. The formation of hydrazine may depend on amidase activity (Sarich, Adams 
et al. 1999) and the activation of hydrazine to interact with cellular proteins may require 
activation by P450 enzymes (Nelson, Mitchell et al. 1976, Lauterburg, Smith et al. 1985, 
Delaney and Timbrell 1995, Sarich, Adams et al. 1999). Human cell lines and primary 
hepatocytes may not quantitatively reflect the in vivo activity of enzymes that metabolize 
xenobiotics (Guillouzo, Morel et al. 1993, Bjornsson, Callaghan et al. 2003, Guillouzo 
and Guguen-Guillouzo 2008, Turpeinen, Tolonen et al. 2009). Thus, higher levels of 







Figure 3-15. Detection of hydrazine adduct following isoniazid application. 
 
LC/MS analysis of hydrazine-adduct in HepG2/C3A cell culture media at various times 
after treatment with a single dose of 200 μM isoniazid (A), various single isoniazid doses 
after 24 hours (C), and 3 daily isoniazid doses at 72 hours (B). LC/MS analysis of 
hydrazine-adduct in primary human hepatocyte cell culture media at 72 hours after 3 
daily doses of 200 μM isoniazid (D). LC/MS analysis of phosphate buffered saline after 
96 hour incubation with 1 mM isoniazid at the indicated temperature (E). Hydrazine-
adduct levels in HepG2/C3A and phosphate buffered saline are represented as the mean ± 
SEM of 3 biological replicates. Hydrazine-adduct levels in primary human hepatocytes 
are represented as the mean +/- SEM of 3 biological and 3 technical replicates. 2-way 
ANOVA followed by Tukey’s post-hoc analysis was used to compare group means for 
LC/MS analysis of primary human hepatocytes. 1-way ANOVA followed by Dunnett’s 
post-hoc analysis was used to compare group means for LC/MS/MS analysis of 





down-regulation and to associate this with iron chelation directly. In HepG2/C3A 
(Figure 3-16A) and PHH (Figure 3-16B), the decrease in FECH protein levels due to 50 
μM PIH can be rescued by the co-administration of FeCl3. 50 μM PIH treatment of 
HepG2/C3A for 24 hours results in a 40% decrease of FECH protein (p< 0.05) compared 
to PBS treatment (Figure 3-16A). The addition of 0.01 μM FeCl3 abrogates the 
significance of the decrease in FECH protein due to 50 μM PIH and the addition of 10 
and 100 μM FeCl3 results in a significant increase of FECH protein compared to 50 μM 
PIH. Isoniazid treatment of PHH for 24 hours results in a 40% decrease of FECH protein 
(p< 0.01) that is not rescued by FeCl3 addition (Figure 3-16B). However, PIH treatment 
of PHH for 24 hours results in a 40% decrease of FECH protein (p< 0 .01) that is 
abrogated by 0.1 and 1 mM FeCl3. PIH (Figure 3-16D), similar to (Figure 3-16C) 
deferoxamine, chelates iron. The CAS shuttle assay has iron present and chelation of this 
iron results in a decrease of absorbance at 630 nm. In other words, the more free iron 
available, the higher the absorbance at 630 nm. This iron chelation is also seen due to the 
product of pyridoxal HCl and isoniazid formation at 96 hours (Figure 3-16E; p< 0.0001) 
in 37oC in PBS and in HepG2/C3A cell culture medium (Figure 3-16F; p< 0.01) treated 
for 24 hours  at 50 μM pyridoxal HCl and 200 μM isoniazid and p<0.0001 at 100 μM 
pyridoxal HCl and 200 μM isoniazid). Together these data demonstrate the PIH-mediated 
iron chelation decreases FECH levels.  
 
 





 After characterizing the effect of isoniazid metabolites on the heme biosynthesis 
pathway that may lead to PPIX accumulation, the possible role of rifampicin was 
investigated by TMT-labeled proteomics screening of mice treated with rifampicin and 
isoniazid. Previous reports have shown that isoniazid alone is not sufficient for PPIX up-
regulation of 60-fold (Li, Lu et al. 2013, Sachar, Li et al. 2016). Clustering analysis 
revealed similar protein changes within groups (Figure 3-17 and Figure 3-18). 
Proteomics profiling identified proteins that (1) were changed in each treatment group 
and the overlap between treatment groups and (2) proteins changed in pathways relevant 
to heme synthesis and degradation, CYP450 and steroid metabolism enzymes, nuclear 
receptors, organic transporters, iron metabolism, oxidative stress, [Fe-S] cluster assembly 
machinery, wound healing and inflammation, vitamin B6 metabolism, and [Fe-S] cluster-
containing proteins. 8,466 proteins were identified and quantified. Compared to hPXR 
mice administered control food and water, 101 proteins were increased in rifampicin and 
isoniazid treated mPXR -/- mice, but were not increased in hPXR mice treated with 
rifampicin and isoniazid (Figure 3-19). 179 proteins are up-regulated at a p < 0.01 in 
hPXR mice treated with rifampicin and isoniazid compared to hPXR mice fed the control 
diet and water (Figure 3-19). 101 proteins are up-regulated in mPxr -/- mice treated with 
rifampicin and isoniazid compared to hPXR mice (Figure 3-20) on the control diet and 
water. 49 proteins are up-regulated due to the combination of rifampicin and isoniazid in 
both hPXR and mPxr -/- mice (Figure 3-20). 21 proteins are up-regulated in hPXR mice  
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Figure 3-16. PIH decreases FECH levels by decreasing iron availability. 
 
Western blot analysis of HepG2/C3A (A) and primary human hepatocytes (B) treated 
with increasing doses of FeCl3 in the presence or absence of PIH in HepG2/C3A and the 
presence and absence of PIH and isoniazid in primary human hepatocytes. 
Spectrophotometric analysis of CAS shuttle assay of deferoxamine (C), PIH (D), 
biochemical reaction products (E) of pyridoxal HCl and isoniazid, and HepG2/C3A cell 
culture medium (F) treated with pyridoxal in the presence or absence of isoniazid (100 
μM). The mean fold change in expression ± SEM of 3 biological repeats each with 3 
technical repeats are represented for Western blot analysis for FECH in HepG2/C3A. The 
mean fold change in expression +/- SEM of donors are represented for Western blot 
analysis for FECH in primary human hepatocytes. Spectrophotometric analysis of the 
background subtracted absorbance (630 nm) of the CAS shuttle solution is represented as 
the mean ± SEM of 3 repeats for deferoxamine and PIH dilution and biochemical 
reaction product, and 3 biological repeats each with 3 technical repeats for the 
HepG2/C3A cell culture medium. 1-way ANOVA followed by Dunnett’s post-hoc 
analysis was used to compare group means for Western blot analysis and 









Figure 3-17. Clustering analysis of top 100 most variable proteins. 
 
Hierarchical clustering of differentially expressed proteins due to treatment group. Low 
expression proteins (peptide sequence matches < 10) were filtered and the top 100 most 
variable proteins are displayed. Only changes with a significance of p < 0.01 are 
displayed as determined by one-way ANOVA with Dunnett’s post-hoc analysis. Z-scores 












Figure 3-18. Clustering analysis of hPXR-dependent changes. 
 
Clustering analysis of genes up-regulated in hPXR mice treated with rifampicin and 
isoniazid compared to control hPXR mice and down-regulated in mPxr -/- mice treated 
with rifampicin and isoniazid. Only changes with a significance of p < 0.01 are displayed 
as determined by one-way ANOVA with Dunnett’s post-hoc analysis. Z-scores are 





Figure 3-19. Venn diagram showing the overlap between proteins up-regulated in 
hPXR and mPXR -/- mice treated with rifampicin and isoniazid. 
 
Venn diagram displaying proteins up-regulated in hPXR and mPxr-/- mice treated with 






Figure 3-20. Venn diagram of the overlap in up-regulated proteins between all 
treatment groups. 
 
Venn diagram displaying proteins up-regulated in all treatment groups compared to 
control. hPXR_I = hPXR mice treated with isoniazid, hPXR_R = hPXR mice treated with 
rifampicin, KO_R_I = mPxr -/- mice treated with rifampicin and isoniazid, hPXR_R_I = 




treated with isoniazid, but not in other treatment groups, 210 proteins are up-regulated 
due to rifampicin alone in hPXR mice, 70 proteins are up-regulated in mPxr-/- mice 
treated with rifampicin and isoniazid, and 61 proteins are up-regulated due to rifampicin 
and isoniazid in hPXR mice, but not in other groups (Figure 3-20). All of these changes 
are significant p< 0.01. Only 4 proteins are up-regulated in all groups and only 13 are up-
regulated in all hPXR groups (Figure 3-20).  
 
 
Heme Biosynthesis and Degradation 
 
ALAS1 was highly up-regulated (1.9 fold-change in hPXR mice treated with 
rifampicin and isoniazid, 2.6 fold-change in hPXR mice treated with isoniazid, and 1.4 
fold-change in mPxr -/- mice treated with rifampicin and isoniazid), but not significantly 
across groups (Table 3-1; p = 0.28). Interestingly ALAS2 was significantly (p =0.018) 
changed at 1.38 fold in hPXR mice treated with isoniazid and 1.18 fold in mPxr -/- treated 
with rifampicin and isoniazid up-regulated, but down-regulated due to rifampicin (0.73 
fold) and the combination of rifampicin and isoniazid. Isoniazid up-regulates ALAS1 and 
to a lesser magnitude ALAS2 (the presence of which may possibly be due to blood 
contamination). Rifampicin may suppress ALAS2 levels in hPXR mice. 
Uroporphyrinogen-III synthase (Uros) was significantly changed (p = 0.012) by an 
increase of 1.19 fold in hPXR mice treated with rifampicin and isonaiazid and 1.31 fold 
in hPXR mice treated with rifampicin and isoniazid as well as 1.38 fold increase in mPxr -
/- mice treated with rifampicin and isoniazid. These data suggest that Uros may be up-
regulated by rifampicin in an hPXR-independent manner. Protoporphyrinogen oxidase 
(Ppox) is significantly down-regulated (p = 0.013) by all treatments in an hPXR 
dependent manner by from 0.69 to 0.85 fold, and the effect may be more pronounced in 
hPXR mice compared treated with rifampicin and isoniazid (0.69 fold) to mPxr -/- mice 
(0.83 fold). Fech is down-regulated (p < 0.0001) due to all groups, but to a much lower 
extent in hPXR mice treated with rifampicin (0.88 fold) to between 0.39 fold to 0.5 fold 
in the groups treated with isoniazid. Biliverdin reductase (Blvra) is significantly (p = 
0.032), but slightly (0.82 to 0.92 fold) down-regulated in all treatment groups 
independent of hPXR status. NADPH-cytochrome P450 reductase (Por) was up-regulated 
in both combination groups (1.28 fold to 1.12 fold) and due to rifampicin (1.18 fold), but 
was slightly down-regulated due to isoniazid (0.92). In Fechm1Pas Balb/c mouse livers 
with increased PPIX levels, Alas1 was increased and Alas2 was decreased (Davies, 
Schuurman et al. 2005). Alas2, Ppox, and Fech from a complex in the mitochondria 
(Medlock, Shiferaw et al. 2015).  
 
 
CYP450 and Steroid Metabolism Enzymes  
 
Cyp2b10 is the most up-regulated CYP450 and is significantly (p = 0.0003) 
increased by rifampicin (2.49 fold) and rifampicin and isoniazid (4.95 fold) in hPXR mice 
but not more than a 10% change in mPxr -/- mice or hPXR mice treated with isoniazid 
(Table 3-2). 3-beta-hydroxysteroid dehydrogenase type 4 (Hsd3b4)  was the most down-
regulated significantly (p = 0.0012) due to rifampicin (0.098 fold) in hPXR mice with a. 
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Table 3-1. Heme biosynthesis and degradation. 
 
  Fold Change to Control   
  hPXR  KO   
Protein Description GN RIF/INH INH RIF  RIF/INH p-Value FDR 
5-aminolevulinate synthase Alas1 1.90 2.61 1.05  1.41 0.28 0.53 
5-aminolevulinate synthase Alas2 0.86 1.38 0.73  1.18 0.018 0.17 
Delta-aminolevulinic acid 
dehydratase 
Alad 0.96 1.00 1.02  0.95 0.75 0.87 
Porphobilinogen deaminase  Hmbs 1.04 0.99 1.10  1.05 0.67 0.8 
Uroporphyrinogen-III synthase  Uros 1.19 1.09 1.31  1.38 0.012 0.16 
Uroporphyrinogen 
decarboxylase  
Urod 0.92 1.03 0.94  0.92 0.33 0.58 
Oxygen-dependent 
coproporphyrinogen-III oxidase,  
Cpox 1.13 1.04 1.18  1.15 0.20 0.46 
Protoporphyrinogen oxidase  Ppox 0.69 0.81 0.85  0.83 0.013 0.16 
Ferrochelatase, Fech 0.39 0.50 0.88  0.43 0.000002 0.0026 
Heme oxygenase 1  Hmox1 1.15 0.86 0.91  1.11 0.34 0.59 
Heme oxygenase 2  Hmox2 0.96 0.98 0.89  0.88 0.22 0.48 
Biliverdin reductase A  Blvra 0.84 0.92 0.82  0.92 0.032 0.22 
UDP-glucuronosyltransferase 1-
6  
Ugt1a6 1.22 0.96 1.10  1.13 0.30 0.55 
NADPH--cytochrome P450 
reductase  





Table 3-2. CYP450 and steroid metabolism enyzmes. 
 
  Fold Change to Control   
  hPXR  KO   
Protein Description GN RIF/INH INH RIF  RIF/IN
H 
p-Value FDR 
Cytochrome P450 1A2  Cyp1a2 0.60 0.48 1.47  0.53 0.037 0.23 
Cytochrome P450 2A12  Cyp2a12 0.98 0.78 1.53  0.91 0.022 0.19 
Cytochrome P450 2A5  Cyp2a5 1.77 0.62 2.93  1.01 0.00076 0.047 
Cytochrome P450 2B10  Cyp2b10 4.96 0.91 2.49  0.98 0.00032 0.030 
Cytochrome P450 2C29  Cyp2c29 1.17 1.02 1.56  0.67 0.038 0.23 
Cytochrome P450 2D10  Cyp2d10 0.98 0.90 1.03  0.99 0.92 0.97 
Cytochrome P450 2D26  Cyp2d26 0.76 0.71 1.13  0.75 0.0021 0.072 
Cytochrome P450 2E1  Cyp2e1 1.22 1.18 0.93  1.47 0.00035 0.032 
Cytochrome P450 2F2  Cyp2f2 0.61 0.61 0.75  0.52 0.028 0.21 
Cytochrome P450 2J6  Cyp2j6 0.98 0.89 1.04  1.06 0.68 0.82 
Cytochrome P450 3A11  Cyp3a11 3.89 1.18 4.64  1.31 0.00086 0.050 
Cytochrome P450 3A25  Cyp3a25 1.64 0.95 1.36  1.15 0.037 0.23 
Cytochrome P450 4A10  Cyp4a10 2.38 1.61 4.45  1.78 0.012 0.15 
Cholesterol 7-alpha-
monooxygenase  
Cyp7a1 1.08 0.65 0.86  1.85 0.095 0.33 
25-hydroxycholesterol 7-alpha-
hydroxylase  
Cyp7b1 0.49 0.55 0.39  0.64 0.12 0.36 
Sterol 26-hydroxylase Cyp27a1 0.70 0.73 0.82  0.80 0.032 0.22 
Lanosterol 14-alpha 
demethylase  
Cyp51a1 0.94 0.66 1.30  1.56 0.43 0.66 
Hydroxymethylglutaryl-CoA 
synthase 
Hmgcs1 1.51 1.29 1.74  2.53 0.036 0.22 
Hydroxymethylglutaryl-CoA 
synthase 
Hmgcs2 1.26 1.55 1.23  1.19 0.027 0.20 
3-hydroxy-3-methylglutaryl-
coenzyme A reductase  
Hmgcr 1.56 1.27 1.51  1.74 0.35 0.60 
3 beta-hydroxysteroid 
dehydrogenase type 4  
Hsd3b4 0.20 1.07 0.10  0.48 0.0012 0.058 
Corticosteroid 11-beta-
dehydrogenase isozyme 1  





lesser decrease (0.20 fold) in hPXR mice treated with rifampicin and isoniazid and a 
further reduced decrease (0.48 fold) in mPxr-/- mice treated with rifampicin and isoniazid 
Cyp3a11, the mouse CYP3A4 ortholog (Muruganandan and Sinal 2008), was 
significantly changed (p = 0.0008) in all treatment groups, but to a much lower 
magnitude (1.30 fold) in mPxr -/- mice and hPXR mice treated with isoniazid (1.18 fold) 
than in hPXR mice treated with rifampicin (4.64 fold) and treated with both rifampicin 
and isoniazid (3.89 fold). Several CYP450s were down-regulated due to isoniazid to a 
much higher extent than in the rifampicin only treatments; Cyp1a2 (0.48 fold), Cyp2a12 
(0.78 fold), Cyp2a5 (0.62 fold), and Cyp2d26 (0.71 fold). Cyp2e1 was significantly 
changed (p = 0.00035) and was increased in hPXR mice treated with rifampicin and 
isoniazid (1.22 fold) and with hPXR mice treated with isoniazid (1.18 fold). Cyp2e1 was 
also increased in mPxr -/- mice treated with rifampicin and isoniazid (1.47 fold). 
Polymorphisms associated with increased CYP2E1 function in humans leads to an 
increased incidence of DILI (Leiro-Fernandez, Valverde et al. 2010, Gogtay, 
Kapileshwar et al. 2016, Antonenko, Butov et al. 2017). Inhibition of Cyp2e1 has been 
shown to be protective against isoniazid-induced hepatoxicity in mice (Lian, Zhao et al. 
2017). Cyp2e1 WT mice may be more susceptible to DILI (Cheng, Krausz et al. 2013). 
Therefore, the up-regulation of Cyp2e1 by rifampicin in an hPXR-dependent manner may 





Very few transcription factors were up- or down-regulated more than 10%. Hnf1a 
is significantly changed (p = 0.026) and down-regulated in all rifampicin treatment 
groups (0.79 to 0.87 fold) independent of hPXR status (Table 3-3). The glucocorticoid 
receptor (Nr3c1) was significantly (p = 0.49) down-regulated by rifampicin in hPXR mice 
(0.88 fold). Nuclear receptor subfamily 5 group A member 2 (Nr5a2) was significantly (p 
= 0.016) down-regulated in hPXR mice treated with rifampicin (0.83 fold) and rifampicin 
and isoniazid combination (0.80 fold). Human NR5A may up-regulate ALAS1 expression 





Multidrug resistance protein 1A (Abcb1a) was significantly (p = 0.030) changed 
in all rifampicin treatment groups (fold change 1.35 to 1.38) regardless of hPXR status 
(Table 3-4). The canalicular multispecific oganic anion transporter 1  (Abcc2) was 
significantly (p  = 0.009) changed in all isoniazid groups with the hPXR groups with 
isoniazid changed 0.84 fold, but the mPxr -/- mice treated with isoniazid and rifampicin 
had a fold change of 0.68. The sodium/bile acid co-transporter (Slc10a1) was 
significantly changed (p = 0.012) by isoniazid (1.30 fold), rifampicin (0.85), and the 
combination of rifampicin and isoniazid (0.88 fold) in hPXR mice. The solute carrier 
organic anion transporter family member 1A1  (Slc1a1) was significantly changed (p = 




Table 3-3. Nuclear receptors. 
 
  Fold Change to Control   
  hPXR  KO   
Protein Description GN RIF/INH INH RIF  RIF/INH p-Value FDR 
Aryl hydrocarbon receptor  Ahr 1.09 0.91 1.00  1.26 0.092 0.33 
Hepatocyte nuclear factor 1-alpha  Hnf1a 0.87 0.97 0.82  0.79 0.027 0.20 
Hepatocyte nuclear factor 4-alpha  Hnf4a 0.95 1.05 0.97  1.08 0.20 0.46 
Oxysterols receptor LXR-alpha  Nr1h3 0.94 1.16 1.03  1.02 0.42 0.65 
Bile acid receptor  Nr1h4 1.05 1.17 0.98  1.19 0.12 0.36 
Retinoic acid receptor RXR-alpha  Rxra 0.88 1.03 0.83  0.95 0.12 0.37 
Peroxisome proliferator-activated 
receptor alpha  
Ppara 0.85 0.96 0.79  0.94 0.64 0.80 
Nuclear receptor subfamily 1 
group D member 1  
Nr1d1 0.32 0.32 0.51  0.90 0.37 0.61 
Oxysterols receptor LXR-beta  Nr1h2 1.11 1.14 1.08  1.05 0.62 0.79 
Bile acid receptor  Nr1h4 1.05 1.17 0.98  1.19 0.12 0.36 
COUP transcription factor 1  Nr2f1 0.98 1.04 0.94  1.00 0.67 0.82 
COUP transcription factor 2  Nr2f2 0.98 1.04 0.94  1.00 0.67 0.82 
Nuclear receptor subfamily 2 
group F member 6  
Nr2f6 1.01 1.04 0.97  1.08 0.45 0.68 
Glucocorticoid receptor  Nr3c1 0.91 1.03 0.88  0.96 0.049 0.25 
Nuclear receptor subfamily 5 
group A member 2  





Table 3-4. Organic transporters. 
 
  Fold Change to Control   
  hPXR  KO   
Protein Description GN RIF/INH INH RIF  RIF/INH p-Value FD
R 
Multidrug resistance protein 1A  Abcb1a 1.39 1.08 1.40  1.35 0.030 0.21 
Multidrug resistance protein 1B  Abcb1b 1.26 1.06 1.27  1.19 0.13 0.38 
Multidrug resistance protein 3  Abcb4 1.22 1.03 1.11  1.11 0.41 0.64 
Bile salt export pump  Abcb11 1.00 0.85 1.01  0.88 0.051 0.25 
Canalicular multispecific organic 
anion transporter 1  
Abcc2 0.85 0.85 1.04  0.68 0.0094 0.14 
Sodium/bile acid cotransporter  Slc10a1 0.88 1.31 0.85  0.92 0.019 0.18 
Solute carrier organic anion 
transporter family member 1A1  





combination of rifampicin and isoniazid (0.77 fold), but are up-regulated in mPxr -/- mice 
treated with rifampicin and isoniazid (1.29 fold). Abcb1a was up-regulated and Abcc2, 
Slc10a1, and Slco1a1 was down-regulated in Fechm1Pas Balb/c mice (Davies, Schuurman 





Lactotransferrin (Ltf) was significantly (p = 0.036) down-regulated in all 
treatment groups (Table 3-5). Ltf was most down-regulated in mPxr -/- mice treated with 
rifampicin and isoniazid (0.27 fold) and down-regulated to a lesser extent in hPXR mice 
(0.38 to 0.40 fold). Ferritin light chain (Ftl1) was significantly (p = 8.42 X 10-5) down-
regulated in all treatment groups. Ftl1 is most severely down-regulated in hPXR mice 
treated with rifampicin and isoniazid (0.28 fold), followed by hPXR mice treated with 
isoniazid (0.36 fold), mPxr-/- mice treated with rifampicin and isoniazid (0.44 fold), than 
hPXR mice treated with rifampicin (0.58 fold). Abcb7 is significantly changed (p = 0.019) 
by 0.83 fold in hPXR mice treated with rifampicin and isoniazid to 0.79 fold in hPXR 
mice treated with rifampicin and a more modest decrease in mPxr -/- mice treated with 
rifampicin and isoniazid (0.91 fold). Ftl1 was up-regulated in Fechm1Pas Balb/c mice 
(Davies, Schuurman et al. 2005).  
 
 
Oxidative Stress  
 
Phospholipid hydroperoxide glutathione peroxidase  (Gpx4) was significantly 
changed (p = 0.0015) in hPXR mice treated with rifampicin (1.56 fold) and the 
combination of rifampicin and isoniazid (1.44 fold) and to a lower extent mPxr -/- mice 
treated with rifampicin and isoniazid (Table 3-6). Many isoforms of glutathione S 
transferase (Gst) mu, which detoxicfies electrophilic compounds and cluster on 
chromosome 1p13.3 were significantly changed (p < 0.0001). Gstm1, 2, 3, 4, 5, 6, and 7 
were increased 1.59 to 3 fold in hPXR mice treated with rifampicin and isoniazid, slightly 
decreased 0.79 to 0.87 fold in hPXR mice treated with isoniazid, slightly increased in 
mPxr-/- mice treated with rifampicin and isoniazid 1.16 to 1.61 fold, and with the highest 
magnitude increase in hPXR mice treated with rifampicin 1.55 fold to 4.5 fold. The 
increase due to rifampicin in hPXR mice was a higher magnitude than the increase in the 
combination therapy for each protein. GSTM1 has been shown to be protective in humans 
treated with anti-tubercular drugs and null alleles have been associated with a higher 
incidence of hepatotoxicity (Gupta, Singh et al. 2013, Li, Long et al. 2013, Singla, Gupta 
et al. 2014). Gsta1 was changed in a similar manner to the mu isoforms. Gstt2 was 
significantly changed (p = 0.033) due to rifampicin and isoniazid (1.40 fold) and 
rifampicin (1.51 fold). Catalase was also significantly changed (p = 0.038) and increased 
in hPXR mice treated with both rifampicin and isoniazid (1.16 fold) and by rifampicin 
(1.45 fold). NAD(P)H dehydrogenase [quinone] 1 (Nqo1) was significantly changed (p = 
0.00027) and was increased in hPXR mice treated with rifampicin and isoniazid (1.52 




Table 3-5. Iron metabolism.  
 
  Fold Change to Control   
  hPXR  KO   
Protein Description GN RIF/INH INH RIF  RIF/INH p-Value FDR 
Serotransferrin  Tf 1.33 1.04 1.15  1.11 0.144145 0.397184 
Transferrin receptor protein 1  Tfrc 1.28 0.98 1.13  1.14 0.46 0.68 
Lactotransferrin  Ltf 0.40 0.38 0.38  0.27 0.036 0.23 
Transferrin receptor protein 2  Tfr2 0.99 1.02 0.82  0.86 0.13 0.38 
Hereditary hemochromatosis 
protein homolog 
Hfe 0.93 0.92 0.90  0.94 0.70 0.84 
Ferritin light chain 1  Ftl1 0.28 0.36 0.58  0.44 8.42E-05 0.014 
Ferritin heavy chain  Fth1 0.47 0.63 0.70  0.59 0.097 0.33 
Cytoplasmic aconitate hydratase  Aco1 1.05 1.00 1.08  1.00 0.53 0.73 
ATP-binding cassette sub-family B 
member 7 





Table 3-6. Oxidative stess.  
 
  Fold Change to Control   
  hPXR  KO   
Protein Description GN RIF/INH
 
INH RIF  RIF/INH p-Value FDR 
Glutathione synthetase  Gss 0.95 0.80 0.91  0.76 0.084 0.31 
Phospholipid hydroperoxide 
glutathione peroxidase 
Gpx4 1.44 1.05 1.56  1.23 0.0016 0.064 
Glutathione S-transferase Mu 1  Gstm1 1.59 0.80 2.50  1.19 7.23E-06 0.0034 
Glutathione S-transferase Mu 2  Gstm2 2.01 0.85 2.96  1.61 5.54E-06 0.0034 
Glutathione S-transferase Mu 3  Gstm3 3.02 0.87 4.54  1.33 4.5E-06 0.0034 
Glutathione S-transferase mu 4  Gstm4 1.50 0.84 2.37  1.28 9.418E-06
 
0.0034 
Glutathione S-transferase Mu 5  Gstm5 1.35 0.88 1.79  1.14 5.69E-05 0.011 
Glutathione S-transferase Mu 6  Gstm6 1.67 0.79 2.41  1.16 1.25E-05 0.0038 
Glutathione S-transferase Mu 7  Gstm7 1.57 0.81 2.30  1.16 1E-05 0.0034 
Glutathione S-transferase A1  Gsta1 1.72 0.86 2.70  1.40 0.00019 0.023 
Glutathione S-transferase theta-1  Gstt1 1.08 1.12 1.30  0.92 0.22 0.48 
Glutathione S-transferase theta-2  Gstt2 1.40 0.99 1.51  1.01 0.034 0.22 
Fumarylacetoacetase  Fah 0.93 0.97 0.93  0.99 0.62 0.79 
Catalase  Cat 1.16 1.02 1.44  1.08 0.038 0.23 
Superoxide dismutase  Sod2 0.82 0.92 0.85  0.93 0.052 0.26 
NAD(P)H dehydrogenase [quinone] 
1  





(1.92 fold). Nqo1 was decreased in hPXR mice treated with isoniazid (0.87 fold). Nqo1 is 
protective against APAP- induced hepatotoxicity and is up-regulated in liver injury from 
APAP (Hwang, Kim et al. 2015) and primary biliary cirrhosis (Aleksunes and Klaassen 
2012). Gpx4, Gstm1, and Gstm5 were up-regulated in Fechm1Pas Balb/c mice (Davies, 
Schuurman et al. 2005).  
 
 
[Fe-S] Cluster Assembly Machinery 
 
Cysteine desulfurase (Nfs1) was significantly (p = 0.042) changed in hPXR mice 
by rifampicin and isoniazid (0.89 fold) and rifampicin (0.84 fold) and to a lower extent in 
mPxr -/- mice treated with rifampicin and isoniazid (0.90 fold), but changed less than 4% 
due to isoniazid in hPXR mice (Table 3-7). Adrenodoxin (Fdx1) was significantly (p = 
0.016) decreased by all treatments, and may be decreased by isoniazid to a greater degree 
than rifampicin. Fdx1 was slightly decreased by rifampicin in hPXR mice (0.84 fold), to a 
greater degree by isoniazid (0.77 fold), and is most down-regulated by the combination of 
rifampicin and isoniazid in hPXR mice (0.64 fold). Fdx1 is also down-regulated in mPxr -
/- mice treated with rifampicin and isoniazid (0.79 fold). Iron-sulfur cluster co-chaperone 
protein (Hscb) is significantly changed (p = 0.0056). Hscb is increased to the greatest 
degree in mPxr -/- mice treated with rifampicin and isoniazid (1.44 fold), less of an 
increase was observed in hPXR mice treated with rifampicin (1.40 fold), and to a lower 
extent in the other treatment groups. Hscb is increased in hPXR mice treated with 
rifampicin and isoniazid (1.23 fold) and in hPXR mice treated with rifampicin (1.20 fold). 
Iron-sulfur cluster assembly 1 homolog (Isca1) was significantly changed (p = 0.0037) by 
down-regulation in all treatment groups from 0.66 to 0.81 fold. Putative transferase 
CAF17 homolog (Iba57) was significantly (p = 0.0090) increased in hPXR mice treated 
with rifampicin (1.15 fold) and mPxr -/- mice treated with rifampicin and isoniazid (1.14). 
BolA-like protein 3 (Bola3) was significantly (p=0.012) changed in hPXR mice treated 
with isoniazid (0.91 fold) and the combination of rifampicin and isoniazid (0.89 fold), but 
was increased in hPXR mice treated with rifampicin (1.12 fold). Anamorsin (Ciapin1) 
was significantly changed (p = 0.0095) and was up-regulated across treatment groups. 
Ciapin 1 was increased 1.34 fold in hPXR mice treated with rifampicin, 1.28 fold when 
treated with the combination of rifampicin and isoniazid, 1.19 fold when treated with 
isoniazid alone, and 1.10 fold in mPxr -/- treated with rifampicin and isoniazid. 
 
 
Wound Healing and Inflammation 
 
Protein-glutamine gamma-glutamyltransferase 2 (Tgm2) was significantly 
changed (Table 3-8; p = 0.0058). Tgm2 was up-regulated in hPXR mice treated with 
rifampicin and isoniazid (1.12 fold) and rifampicin alone (1.19 fold). Tgm2 was down-
regulated in hPXR mice treated with isoniazid (0.81 fold) and mPxr -/- mice treated with 
rifampicin and isoniazid (0.88 fold). Collagen alpha-1 (IV) (Col4a1) and collagen alpha-
1 (VI) (Col6a1) were significantly changed with p values of 0.0033 and 0.0091 
respectively. Col4a1 and Col6a1 were increased in hPXR mice treated with rifampicin 
and isoniazid (1.27 and 1.10 fold, respectively). Col4a1 and Col6a1 were decreased in  
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Table 3-7. [Fe-S] cluster assemblymachinery.  
 
  Fold Change to Control   
  hPXR  KO   
Protein Description GN RIF/INH INH RIF  RIF/INH p-Value FDR 
Cysteine desulfurase Nfs1 0.89 0.96 0.84  0.90 0.042 0.24 
Isoform 2 of Low molecular weight 
phosphotyrosine protein phosphatase  
Acp1 0.96 0.98 1.03  1.00 0.63 0.80 
Frataxin, mitochondrial  Fxn 0.84 0.98 0.89  0.88 0.11 0.35 
Ferredoxin-fold anticodon-binding 
domain-containing protein 1 homolog  
Fdxacb1 1.06 0.96 1.09  1.15 0.94 0.98 
Adrenodoxin Fdx1 0.64 0.77 0.84  0.79 0.0016 0.064 
NADPH:adrenodoxin oxidoreductase, Fdxr 0.83 0.93 0.85  0.91 0.16 0.42 
Stress-70 protein Hspa9 1.07 1.07 0.94  1.05 0.32 0.57 
Iron-sulfur cluster co-chaperone 
protein  
Hscb 1.23 1.20 1.40  1.44 0.0056 0.11 
GrpE protein homolog 2, 
mitochondrial  
Grpel2 1.24 1.18 1.04  1.19 0.78 0.89 
GrpE protein homolog 1 Grpel1 1.10 1.07 0.98  1.05 0.69 0.83 
Glutaredoxin-related protein 5 Glrx5 1.60 1.69 1.24  1.39 0.078 0.30 
Iron-sulfur cluster assembly 1 
homolog 
Isca1 0.76 0.68 0.66  0.81 0.0037 0.095 
Iron-sulfur cluster assembly 2 
homolog 
Isca2 0.90 0.91 1.13  1.02 0.20 0.46 
Putative transferase CAF17 homolog Iba57 1.00 0.98 1.15  1.14 0.0090 0.14 
NFU1 iron-sulfur cluster scaffold 
homolog 
Nfu1 0.82 0.98 0.90  1.01 0.13 0.37 
NFU1 iron-sulfur cluster scaffold 
homolog, mitochondrial (Fragment)  
Nfu1 0.82 0.99 0.87  0.96 0.059 0.27 
BolA-like protein 3  Bola3 0.89 0.91 1.12  1.03 0.012 0.15 
Iron-sulfur protein  Nubpl 1.27 1.77 1.37  0.91 0.067 0.29 
Cytosolic Fe-S cluster assembly factor  Nubp1 1.07 0.91 0.94  1.03 0.33 0.58 
Cytosolic Fe-S cluster assembly factor  Nubp2 1.03 1.06 1.01  1.14 0.35 0.60 
Anamorsin  Ciapin1 1.28 1.19 1.34  1.10 0.0095 0.14 
BolA-like protein 2  Bola2 0.98 0.90 0.92  0.88 0.58 0.77 
Cytosolic Fe-S cluster assembly factor  Narfl 1.00 1.01 1.06  1.01 0.65 0.81 
Probable cytosolic iron-sulfur protein 
assembly protein  
Ciao1 0.96 1.03 0.98  1.12 0.10 0.34 
MMS19 nucleotide excision repair 
protein homolog  





Table 3-8. Wound healing and inflammation. 
 
  Fold Change to Control   
  hPXR  KO   
Protein Description GN RIF/INH INH RIF  RIF/INH p-Value FDR 
Glutamine synthetase  Glul 0.85 1.03 0.72  1.17 0.16 0.41 
Carbonic anhydrase 3  Ca3 1.23 1.14 1.18  1.19 0.81 0.91 
Transforming growth factor-beta-
induced protein ig-h3  
Tgfbi 0.88 0.75 0.60  0.69 0.44 0.67 
Protein-glutamine gamma-
glutamyltransferase 2  
Tgm2 1.12 0.81 1.19  0.88 0.0059 0.12 
SPARC  Sparc 0.85 0.86 0.72  0.83 0.089 0.32 
Collagen alpha-1(III) chain  Col3a1 1.94 0.34 0.28  0.35 0.056 0.26 
Collagen alpha-1(IV) chain  Col4a1 1.27 0.86 0.83  0.90 0.0033 0.089 
Collagen alpha-1(VI) chain  Col6a1 1.10 0.67 0.47  0.63 0.0091 0.14 
Annexin A2  Anxa2 1.43 0.89 0.94  1.08 0.30 0.55 
Annexin A5  Anxa5 1.56 0.98 1.57  1.22 0.032 0.22 
Biglycan  Bgn 1.37 0.94 0.74  1.08 0.44 0.67 
G1/S-specific cyclin-D1  Ccnd1 1.40 0.69 1.24  1.03 0.19 0.45 
T-lymphocyte activation antigen 
CD86  





the other treatment groups from 0.83 to 0.90 fold and 0.47 to 0.67 fold, respectively. 
Annexin A5 (Anxa5) was significantly changed (p = 0.031). Anxa5 was increased by 1.56 
fold in hPXR mice treated with rifampicin and isoniazid and rifampicin alone, but less 
than 2% change was observed in hPXR mice treated with isoniazid. Anxa5 was also 
decreased in mPxr -/- treated with rifampicin and isoniazid (1.22 fold). 
 
 
Vitamin B6 Metabolism 
 
The vitamin B6 metabolism enzymes pyridoxal kinase (Pdxk), pyridoxal 
phosphate phosphatase (Phospho2), and pyridoxal-dependent decarboxylase domain-
containing protein 1 (Pdxdc1) were not significantly changed (Table 3-9). Pyridoxal 
phosphate phosphatase (Pdxp) was significantly changed (p = 0.0004) by 1.49 fold in 
hPXR mice treated with rifampicin and isoniazid, 2.18 fold in hPXR mice treated with 
rifampicin alone, and 1.34 fold in mPxr -/- mice treated with rifampicin and isoniazid. 
Pdxp dephosphorylates pyridoxal 5’ phosphate to 4-pyridoxic acid, but also 
dephosphorylates pyridoxine 5’ phosphate, and pyridoxamine 5’ phosphate (Jang, Kim et 
al. 2003). Increased degradation of vitamin B6 by up-regulation of Pdxp by rifampicin 
may reduce the amount of PIH formed and this may be protective. Further investigation 
is warranted to determine into this effect that may further deplete vitamin B6 levels and 
contribute to the development of peripheral neuropathy.  
 
 
[Fe-S] Cluster Containing Proteins  
 
There is not a significant global down-regulation of Fe-S containing proteins due 
to isoniazid (Table 3-10). NADH dehydrogenase [ubiquinone] iron-sulfur protein 8 
(Ndufs8) was significantly (p = 0.0012) changed. Ndufs8 was decreased in all treatment 
groups (only 4% decrease due to isoniazid in hPXR mice) by 0.91 fold in hPXR mice 
treated with rifampicin and isoniazid, 0.82 fold in hPXR mice treated with rifampicin, 
and by 0.75 fold in mPxr -/- treated with rifampicin and isoniazid. Succinate 
dehydrogenase [ubiquinone] iron-sulfur subunit (Sdhb) was significantly changed (p = 
0.035). Sdhb was decreased in hPXR mice treated with rifampicin and isoniazid (0.86 
fold) and with rifampicin alone (0.92 fold), but changed less than 1% in hPXR mice 
treated with isoniazid and in mPxr -/- treated with rifampicin and isoniazid. The changes 
in Sdhb may be hPXR mediated by rifampicin and further decreased by isoniazid 
administration. NADH dehydrogenase [ubiquinone] iron-sulfur protein 7 (Ndufs7) was 
significantly changed (p = 0.012) and was increased in hPXR mice treated with isoniazid 
(1.14 fold) and mPxr -/- mice treated with rifampicin and isoniazid (1.23 fold). NADH 
dehydrogenase [ubiquinone] iron-sulfur protein 4 (Ndufs4) was significantly changed (p 
= 0.034) and increased by isoniazid (1.12 fold) and rifampicin (1.10 fold) in hPXR mice 
and increased in mPxr -/- mice treated with rifampicin and isoniazid (1.23 fold). Iron-
responsive element-binding protein 2 (Ireb2) was significantly (p = 0.039) increased in 
all treatment groups 1.18 to 1.42 fold. Fdx, Fech, Fdx and Fech were significantly 
decreased by isoniazid treatment. Cisd1, Cisd2, and Cisd3 are non-significantly down-
regulated by approximately 10% by isoniazid. The NADH dehydrogenase [ubiquinone]  
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Table 3-9. Vitamin B6 metabolism.  
 
  Fold Change to Control   
  hPXR  KO   
Protein Description GN RIF/INH INH RIF  RIF/INH p-Value FDR 
Pyridoxal kinase  Pdxk 1.07 1.05 1.13  1.17 0.75 0.87 
Pyridoxal phosphate phosphatase  Pdxp 1.49 0.95 2.18  1.34 0.00049 0.038 
Pyridoxal phosphate phosphatase  Phospho2 1.04 1.08 1.07  1.04 0.90 0.96 
Pyridoxal-dependent decarboxylase 
domain-containing protein 1  





Table 3-10. [Fe-S] cluster containing proteins.  
 
  Fold Change to Control   
  hPXR  KO   
Protein Name GN RIF/INH INH RIF  RIF/INH p-Value FDR 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 3 
Ndufs3 0.94 1.09 1.01  1.09 0.74 0.86 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 2  
Ndufs2 1.00 1.04 1.03  1.04 0.65 0.81 
CDGSH iron-sulfur domain-
containing protein 1  
Cisd1 0.90 0.97 0.98  1.03 0.14 0.39 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 8 
Ndufs8 0.91 0.96 0.82  0.75 0.0012 0.058 
Succinate dehydrogenase 
[ubiquinone] iron-sulfur subunit 
Sdhb 0.86 0.99 0.92  0.99 0.036 0.22 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 7 
Ndufs7 1.00 1.14 1.09  1.20 0.012 0.15 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 4 
Ndufs4 0.94 1.12 1.10  1.23 0.033 0.22 
NFU1 iron-sulfur cluster scaffold 
homolog 
Nfu1 0.82 0.98 0.90  1.01 0.13 0.37 
NFU1 iron-sulfur cluster scaffold 
homolog, mitochondrial (Fragment)  
Nfu1 0.82 0.99 0.87  0.96 0.059 0.27 
Iron-sulfur protein NUBPL  Nubpl 1.27 1.77 1.37  0.91 0.067 0.29 
Iron-sulfur cluster assembly enzyme  Iscu 0.95 1.01 0.96  0.98 0.84 0.93 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 6 
Ndufs6 0.94 0.96 0.86  0.82 0.13 0.38 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 5  
Ndufs5 0.87 0.97 0.91  1.03 0.22 0.48 
CDGSH iron-sulfur domain-
containing protein 2  
Cisd2 0.90 0.88 0.89  0.82 0.94 0.98 
Iron-responsive element-binding 
protein  
Ireb2 1.19 1.21 1.42  1.28 0.039 0.23 
2-oxoglutarate and iron-dependent 
oxygenase domain-containing protein 
2  
Ogfod2 1.11 0.97 1.15  0.99 0.51 0.71 
Probable cytosolic iron-sulfur protein 
assembly protein  
Ciao1 0.96 1.03 0.98  1.12 0.10 0.34 
Iron-sulfur cluster assembly 2 
homolog, mitochondrial  
Isca2 0.90 0.91 1.13  1.02 0.20 0.46 
CDGSH iron-sulfur domain-
containing protein 3 
Cisd3 0.84 0.88 1.02  1.07 0.060 0.27 
2-oxoglutarate and iron-dependent 
oxygenase domain-containing protein 
3  
Ogfod3 1.03 0.98 0.91  0.87 0.25 0.51 
Aldehyde oxidase 1  Aox1 1.30 0.82 1.65  1.48 0.0023 0.075 







or complex 1 is composed of multiple sub-units and contains 8 [Fe-S] clusters; multiples 
of [2Fe-2S], [4Fe-4S], and [3Fe-4S]. Ndufs8 is significantly down-regulated by isoniazid, 
but contains 2 [4Fe-4S] clusters. (Loeffen, Smeitink et al. 1998) Sdhb contains 3 [Fe-S] 
clusters; [2Fe-2S], [4Fe-4S], and [3Fe-4S] and is down-regulated by rifampicin and 
isoniazid in hPXR mice. Aox1 and Adh are [2Fe-2S]-containing proteins that are also 





CHAPTER 4.    DISCUSSION 
 
 
Previous Animal Models of Isoniazid DILI 
 
Isoniazid displays different hepatotoxic patterns dependent on dose and animal 
model. Different groups have examined the role of isoniazid in anti-tubercular therapy 
DILI and have reached different conclusions. Therefore, the role of isoniazid in anti-
tubercular therapy toxicity remains elusive.  Studies performed in rats and human liver 
microsomes continue to form the consensus for the isoniazid/hydrazine model of liver 
injury (Mitchell, Zimmerman et al. 1976, Nelson, Mitchell et al. 1976). A single large 
dose (300 mg/kg) of isoniazid did not result in liver necrosis, but six lower oral doses 
(100 mg/kg) produced small amounts of necrosis when the rats were pre-administered 
phenobarbital (Nelson, Mitchell et al. 1976). However, administration of acetyl-
hydrazine increased the amount of necrosis compared to the administration of acetyl-
isoniazid. Further, the application of radiolabeled acetyl-isoniazid showed that the acetyl 
group was detected bound to cellular proteins and that the inhibition of the acetyl-
isoniazid to acetyl-hydrazine conversion decreased the necrosis seen after acetyl-
isoniazid, but not acetyl-hydrazine application. Thus, isoniazid acetylation and 
hydroxylation to acetyl-hydrazine and the interaction of further hydrolyzed acetyl-
hydrazine with cellular proteins was the suggested route of toxicity. A contemporary 
study may support this model with the findings that low N-acetyl transferase (NAT) 
activity is associated with increased risk of hepatic damage with the suggestion that the 
majority of acetyl-hydrazine is oxidized by CYP3A4 and 2E1 (Zabost, Brzezinska et al. 
2013). This model is problematic in that it may not completely recapitulate the pathology 
seen in clinic in combination therapy because the effects observed due to the combination 
of rifampicin and isoniazid are a cholestatic pattern of injury and this relatively short 
dosing regimen would not recapitulate chronic toxicity. This model may fit the clinical 
pattern seen in acute, hepatocellular isoniazid toxicity resulting from large doses of 
isoniazid, but not chronic, cholestatic rifampicin and isoniazid toxicity.   
 
Treatment of rats with acetyl hydrazine or acetyl isoniazid can cause 
hepatotoxicity, but isoniazid treatment itself does not cause toxicity in rats (Black, 
Mitchell et al. 1975, Nelson, Mitchell et al. 1976). When the acetyl group is radio-labeled 
in acetyl isoniazid, but not the aromatic ring, covalent binding of liver proteins was 
observed (Mitchell, Zimmerman et al. 1976, Nelson, Mitchell et al. 1976). This suggests 
that the toxicity observed in rats after treatment of acetyl isoniazid was due to the 
breakdown product of acetyl isoniazid, acetyl hydrazine. However, high doses of 
hydrazine administered to mice resulted in hepatotoxicity, but not high doses of acetyl 
hydrazine (Richards, Chau et al. 2004). There is no validated animal model that captures 
the chronic cholestatic pattern of hepatotoxicity seen in humans taking rifampicin and 
isoniazid as part of a multi-drug anti-tubercular therapy (Boelsterli and Lee 2014). A 
previous report (Li, Lu et al. 2013) that linked hPXR to rifampicin and isoniazid 
hepatotoxicity in mice only shows bile plugs on histopathologic examination without 
semi-quantitative histopathologic scoring of lesions. Multiple high doses of isoniazid can 
cause hepatocellular toxicity in rats pre-treated with phenobarbital, but this does not 
 
96 
recapitulate the human pattern of toxicity. (Mitchell, Zimmerman et al. 1976) Rats could 
be a poor model system due to the lack of a gall bladder which may be required for 
cholestatic hepatotoxicity or due to the differences in isoniazid bound proteins in rat, 
mouse, and human microsomes (McKennis, Yard et al. 1956, Metushi, Cai et al. 2014). 
There are two large differences in bile storage in mice and rats. The first is that mouse 
bile is more concentrated than rat bile when excreted into the duodenum (McMaster 
1922). Indeed, bile does not become more concentrated in rat even in stasis, whereas it 
does in the mouse. The other difference is that the gall bladder serves as a reservoir in 
mice and secretes bile upon relaxation of the sphincter of Oddi by cholecystokinin 
induced by a fatty meal. In contrast, the sphincter of Oddi is relaxed in rats. Bile in rats is 
not concentrated in the gall bladder, but in the liver unlike in mice whose livers see much 
lower concentrations of bile acid constituents. Therefore, it may be inappropriate to draw 
too many conclusions about cholestatic liver injury from rat models. 
 
 
Failure to Re-Capture DILI Phenotype in Mouse Model 
 
 
The Hepatotoxicity of PPIX 
 
The relationship between PPIX and hepatotoxicity has been reported previously 
(Davies, Schuurman et al. 2005, Lyoumi, Abitbol et al. 2011, Liu, Yan et al. 2015). The 
mechanism of toxicity may depend on the site of PPIX accumulation. For example, the 
intracellular accumulation of PPIX in hepatocytes is associated with a hepatocellular 
subtype of liver injury, whereas extracellular accumulation in the bile is associated with a 
cholestatic subtype. The site of accumulation differs between strains of mice. 
BALB/cm1Pas and C57BL/6m1Pas mice have a point mutation in the Fech gene and express 
a protein with less than 5% of the activity of the original enzyme (Davies, Schuurman et 
al. 2005). These mice develop phototoxicity and are more vulnerable to griseofulvin 
induced hepatotoxicity. Female C57BL/6m1Pas and BALB/cm1Pas mice were compared at 
12-14 weeks of age. C57BL/6m1Pas mice had porphyrin deposits in Kupffer cells and 
hepatocytes, whereas in BALB/cm1Pas porphyrin was deposited into bile canaliculi 
(Lyoumi, Abitbol et al. 2011). BALB/cm1Pas mice had 7-fold increases in AST and ALT, 8-
fold increase in ALP, and a 71-fold increase in total bilirubin. However, the changes in 
LFTs for C57BL6m1Pas mice were less marked. C57BL/6 mice had a 4-fold increase in 
AST, a 5-fold increase in ALT, a 1.5-fold increase in ALP, and a 2.5-fold increase in 
bilirubin. The pattern of PPIX deposition matches the pattern in the degree of LFT 
changes; the ALT/ALP ratio for BALB/cm1Pas mice of 0.74, a more than 2-fold increase in 
ALP, and a 71-fold increase in total bilirubin suggested an intrahepatic cholestatic type of 
liver injury (Robles-Diaz, Garcia-Cortes et al. 2015). Unfortunately, the authors did not 
test for direct bilirubin so a splenic or hematological source cannot be ruled out. On the 
other hand, the ALT/ALP ratio for C57BL/6m1Pas mice is 2.7 and is associated with a more 
than 2-fold increase in ALT and a less than 2-fold increase in ALP suggesting a 
hepatocellular type of liver injury. Interestingly, C57BL/6m1Pas mice had 8-fold higher 
liver PPIX levels than BALB/cm1Pas mice, but histopathological signs of bile duct 
destruction and sclerosing cholangitis were observed only in BALB/cm1Pas mice. 
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Therefore, PPIX accumulation via genetic disruption of the heme biosynthetic enzyme, 
FECH, is associated with a pattern of hepatotoxicity that is dependent upon the site of 
PPIX accumulation and this may differ between mouse strains. 
 
PPIX accumulation has been associated with pharmacologic disruption of heme 
biosynthesis by both isoniazid and griseofulvin. Griseofulvin treatment of 14 days in 
male FVB/NJ mice leads to an increase of PPIX, bile acids, and GSH in the liver. 
Griseofulvin is metabolized by CYP450 enzymes to reactive metabolites that form 
adducts with PPIX and N-methyl PPIX which may inhibit Fech. Griseofulvin up-
regulates Alas1 expression. These changes resulted in increased liver PPIX that was 
associated with a bile duct blockage that resulted in increased bile acids that were not 
associated with an increase in the enzymes responsible for bile acid synthesis (Liu, Yan 
et al. 2015).  
 
A recent report detailed the role that hPXR plays in rifampicin and isoniazid 
induced hepatotoxicity (Li, Lu et al. 2013). This report discussed the finding of bile 
plugs, high levels of PPIX in the bile, a 5-fold increase in ALT, a 2.2-fold increase in 
ALP, and an ALT/ALP ratio of approximately 0.5 in hPXR, but not WT or mPxr -/- mice 
treated with rifampicin and isoniazid compared to control hPXR mice. Rifampicin treated 
hPXR mice had a 2-fold increase in ALT and a 1.5-fold increase in ALP. There was no 
increase in ALT or ALP when hydrazine or acetyl-hydrazine was added with rifampicin, 
but ALP and ALT increased only when isoniazid was administered with rifampicin. In 
hPXR mice, rifampicin or isoniazid alone had a 5-fold increase in bile PPIX and 
rifampicin and isoniazid combination treated mice had a 60-fold increase in bile PPIX. In 
hPXR mice treated with both rifampicin and isoniazid, the addition of ALA resulted in a 
10-fold increase in ALT and ALP. Semi-quantitative histopathologic scores were not 
included in this report, nor were severe histopathologic signs of liver injury observed 
apart from bile plugs and signs of bile stasis. There is hPXR-mediated PPIX accumulation 
associated with elevated LFTs due to the combination of rifampicin and isoniazid with an 
unfortunately mild degree of histopathologic change. The phenotype may have been 
relatively mild, but the changes were hPXR-dependent. This phenotype may have been 
achievable if the length of my study may have led to an increase in liver injury in two 
control mice that may have been due to age. 
 
Other studies have observed hPXR-independent DILI due to the combination of 
rifampicin and isoniazid in mice in other strains of mice. Female WT CD-1 mice treated 
via oral gavage with 75 mg/kg isoniazid and 150 mg/kg rifampicin for 1 week had 
increased liver weight/body weight ratio, increased ALT, increased ALP, reduced GSH, 
and increased caspase 3 cleavage. The observed hepatotoxicity was attenuated with co-
administration of ursodeoxycholic acid, which is an hPXR agonist (Chen, Xu et al. 2011). 
This toxicity is observed in mice expressing WT mPxr and is therefore independent of 
hPXR. Male ICR mice treated via intraperitoneal injection with 75 mg/kg isoniazid and 
150 mg/kg rifampicin for 21 days had elevated ALT and AST, 1.25-fold increase in liver 
PPIX, and decreased Fech protein levels. These effects were attenuated by co-
administration of curcumin (Kluth, Banning et al. 2007, He, Guo et al. 2017). Several 
studies have shown that a low magnitude of increase in liver PPIX may not be required 
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for hepatotoxicity. Male FVB/NJ wild type mice were treated with 400 mg/L isoniazid in 
the drinking water and had 2-fold increase in liver PPIX at 3 days, 4-fold at 7 days, and 
8-fold at 14 days with a 60% decrease in Fech protein and a 6-fold increase in Alas1 
protein at 3 days through 14 days without significant mRNA changes. However, this was 
not associated with hepatotoxicity via LFTs or histopathology. There is strong literature 
evidence to support the relationship between PPIX and cholestatic liver injury. However, 
I was not able to reliably or robustly induce PPIX accumulation in our mouse model. I 
only robustly observed a 3-6 fold increase in liver PPIX in my in vivo studies. All of 




Attempt to Establish an Animal Model of Rifampicin and Isoniazid DILI 
 
I was unable to induce a robust hepatotoxicity phenotype in the hPXR mouse 
model. The hepatotoxicity associated with combination anti-tubercular therapy is 
cholestatic, whereas the hepatotoxicity associated with either rifampicin or isoniazid 
alone is hepatocellular (Li, Lu et al. 2013, Boelsterli and Lee 2014, Wang, Pradhan et al. 
2016). Furthermore, the combination therapy, due in part to the use of lower doses, is 
chronic and typically develops after weeks or months of treatment. However, the 
hepatotoxicity of the monotherapy is more typically acute and observed relatively quickly 
after the administration of a supra-clinical dose, especially in the case of isoniazid (Li, Lu 
et al. 2013, Boelsterli and Lee 2014, Wang, Pradhan et al. 2016). Additionally, the 
molecular mechanism of cholestatic or hepatocellular pattern of liver injury would be 
different from the other and may differ in the dependence upon hPXR status. Therefore, 
to recapitulate the hepatotoxicity phenotype in hPXR mice, a relatively narrow set of 
conditions may be required. A set of conditions, I was unable to recapitulate.  
 
 
Findings of In Vivo Studies 
 
In Vivo Study 1. The first mouse study (6 weeks, 100 mg/kg chow rifampicin, 
and 400 mg/L water isoniazid) resulted in no increase in serum liver function enzyme 
levels, no significant histopathologic change, and a slight increase in liver PPIX levels. 
Rifampicin was added to the food because it was much less water soluble than isoniazid. 
The increase in PPIX levels was much less than the increase observed in hPXR mouse 
models with a hepatoxicity phenotype (Li, Lu et al. 2013). However, it was similar to the 
increase observed due to isoniazid treatment alone (Sachar, Li et al. 2016). Isoniazid 
decreased Fech protein levels and increased Alas1 protein levels in an hPXR-independent 
manner (Figure 3-8). Rifampicin increased Cyp3a levels in an hPXR-dependent manner 
(Figure 4-1). There was no significant differences in total bilirubin, direct bilirubin, ALT, 







Figure 4-1. In vivo study 1 Cyp3a expression.  
 
Western blot analysis of Cyp3a in C57BL6 mouse liver after 6 weeks treatment with 









Figure 4-2. In vivo study 1 endpoint LFTs.  
 
Analysis of endpoint LFTs. ALT (A), ALP (B), total bilirubin (C), and direct bilirubin 




In Vivo Study 2. The second mouse study (6 months, 300 mg/kg chow 
rifampicin, and 1.2 g/L water isoniazid) resulted in a significant increase in of direct 
bilirubin and ALP in hPXR mice treated with both rifampicin and isoniazid (Figure 4-3). 
Rifampicin increased Cyp3a protein expression (Figure 4-4) in an hPXR-dependent 
manner. Isoniazid decreased (Figure 4-4) Fech expression and increases Alas1 
expression. Histopathological examination (which was not reported previously (Li, Lu et 
al. 2013) revealed the presence of hepatopathic lesions in hPXR mice treated with 
rifampicin and isoniazid (Figure 4-5). However, the difference in the scoring of these 
lesions between drug treatment groups in hPXR mice was not significant (Figure 4-6). 
This was due the presence of hepatopathic lesions in 2 control treatment hPXR mice. 
These mice were not older than other mice in the study, but at 8-10 months of age these 
mice may have developed liver disease spontaneously. However, these mice were not 
older than other mice in the study. Additionally, the Grubb’s test did not identify either of 
these data points as an outlier.  
 
In the context of the sole previous report of hPXR-dependent rifampicin and 
isoniazid DILI in mice, the phenotype reported was replicated with more moderate 
changes in terms of ALP and direct bilirubin (Figure 4-3) (Li, Lu et al. 2013). However, 
ALT had no significant increase and histopathologic scoring reveal a significant increase 
only in bile pigment (Figure 4-5). Additionally , many previous other studies reported 
hPXR-independent rifampicin and isoniazid DILI have moderate, but significant changes 
in LFTs, but not pathologic scoring (Chen, Xu et al. 2011, He, Guo et al. 2017).  
 
In Vivo Study 3. Two problems with in vivo study 2 were the intragroup 
variability and the low magnitude of histologic change. I addressed the variability by 
administering rifampicin and isoniazid via oral gavage. I addressed the low magnitude of 
changes by calculating the doses for study 2 based on (1) the estimated doses, (2) 
literature reports, and (3) converting the human dose to the mouse dose. The third mouse 
study (3.5 months, 80 mg/kg rifampicin and 75 mg/kg isoniazid administered by daily 
oral gavage) was monitored for hepatotoxicity by weekly serum collections and analysis 
of the liver function enzymes, ALT and ALP. At 3.5 months, no significant increases due 
to any treatment was observed in liver function tests throughout the duration of the study. 
The doses of rifampicin and isoniazid used in study 3 were lower than literature reports 
of doses reported to cause hepatotoxicity after oral administration in mice (Chen, Xu et 
al. 2011), lower than the doses used in study 2 (for isoniazid), and lower than the doses I 
calculated based on the dose commonly administered in humans. 
 
 
Suitability of Pyrazinamide Inclusion 
 
Pyrazinamide is only used in combination treatment of M. tuberculosis to reduce 
the duration of treatment. Pyrazinamide is a prodrug that is activated by a bacterial 
enzyme. The PZase/nicotinamidase ecoded by the M. tuberculosis gene, pncA, converts 
pyrazinamide to pyrazinoic acid. Pyrazynoic acid accumulations in M. tuberculosis at 
acidic pH and causes cytosolic acidification (Zhang, Shi et al. 2013). Pyrazinamide can 





Figure 4-3. In vivo study 2 endpoint LFTs. 
 
ALP (A), ALT (B), direct bilirubin (C), and total bilirubin (D) are represented. Data are 
expressed as the mean ± SEM. 1-way ANOVA followed by Dunnett’s post-hoc analysis 





Figure 4-4. In vivo study 2 gene expression changes. 
 
Protein levels in livers of study mice. For 6 months, mice were provided 300 mg 
rifampicin/kg in chow and 1.2 g/L isoniazid in water ad libitum. Livers were flash-frozen, 
homogenized, and lysed before western blotting analysis was performed. Cyp3a (A, B), 
Alas1 (C, D; shorter band is mature form), and Fech (E, F) levels are displayed. 
HepG2/C3A transiently transfected with MT (lipid only), NT3 (non-targeting siRNA), 
siRNA targeting gene being probed for, empty vector (EV), or target (FECH/ALAS1) are 
used as controls. The lower band recognized by the Alas1 antibody is the mature, active 
form of Alas1. Cyp3a (G), Fech (H), and Alas1 (I.) mRNA expression in the livers of 
C57BL/6 mPxr -/- and hPXR mice. For 6 months, mice were provided 300 mg 
rifampicin/kg in chow and 1.2 g/L isoniazid in water ad libitum. Mice were euthanized, 
and their livers were collected and stored in RNAlater (Thermo Fisher; Waltham, ME) at 
-80°C. RNAlater was removed and liver slices were washed with PBS before 
homogenization on the Bullet Blender Storm 24 Homogenizer (Thomas Scientific; 
Swedesboro, NJ). RNA was extracted and analyzed by qRT-PCR. The ΔΔCT method 
was used to normalize fold change in expression to expression in the control group of 
each mouse strain. 2-way ANOVA followed by Tukey’s post-hoc analysis was used to 













Figure 4-5. Representative liver micrographs of in vivo study 2 mice. 
 







Figure 4-6. Histopathologic scores of in vivo study 2 mice. 
 
Semi-quantitative histopathologic scoring was performed by a board certified vertinary 
pathologist. Total hepatotopathy (A), inflammation score (B), karyomegaly (C), steatosis 
(D), bile pigment (E), and necrosis (F) scores. Data are expressed as the mean ± SEM. 1-
way ANOVA followed by Dunnett’s post-hoc analysis was used to compare group 




Indeed, 5-OH pyrazinamide, 5-OH pyrazinoic acid, and pyrazinoic acid were associated 
with purine metabolism products in patients, but was not associated with hepatotoxicity 
(Cao, Mi et al. 2018). Pyrazinamide is a pyrazine analogue of nicotinamine and is both 
bactericidal and bacteriostatic. Pyrazinamide is typically administered as a dose of 15-30 
mg/kg/day. Adding pyrazinamide to an anti-tubercular therapy regimen that contains 
rifampicin and isoniazid results in a significant increase in the incidence of hepatotoxicity 
(Chang, Leung et al. 2008). 0.8% of patients developed hepatotoxicity while taking a 
combination of rifampicin and isoniazid, whereas 2.6% of patients taking pyrazinamide, 
rifampicin, and isoniazid. The adjusted odds ratio for developing hepatotoxicity when 
taking pyrazinamide, isoniazid, and/or rifampicin was 2.8 compared to taking only 
isoniazid and pyrazinamide. Likewise, the combination of pyrazinamide with rifampicin 
was significantly more likely to cause hepatotoxicity than preventative treatment 
isoniazid alone with an odds ratio of 2.6 (van Hest, Baars et al. 2004). Inclusion of 
pyrazinamide to the animals being administered rifampicin and isoniazid would have 
likely increased the incidence and severity of liver injury based on observations from 
previous reports. However, this hepatotoxicity from pyrazinamide, rifampicin, and 




Significance of PIH and Hydrazine Findings 
 
Iron sulfur [2Fe-2S] clusters bind a [Cys-X-Cys-X-Cys-X-Cys] motif. Four 
cysteine residues are conserved between Drosophila and humans, Cys-196, Cys-403, 
Cys-406, and Cys-411 are ligands for the [2Fe-2S] cluster in FECH (Crouse, Sellers et al. 
1996). NOS inhibits Fech in rat hepatocytes and purified recombinant human FECH 
(Kim, Bergonia et al. 1995, Rouault and Klausner 1996). A labile iron sulfur [2Fe-2S] 
cluster is found in animal ferrochelatase but is missing from the analogous plant, 
bacterial, and yeast enzymes (Dailey, Finnegan et al. 1994, Ferreira and Gong 1995, Day, 
Parsons et al. 1998). Therefore the [2Fe-2S] cluster does not appear to be necessary for 
catalysis. However, in mammal enzymes, when this structure is targeted by NOS, 
degradation of FECH/Fech are increased (Sellers, Johnson et al. 1996). Indeed, NOS 
decrease the visible absorption spectrum of the [2Fe-2S] cluster of human and mouse 
FECH as observed by EPR spectroscopy (Kim, Bergonia et al. 1995, Rouault and 
Klausner 1996, Sellers, Johnson et al. 1996). The yeast enzyme was affected by NOS to a 
much lower degree, presumably due to the lack of the [2Fe-2S] cluster. Iron limiting 
conditions have previously been reported to decrease FECH protein levels, this was 
shown to be due to the formation of an unstable protein with a half-life of about 1 hour 
compared to the protein formed in iron replete conditions with a half-life of over 35 hours 
(Crooks, Ghosh et al. 2010). Therefore, the iron-limiting conditions in the presence of the 
vitamin B6-isoniazid conjugate, PIH, may lead to the formation of a FECH protein that is 
less stable than the form formed in iron-replete conditions.  
 
Isonicotinic acid, hydrazine, acetylisoniazid, acetyl hydrazine, diacetyl hydrazine, 
and hydrazone derivatives of pyruvic and α-ketoglutaric acids have been identified as 
metabolites of isoniazid (Hughes 1953, Preziosi and Porcellati 1953, Defranceschi and 
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Zamboni 1954, Johnson 1954, Zamboni and Defranceschi 1954, Kaneo, Kubo et al. 1981, 
Blair, Mansilla Tinoco et al. 1985). The aroyl hydrazone iron chelator, PIH, was the only 
one tested found to decrease FECH protein levels (Figure 3-12A and Figure 3-12C). 
This down-regulation was found to be iron-dependent (Figure 3-16A and Figure 3-16B). 
The iron-limiting condition induced by deferoxamine has previously been shown to 
reduce the half-life of FECH formed after treatment (Crooks, Ghosh et al. 2010). This 
may be due to reducing the availability of iron to form [2Fe-2S] clusters or an effect at 
another point in iron-sulfur cluster assembly machinery. Further studies such as EPR 
spectroscopy of FECH formed following PIH application similar to a previous report 
(Sellers, Johnson et al. 1996) to observe if purified recombinant FECH formed in the 
presence of PIH differ from those formed in iron-replete conditions. Likewise, a 
proteomics analysis following isoniazid treatment in mice might elucidate additional 
possible mechanisms and other [2Fe-2S] containing proteins that may be affected by PIH. 
 
Isoniazid treatment has been linked to peripheral neuropathy secondary to vitamin 
B6 depletion (Aita and Calame 1972, Mahashur 1992) and may be associated with 
conjugation of isoniazid to the vitamin B6 species, pyridoxal, pyridoxine, and pyridoxal 
5’ phosphate, resulting in decreased pyridoxal levels in humans and rats (Carlson, 
Anthony et al. 1956, Sevigny, White et al. 1966, Demiroglu and Dundar 1997, Cilliers, 
Labadarios et al. 2010). Isoniazid-induced vitamin B6-dependent peripheral neuropathy is 
treated in part by the administration of vitamin B6. Further studies would be necessary to 
study the potential relationship of vitamin B6 levels to hepatotoxicity in anti-tubercular 
therapy. Hydrazine increases ALAS1 protein (Figure 3-12E and Figure 3-12G) and 
mRNA (Figure 3-12F and Figure 3-12H) levels, but we did not elucidate the mechanism 
by which hydrazine up-regulates ALAS1. However, hydrazine has been previously 
reported to N-alkylate, deactivate, and increase the turnover of CYP450 enzymes 
(Battioni, Mahy et al. 1983, Ator, David et al. 1987, Jenner and Timbrell 1994, Wen, 
Wang et al. 2002). If this leads to a decrease in the regulatory heme pool, then this could 
be expected to result in ALAS1 up-regulation at both the protein and mRNA levels 
(Zheng, Shan et al. 2008). Previous studies have elucidated the role of heme regulation 
on ALAS1 levels (Kolluri, Sadlon et al. 2005, Yoshino, Munakata et al. 2007, Zheng, 
Shan et al. 2008, Gotoh, Nakamura et al. 2011, Kubota, Nomura et al. 2016). 
 
Cholestatic liver injury due to rifampicin and isoniazid is associated with PPIX 
accumulation and heme biosynthesis disruption. The heme biosynthesis disruption 
observed in animal systems (Sachar, Li et al. 2016) after isoniazid administration also 
affects the human proteins (Figure 3-9 and Figure 3-10). Furthermore, the effects are not 
due to isoniazid itself, but due to a metabolite of isoniazid, hydrazine (Figure 3-12 and 
Figure 3-15), and a vitamin B6 conjugate, PIH (Figure 3-12 and Figure 3-13). PIH 
forms in an enzyme-independent reaction between multiple vitamin B6 orthologs and 
isoniazid (Figure 3-13) and decreases FECH protein levels in an iron-dependent manner 
(Figure 3-16). Hydrazine is formed in the culture media of primary human hepatocytes 
and HepG2/C3A and may require metabolic activation of isoniazid to achieve high 
concentrations (Figure 3-15). Hydrazine up-regulates ALAS1 at the mRNA and protein 
levels (Figure 3-12). Together these effects would begin to explain the observed increase 
in PPIX accumulation after isoniazid co-administration. 
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Significance of Proteomics Profiling Findings 
 
Proteomics profiling revealed protein changes in hPXR mice treated with 
rifampicin and/or isoniazid and changes in mPxr -/- mice treated with rifampicin and 
isoniazid compared to hPXR control mice. With these treatments it is possible to tell what 
changes are due to the drug combination and what changes are dependent on hPXR status 
and what changes are due to the single therapy of either drug or due to the combination 
therapy in hPXR mice. The analysis revealed down-regulation of heme biosynthesis 
genes (Alas2, Ppox, and Fech) that participate in a mitochondrial protein complex 
(Medlock, Shiferaw et al. 2015). This complex or the individual proteins of this complex 
were decreased by the combination (Table 3-1) of rifampicin and isoniazid in hPXR 
mice. Further validation of these findings may elucidate what level (transcriptional, 
translational, or post-translational) that these changes occur and reveal the heme 
biosynthesis metabolite (the Ppox substrate, PPG or the Fech substrate, PPIX) that 
accumulates from these changes.  
 
Proteomics profiling also identified CYP450 enzyme changes and the differences 
due to drug treatment and hPXR status (Table 3-2). High CYP2E1 activity has been 
reported to contribute to an increased incidence of isoniazid DILI in humans (Leiro-
Fernandez, Valverde et al. 2010, Gogtay, Kapileshwar et al. 2016, Antonenko, Butov et 
al. 2017). In mice, Cyp2e1 has not been associated with a protective effect on the 
development of isoniazid DILI in mice, but pan-CYP450 inhibitors have been shown to 
affect the development of DILI in mice (Mitchell, Thorgeirsson et al. 1975, Mitchell, 
Zimmerman et al. 1976, Lauterburg, Smith et al. 1985, Lauterburg, Todd et al. 1985). 
Analysis revealed an hPXR-independent increase in Cyp2e1 protein in mice due to the 
combination of rifampicin and isoniazid.  
 
The nuclear receptors, Hnf1a, Nr3c, and Nr5a were significantly changed and are 
down-regulated due to rifampicin and isoniazid (Table 3-3). The glucocorticoid receptor 
(Nr3c) and Nr5a may be down-regulated due to rifampicin in hPXR mice. Hnf1a may be 
down-regulated due to rifampicin in an hPXR-independent manner. Other nuclear 
receptors were not significantly changed, suggesting that changes observed in target 
genes may be due to activation of these nuclear receptors.  
 
 The organic transporters Abcb1a, Abcc2, Slc10a1, and Slco1a were significantly 
changed (Table 3-4). Rifampicin may have increased Abcb1a in an hPXR-dependent 
manner, which could result in increased efflux of xenobiotic substrates of Abcb1a taken 
in combination with anti-tubercular therapy. Abcc2 may have been decreased due to 
isoniazid independent of hPXR-status. Slc10a1 and Slco1a1 may be decreased due to 
rifampicin dependent on hPXR status. 
 
 Ltf modulates the immune system, both innate and adaptive responses, and a 
decrease may be expected to produce an exaggerated immune response to injury (Actor, 
Hwang et al. 2009). Indeed Ltf is significantly decreased by at least 60% in all treatments 
compared to control hPXR mice (Table 3-5). Ftl11 is down-regulated in all treatment 
groups, with the highest magnitude of decrease (72%) in hPXR mice treated with both 
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rifampicin and isoniazid. Low ferritin levels are a clinical sign of iron deficiency and 
could reflect low iron levels possibly caused by long-term exposure to an iron chelator. 
However, this is less likely as Ftl1 was also decreased in rifampicin treated hPXR mice, 
but to a lower magnitude to all isoniazid-containing treatments. Abcb7 is an iron 
transporter and deficiency is associated with refractory anemia with ring sideroblasts 
from intracellular iron accumulation in erythrocytes. Abcb7 may be decrease in and 
hPXR-independent manner by rifampicin. This effect could be compensatory to low-iron 
levels or a direct effect of drug treatment.  
 
 Profiling analysis revealed many changes in proteins involved in relieving 
oxidative stress (Table 3-6). Multiple GST mu isoforms were up-regulated by rifampicin 
a possibly hPXR-dependent manner. There was an approximately additional 1 fold higher 
increase in hPXR mice treated with rifampicin and isoniazid compared to mPxr -/- mice 
treated with rifampicin and isoniazid. Additional GST isoforms up-regulated where 
Gsta1 and Gstt2. GSTM1 has been reported to be protective in humans treated with 
rifampicin and isoniazid. Null alleles of GSTM1 in humans may lead to increased 
incidence of DILI (Roy, Chowdhury et al. 2001, Huang, Su et al. 2007, Lucena, Andrade 
et al. 2008, Bing, Xiaomeia et al. 2011, Monteiro, El-Jaick et al. 2012, Gupta, Singh et al. 
2013, Li, Long et al. 2013, Tang, Deng et al. 2013). This response may be protective to 
xenobiotic exposure by conjugating allowing for the elimination of xenobiotics. Cat was 
also increase due to rifampicin in a possibly hPXR-dependent manner and may be 
protective by neutralizing H2O2. Nqo1 is up-regulated in APAP-induced DILI and is 
protective against the development of DILI (Hwang, Kim et al. 2015). Nqo1 is increased 
in an hPXR-independent manner due to rifampicin and isoniazid and to a greater extent 
due to rifampicin alone. These changes support the hypothesis that oxidative stress may 
play a role in the response of mouse liver protein expression to rifampicin and isoniazid 
treatment.  
 
 Multiple [Fe-S] cluster assembly proteins are down-regulated by rifampicin and 
isoniazid (Table 3-7). Nfs1, Fdx1, Hscb, Isca11, and Bola3 are decreased by the 
combination of rifampicin and isoniazid in both hPXR and mPxr -/- mice. Whether these 
changes are direct effects of drug treatment or are compensatory to other changes is 
unclear, but it does not seem to be due to isoniazid alone. However, with these decreases 
the ability to produce [Fe-S] clusters and the proteins that contain them may be reduced.  
 
 Histopathologic examination revealed signs of toxicity in hPXR mice treated with 
rifampicin and isoniazid in combination and with rifampicin alone in the mice whose 
livers were used for proteomics profiling (Table 4-1). This was not significant because 
two mice not included in the proteomics analysis had high histopathologic scores. 
However, the control hPXR mice used in the proteomics analysis had lower levels of 
hepatotoxicity, whereas hPXR mice treated with rifampicin and isoniazid and rifampicin 
alone all had much higher histopathogic score (Table 4-1). Correspondingly, up-
regulation of the genes related to wound healing Tgm2, Col4a1 and Anxa5 were increased 




Table 4-1. Histopathologic score of mice in proteomics analysis. 
 
 hPXR  mPXR -/- 
Treatment: RIF   RIF/INH  Control  INH  RIF/INH 
Sample ID: T U  I K L  A C  N O  Z AA 





 Pdxp was significantly increased due to rifampicin alone and in combination with 
isoniazid in hPXR mice and due to the combination of rifampicin and isoniazid in mPxr -/- 
mice (Table 3-9). Multiple [Fe-S] cluster assembly machinery proteins are down-
regulated (Table 3-10). Two [Fe-S]-containing proteins were down-regulated by 
isoniazid that contained multiple [Fe-S] clusters, some of which are [2Fe-2S] clusters. 
Multiple [2F-2S]-containing proteins are down-regulated due to isoniazid, but not all 
these proteins were decreased. Proteomics analysis has revealed many changes due to 
rifampicin and isoniazid treatment in mice that need be validated. 
 
 
Significance of Physiochemical Findings  
 
The proposed hepatotoxicity mechanism of PPIX posits that PPIX precipitates in 
bile canaliculi, possibly upon binding with bile acids and phospholipids. This 
precipitation of PPIX and bile acid constituents may lead to bile stasis and bile pigment 
plugs observed in enlarged canaliculi upon histologic examination. This has not before 
been shown to be the mechanism by which PPIX contributes to cholestatic 
hepatotoxicity. Therefore, I demonstrated that PPIX is insoluble at the higher 
concentrations reported in hepatotoxicity and that PPIX binds to bile acid constituents 
and that this binding may be affected by the presence of rifampicin and isoniazid. The 
hepatotoxicity mechanism of PPIX also presumes that extracellular PPIX is more 
hepatotoxic than intracellular PPIX (Lyoumi, Abitbol et al. 2011). Thus, I selected a 
polar species of PPIX, the disodium salt, which is not membrane permeable. I then found 
that exogenous treatment of PPIX (I cannot exclude cellular import conclusively) 
significantly decreased the viability of HepG2/C3A cells. 
 
The mechanism of PPIX induced cholestatic hepatotoxicity observed in 
BALB/cm1Pas mice (Lyoumi, Abitbol et al. 2011) and as reported in hPXR transgenic 
C57BL/6 mice (Li, Lu et al. 2013), is dependent upon PPIX efflux to the bile and that 
retention in hepatocytes results in a less severe and hepatocellular pattern of 
hepatotoxicity. Therefore, PPIX would be expected to contribute to toxicity upon efflux 
from hepatocytes. This efflux would be expected to be dependent upon ABCG2-mediated 
transport of PPIX and has been reported as such previously (Aust, Obrist et al. 2004). 
Therefore, the expected role of isoniazid or rifampicin upon ABCG2 activity, would be to 
increase possibly by transcriptional up-regulation rather than by inhibition by isoniazid. 
(He, Guo et al. 2017)  Indeed, I report here that isoniazid does not inhibit human or 





The exact molecular mechanism and specific contribution to toxicity from both 
rifampicin and isoniazid should be elucidated before re-attempt of the in vivo study is 
made. When these conditions are known after revelation from mechanistic studies, the 
animal equivalent dose I calculated should be a starting point. Future studies to undertake 
as indicated by the results of this study would broadly be to (1) validate the proteomics 
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profiling findings, (2) successfully observe the DILI phenotype in mouse, (3) to 
specifically define the mechanism by which PIH and hydrazine affect heme biosynthesis 
proteins, and (4) to fully elucidate the effects of the physiochemical properties of PPIX 
on the development of DILI.  
 
 
To Validate and Expand the Proteomics Profiling Results  
 
 The proteomics data set derived by TMT labeled LC/LC/MS/MS revealed 
additional potential contributions to hepatotoxicity from rifampicin as well as potential 
mechanism by which isoniazid affected Fech and Alas1. Down-regulation of a 
mitochondrial heme synthesis protein complex may have been indicated. Further 
validation of these findings may elucidate at what level that these changes occur and 
reveal the heme biosynthesis metabolite (the Ppox substrate, PPG or the Fech substrate, 
PPIX) that accumulates from these changes. 
 
Network analysis of transcription factor target gene networks may identify 
potential transcription factors that are activated in addition to hPXR that may play a role 
in the development of hepatotoxicity. Several organic transporters were changed due to 
rifampicin and isoniazid and these changes may reflect disrupted bile flow either by 
being contributory to cholestasis or by being compensatory. Additionally, potential 
changes were observed that could be reflective of chronically low iron levels. The timing 
and severity of changes in the expression of Fech could be improved by modulation of 
iron levels as well as modulation of pyridoxal phosphorylation.  
 
Changes in [Fe-S] cluster assembly machinery proteins observed from the 
proteomics analysis could be related to the potential for [Fe-S] cluster incorporation into 
Fech, forming a stable protein able to clear PPIX. Up-regulation of CYP450 enzymes due 
to rifampicin could be the major contribution of rifampicin to hepatotoxicity observed in 
hPXR mice treated with rifampicin and isoniazid. To confirm, one would need to robustly 
induce phenotype then test multiple specific and pan inhibitors of CYP450 enzymes in 
the presence of rifampicin and isoniazid. Confirmation of these changes would reveal 
additional conditions to improve the likelihood of obtaining a hepatotoxic phenotype due 
to rifampicin and isoniazid treatment in hPXR mice. 
 
 
To Successfully Observe the DILI Phenotype in Mouse 
 
The inclusion of pyrazinamide to the rifampicin and isoniazid combination 
treatment of hPXR mice may cause a more severe toxicity, but may be (1) too severe to 
be reversed or (2) not hPXR-dependent and not reversible by hPXR antagonism. 
However, pyrazinamide inclusion should be one of several conditions tested for a pilot 
study to induce hepatotoxicity in hPXR mice. Pyrazinamide inclusion to anti-tubercular 
regimens containing rifampicin and isoniazid more than doubles the incidence of 
hepatotoxicity (Centers for Disease and Prevention 2001, Chang, Leung et al. 2008). No 
evidence exists that hPXR plays a role in the hepatotoxicity of pyrazinamide (Shehu, Li 
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et al. 2016). Additionally, the hepatotoxicity of pyrazinamide may be by a separate 
mechanism than either rifampicin or isoniazid and the combination of rifampicin an 
isoniazid. A metabolite of pyrazinamide, 5-hydroxypyrazinoic acid, may be responsible 
for the toxicity seen after pyrazinamide administration and is dependent on an un-
identified amidase (Shih, Pai et al. 2013). The pattern of hepatotoxicity is hepatocellular 
and this study was conducted in rats and caution should be used when extrapolating these 
results to mice or humans. 
 
 The isoniazid dose used in study 3 (70 mg/kg/day) was too low considering the 
estimated dose in study 2 (220 mg/kg/day), previous literature reports (75 mg/kg/day), 
and the calculated dose (185 mg/kg/day) (Chen, Xu et al. 2011, He, Guo et al. 2017). 
Indeed, 300 mg/kg for a month in mPxr expressing C57BL/6 was not toxic (Metushi, Cai 
et al. 2014). The dose used in the 3rd in vivo study (70 mg/kg) was lower than the dose 
used in the 1st in vivo study (73.3 mg/kg). The histopathologic score would have been 
significant for study 2 in hPXR mice treated with rifampicin and isoniazid, but two mice 
in the hPXR control group had liver injury possibly due to age. Therefore, the goal of 
study 3 was to use a higher and more controllable dose of rifampicin and isoniazid to 
induce hepatotoxicity at an earlier time-point. It was believed that my calculated and 
proposed doses were too high. Therefore, I used half of the isoniazid dose I had 
calculated from the human dose and found was in the range used therapeutically in mice 
to treat M. tuberculosis infection.  
 
 To successfully recapitulate the DILI phenotype reported previously, (Li, Lu et al. 
2013) (1) doses should be selected based on the literature evidence, mouse equivalent 
dose calculations, and pilot experiments, (2) multiple diet formulations containing 
various amounts of vitamin B6 analogues should be considered, (3) small pilot studies 
using only hPXR control mice and hPXR mice treated with rifampicin and isoniazid 
should be performed first to find the conditions of DILI, (4) the role of PPIX should be 
elucidated to understand if additional conditions to promote toxicity are necessary, and 
(5) the hPXR mice need to be back-crossed to reduce the variability in drug response. 
 
 
To Fully Elucidate the Role of the Physiochemical Properties of PPIX upon the 
Development of DILI 
 
A full characterization of the contribution of the physiochemical properties of 
multiple species of PPIX should be undertaken to understand the molecular mechanism 
by which PPPIX contributes to hepatotoxicity. Previous reports that have reported PPIX 
in association with hepatotoxicity, have detected PPIX by mass spectrometry which may 
not be able to differentiate between PPIX species with different metal ions coordinated 
(Li, Lu et al. 2013). This is especially necessary given that the toxic effect of PPIX may 
be exerted when in an extracellular space (Davies, Schuurman et al. 2005, Lyoumi, 
Abitbol et al. 2011). Therefore, physiochemical rather than the biologic effects of PPIX 
accumulation may be more imported in the DILI associated with PPIX accumulation. 
Future studies should seek to (1) demonstrate conclusively by comparing Km values that 
rifampicin and/or isoniazid affect binding of bile acid constituents, (2) determine the 
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solubility of multiple species of PPIX and the conditions present in the bile that may 
modulate the solubility of PPIX, and (3) demonstrate the exact molecular mechanism of 
the in vitro hepatotoxicity of PPIX because it will be necessary to understand the in vivo 
mechanism of hepatotoxicity. PPIX is strongly associated with hepatotoxicity, but a 
definitive answer and mechanism has not been reported. 
 
 
To Elucidate the Mechanism by which Hydrazine Up-Regulates ALAS1 and PIH 
Down-Regulates FECH 
 
Low iron levels regulate FECH by preventing the formation of a stable protein by 
decreasing iron levels by chelation (Taketani, Adachi et al. 2000, Crooks, Ghosh et al. 
2010), whether this is by disrupting iron metabolism, transport, or storage, direct 
destruction of the [Fe-S] cluster of FECH, or by the disruption of the [Fe-S] cluster 
assembly machinery proteins remains to be see. Further studies such as EPR 
spectroscopy of FECH formed following PIH application similar to a previous report 
(Sellers, Johnson et al. 1996) to observe the if purified recombinant FECH formed in the 
presence of PIH differ from those formed in iron-replete conditions. Likewise, a 
proteomics analysis following isoniazid treatment in mice might elucidate additional 
possible mechanisms and other [2Fe-2S] containing proteins that may be affected by PIH. 
EPR spectroscopy could directly observe malformation of the [Fe-S] cluster. 
 
Proteomics profiling data suggest that additional [2Fe-2S] cluster-containing 
proteins may be down-regulated by isoniazid in addition to FECH. Proteomics profiling 
also revealed that several proteins involved in the assembly of [Fe-S] cluster proteins 
were also down-regulated by isoniazid. Future studies to determine if there is a global 
decrease in [2Fe-2S] cluster containing proteins by defects in [Fe-S] cluster assembly 
machinery, or another aspect of Fe-mediated protein stability involved are warranted.  
 
 Proteomics profiling also provided insights into the possible mechanism by which 
hydrazine up-regulates ALAS1. Multiple CYP450 enzymes are down-regulated by 
isoniazid (Table 3-2). This could be due to isoniazid and hydrazine covalently binding to 
and destroying heme-containing proteins (Battioni, Mahy et al. 1983, Ator, David et al. 
1987, Jenner and Timbrell 1994, Wen, Wang et al. 2002). This destruction of 
hemoproteins could lead to a compensatory up-regulation of the heme biosynthesis 
pathway once the inhibitory effect of the regulatory heme pool is removed (Srivastava, 
Borthwick et al. 1983, Kolluri, Sadlon et al. 2005, Zheng, Shan et al. 2008). Directly 
measuring the increase in protein size by mass spectrometry when adducted to hydrazine 





 Tuberculosis kills millions of humans every year. A significant portion of these 
deaths is from anti-TB therapy failure due to withdrawal of first-line drugs due to DILI. 
This is more likely in vulnerable populations (Ungo, Jones et al. 1998, Yee, Valiquette et 
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al. 2003, Breen, Miller et al. 2006). I propose additions to the understanding of the 
mechanism of rifampicin and isoniazid DILI whereby separate metabolites of isoniazid 
modulate the heme biosynthesis pathway (Figure 4-7). Models of anti-TB DILI have 
been used for over 50 years (Mitchell, Zimmerman et al. 1976, Nelson, Mitchell et al. 
1976). These early models were useful, but due to the lack of the gallbladder in rats, were 
not fully elucidative. Indeed, the absence of the gallbladder in the rat may interfere the 
development of the clinicopathologic pattern of anti-TB DILI of liver injury observed in 
the livers Of Mice and Men. 
 
In conclusion, I report that the physiochemical properties of PPIX may contribute 
to the toxicity associated with PPIX accumulation, metabolites of isoniazid modulate the 
heme biosynthesis pathway in a manner associated with an increase in PPIX levels, and 
that rifampicin treatment of mice results in gene changes that may contribute to PPIX 







Figure 4-7. The proposed mechanism of regulation of heme biosynthesis by 
isoniazid. 
 
Vitamin B6 analogues form PIH in the presence of isoniazid. PIH chelates iron and 
prevents the stabilization of FECH. Isoniazid breaks down to hydrazine and hydrazine 
up-regulates ALAS1 at the transcriptional level. Both effects may be expected to raise the 
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